Basware announces EUR 1 billion revenue growth vision

Basware’s vision is to deliver the best global solution for networked purchasing, invoicing and paying. All organisations need to manage their purchasing processes from procurement through to handling invoices and paying them. Currently many organisations only have unsophisticated or partial tools to manage these processes and as a result many are faced with unmanaged spending, inefficient manual and paper-based processes and poor visibility of cashflows. Basware offers a uniquely complete solution for these challenges that is differentiated by the Basware Network, the largest e-invoicing network in the world. This enables customers to manage 100 percent of their spending, make their purchasing processes completely digital, and improve their carbon footprint by reducing paper usage. As every organization in the world can benefit from our solutions, the market opportunity is huge, worth EUR 15 billion per year. Growth in demand for our solutions is underpinned by several megatrends, including digitalization, automation, and artificial intelligence. Basware’s ambition is to be the number one by market share in the networked source-to-pay industry in the large European countries and a leader in the US market. As a result, we today announce that our growth vision is to become an EUR 1 billion revenue company. At the end of the second quarter 2018 Basware announced that it has moved to a growth phase after almost two years of simplifying and improving its operations. We are now focused fully on cloud revenue growth and will make the necessary investments to accelerate this growth. Undisputed market leader Basware has four sources of cloud revenue growth: new customer acquisitions, customer expansions, customer transformations, and partnering. New customer acquisitions: Basware’s key growth markets are the US, UK, Germany and France. These continue to be the areas where we see the greatest opportunity to win new customers, and this is where we will continue to invest the majority of our new sales and marketing spending and where the “hunters” in our sales force will focus. Customer expansions: We have a fantastic existing cloud customer base with approximately 200 key customers for whom the average annual recurring cloud revenue is approximately EUR 200 thousand. We want to support each of our customers across the full spectrum of networked source to pay cloud solutions and in all jurisdictions where they operate. We are the best placed in our industry to do so given the global reach of our network, the largest e-invoicing network in the world. By investing in account management, serving our customers more intimately and more globally, and by improving customer satisfaction, we believe that we can significantly increase the average revenues from our key customers. Customer transformations: We are focused on actively transforming the largest of our on-premise customers to our cloud solutions. When our customers transform to the cloud they benefit from a modern, more useable, constantly updated solution and as a result typically the revenues from each of these customers more than doubles. Partnering: In the past Basware has focused more on direct sales than partner sales with the share of cloud revenues in 2017 from partners being approximately 5 percent. Reaching more end customers via partners is a scalable way to grow both in our existing key markets and in the future in new geographies, and therefore a dedicated partnering function was created as part of the move to a functional organisation structure announced in May 2018. The goal is to increase the percentage of cloud revenues from partners to 20 percent in the long run. Increasing investments into sales and marketing Basware will increase its investments significantly into sales and marketing during the strategy period 2019 to 2022 in order to grow cloud order intake. We are confident that this will be a good investment, because our historical ratio of customer life time value to customer acquisition cost has been 7 times. This means that for every one Euro invested in sales and marketing a return of seven Euros will be generated. In fact, with a gross renewal rate of 95 percent and a net renewal rate of 106 percent, a typical customer lifetime is 19 years. Simplify global trade interactions We have a powerful cloud platform which enables customers to manage all source-to-pay processes. We have the largest open e-Invoicing network in the world. These assets combined put us in a unique position to leverage the rapid technological developments in the industry to bring more value to our customers by simplifying global trade interactions. The role of analytics solutions will be increasingly more important to increase the value of our offering to customers - from getting actionable insights to making strategic business decisions. We will selectively consider partnering and acquisitions to complement our technology portfolio. Customer value beyond expectations We strive to provide an excellent customer experience and maximize customers’ service adoption and benefits so that they want to purchase even more of our solutions. We will make our consulting and customer service organization more scalable. A scalable business model The cloud business model that Basware is transforming to, now accounting for 66 percent of revenues, is very scalable. This means that as revenues grow, the cost of sales does not grow as quickly, improving our gross margin over time. Whilst we will invest more in sales and marketing during the strategy period, underlying profitability will improve as cost of sales declines as a percentage of sales and we exercise discipline in research and development and general and administrative spending. As a general cost philosophy, we will continuously reallocate spending from less productive to more productive areas. Basware’s priority is cloud revenue growth. In addition to the long-term growth vision to become a EUR 1 billion revenue company, Basware today announces a mid-term target to replace any previous targets: Basware will accelerate annual organic cloud growth to more than 20 percent by 2022. There is a huge market opportunity ahead of Basware which requires ambition to capture. That is why we today announce our EUR 1 billion revenue growth vision. We believe that Basware has the building blocks to be the leader in our industry and with these actions are confident that we can further strengthen our global position and drive cloud revenue growth. For further information, please contact:Ben Selby, Head of Investor Relations, Basware Corporation+358 50 305 8077, ben.selby@basware.comDistribution:Nasdaq HelsinkiMain mediainvestors.basware.com/enAbout Basware:Basware  (Nasdaq: BAS1V) is the global leader in providing networked source-to-pay solutions, e-invoicing and value-added services. Basware’s commerce and financing network connects businesses in over 100 countries and territories around the globe. As the largest open business network in the world, Basware provides scale and reach for organizations of all sizes, enabling them to grow their business and unlock value across their operations by simplifying and streamlining financial processes. Small and large companies around the world achieve significant cost savings, more flexible payment terms, greater efficiencies and closer relationships with their suppliers. Find out more at investors.basware.com/en.Follow Basware on Twitter: @Basware , join the discussion on the Basware LinkedIn , Basware Facebook  and Basware Blog .

BASWARE INTERIM REPORT JANUARY 1 – SEPTEMBER 30, 2018 (IFRS)

July-September 2018: · Net sales EUR 33 991 thousand (EUR 35 827 thousand): decrease of 5.1 percent, organic growth at constant currencies 5.2 percent · Organic cloud revenue growth at constant currencies 15.0 percent, amounting to 66.0 percent (56.0 %) of net sales · Adjusted EBITDA EUR -877 thousand (EUR 3 661 thousand) · Adjusted operating profit/loss EUR -3 600 thousand (EUR 1 361 thousand) · Adjusted earnings per share (diluted) EUR -0.21 (0.06) · Operating profit/loss EUR -3 787 thousand (EUR 1 205 thousand) · Earnings per share (diluted) EUR -0.22 (0.05) January-September 2018: · Net sales EUR 104 929 thousand (EUR 109 924 thousand): decrease of 4.5 percent, organic growth at constant currencies 5.8 percent · Organic cloud revenue growth at constant currencies 16.3 percent, amounting to 62.5 percent (53.1 %) of net sales ·  Adjusted EBITDA EUR -3 538 thousand (EUR 2 386 thousand) ·  Adjusted operating profit/loss EUR -11 633 thousand (EUR -4 976 thousand) ·  Adjusted earnings per share (diluted) EUR -1.14 (-0.45) ·  Operating profit/loss EUR 2 379 thousand (EUR -6 648 thousand) ·  Earnings per share (diluted) EUR -0.18 (-0.56) Basware is the global leader in providing networked source-to-pay, e-invoicing and value-added services. Basware’s key strategic priority for the strategy period 2018-2022 is cloud revenue growth. The company continues to strengthen its leading market position in order to grow cloud revenue. For 2018 Basware expects the following on an organic basis at constant currencies: · Cloud revenues to be between EUR 90 and 95 million  · Total costs excluding amortization, depreciation and adjustments to be slightly above 2017 levels Basware has adopted IFRS 15 Revenue from Contracts with Customers as of January 1, 2018 (mandatory application), with full retrospective application. In connection with the IFRS 15 application, the Group has also made certain changes to revenue allocation between Cloud and Non-cloud. Comparatives for 2017 presented in the interim report have been updated to include IFRS 15 restatements and revenue reallocations. From Q1 2018 onwards, Basware has made certain changes in the presentation of its financial information. The company has adopted a functional income statement showing the company’s cost of sales, gross profit and operating expenses by function. In addition, the company has changed the presentation of its geographical information. From Q1 2018 onwards, the company reports the following geographical areas: Americas, Europe, Nordics and APAC. In February 2018 Basware completed the divestment of two businesses. As a result, it is important to consider the organic growth rate when comparing 2018 financials with 2017 financials as the divestments decrease revenues and profitability. Additionally, foreign exchange movements, particularly in US dollars and Sterling, have negatively impacted Basware’s headline revenues during the first three quarters. This has a disproportionate effect on our cloud revenues where US dollars and Sterling comprise a larger share than in total revenues. The interim report is unaudited. GROUP KEY FIGURES +---------------------+------+------+-------+--------+-------+---------+--------+| | 7-9/ | 7-9/ |Change,| 1-9/| 1-9/|Change,  | 1-12/|+---------------------+------+------+-------+--------+-------+---------+--------+|EUR thousand  | 2018 | 2017 | %| 2018| 2017| % | 2017|+---------------------+------+------+-------+--------+-------+---------+--------+|Net sales  | 33| 35| -5.1|104 929 |109 924| -4.5 |149 167 || | 991 | 827 | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Cloud revenue | 22| 20| 11.9| 65 566 | 58 720| 11.7| 80 332|| | 440 | 052 | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Cloud order intake* |4 483 |3 475 | 29.0 | 15 531 |12 995 | 19.5 | 17 943 || | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+| | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|EBITDA  | -1|3 505 | | 10 474 | 714 | | 599 || | 064 | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Adjusted EBITDA | -877 |3 661 | | -3 538 | 2 386 | | 3 294 || | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Operating | -3|1 205 | | 2 379 |-6 648 | | -9 509 ||profit/loss  | 787 | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Adjusted operating | -3|1 361 | |-11 633 | -4 976| -133.8 | -6 814 ||profit/loss  | 600 | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+| | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Profit/loss before | -4| 688 | | 756 |-9 013 | |-12 276 ||tax  | 274 | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Profit/loss for the | -3| 694| | -2 558 |-8 093 | 68.4 |-11 524 ||period  | 229 | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+| | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Cash and cash | 46| 25| 82.9| 46 235 | 25 275| 82.9 | 20 683 ||equivalents | 235 | 275 | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+| | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Earnings per share  | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Diluted, EUR  |-0.22 | 0.05 | | -0.18 | -0.56 | 68.7 | -0.80 || | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+|Adjusted earnings per|-0.21 | 0.06 | | -1.14 | -0.45 | -155.7 | -0.61 ||share, diluted, EUR  | | | | | | | |+---------------------+------+------+-------+--------+-------+---------+--------+ *From Q2 2018 onwards cloud order intake is the key order intake figure reported BUSINESS OPERATIONSBasware is the global leader in networked purchase-to-pay solutions, including e-invoicing and financing services. Basware’s commerce network connects businesses in over 100 countries and territories around the globe. As the largest open business network in the world, Basware provides scale and reach for organizations of all sizes, enabling them to grow their business and unlock value across their operations by simplifying and streamlining financial processes. Small and large companies around the world achieve significant cost savings, more flexible payment terms, greater efficiencies and closer relationships with their suppliers. CEO Vesa Tykkyläinen:Our vision at Basware is to deliver the best global solution for networked purchasing, invoicing and paying. There is a huge potential market for our services, worth EUR 15 billion annually. We are the best placed to capitalise on this opportunity thanks to our network, which is the largest electronic invoicing network in the world. As a result of this strong combination of opportunity and capability, our growth vision is to become an EUR 1 billion revenue company. Every day we move closer to becoming a pure cloud company and our cloud revenues now stand at 66 percent of total. This quarter our cloud order intake growth rate accelerated to 29 percent, driven by customer expansions and transformations, new customer acquisitions and partner sales. Customers wins this quarter include National Oilwell Varco, the Government of South Australia, Hoyts and Balenciaga. In July we announced the outsourcing of our scanning services to Xerox. The deal closed at the beginning of October and 387 employees will transfer to Xerox from Basware. The partnership draws on the strengths of both parties, enabling Basware to focus on electronic invoicing whilst our customers will benefit from the best in paper handling from Xerox. It also simplifies our operations at Basware, which enables us to focus more on our core objective of cloud revenue growth. Additionally, this quarter Klaus Andersen joined us as Chief Technology Officer, completing the key leadership announced in May this year as Basware moved to a functional organisation. Basware’s industry leading solutions can seamlessly connect to more than 250 different ERP systems. This quarter we continued to release new functionality including Smart Search, which is differentiated by our smart data model, and enables procurement departments to ensure that end users are directed towards the most appropriate purchasing options. As both CEO and a shareholder of Basware, I am very excited by the progress that we continue to make during this quarter. Our key employees also share my excitement and also invested their own money into Basware this quarter as part of a share matching plan. Together the leadership of Basware is highly confident in our ability to capitalise on the huge market opportunity ahead of us. NET SALES Basware’s net sales year-to-date amounted to EUR 104 929 thousand (EUR 109 924 thousand), a decrease of 4.5 percent. This equated to 5.8 percent organic growth at constant currencies. The difference is related to the sale of Banking and Financial Performance Solutions as well as foreign exchange movements, especially US dollar and Sterling. Basware’s net sales for the third quarter amounted to EUR 33 991 thousand (EUR 35 827 thousand), a decrease of 5.1 percent. This equated to 5.2 percent organic growth at constant currencies. Cloud revenues grew well during the third quarter. Cloud revenues in the third quarter were EUR 22 440 thousand (EUR 20 052 thousand), up by 11.9 percent, and accounted for 66.0 percent (56.0 %) of net sales. This equated to 15.0 percent organic growth at constant currencies. Using 2017 exchange rates to calculate 2018 revenues, Cloud revenues in the third quarter would have been EUR 22 541 thousand. In the third quarter SaaS revenues grew 14.3 percent and transaction services revenues 11.7 percent compared to the third quarter of 2017. The SaaS growth rate equated to 21.0 percent and transaction growth rate to 12.4 percent organic growth at constant currencies. In non-cloud revenues, maintenance and licence revenues declined in line with expectations as we transition customers to the cloud. Non-cloud revenues were significantly impacted by the divestments made in the first quarter. The maintenance revenues declined 8.9 percent and licences 36.7 percent on an organic basis at constant currencies. Consulting revenues declined 8.6 percent on an organic basis at constant currencies. Basware has adopted IFRS 15 Revenue from Contracts with Customers as of January 1, 2018. In connection with the IFRS 15 application, the Group has also made certain changes in revenue allocation between Cloud and Non-cloud. The net impact of IFRS 15 restatements and the changes in revenue allocation between Cloud and Non-cloud for 2017 comparatives is EUR -74 thousand for the full year and EUR 383 thousand for Q3 2017 on Group level, with Cloud revenue increasing by EUR 1 163 thousand for full year 2017 and EUR 700 thousand for Q3 2017 and Non-cloud revenue decreasing by EUR 1 236 thousand for full year 2017 and EUR 317 thousand for Q3 2017. +-------------+-------+-------+--------+-------+-------+--------+--------+|Net sales by | 7-9/ | 7-9/ |Change, | 1-9/ | 1-9/ |Change, | 1-12/ ||revenue type | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|EUR thousand | 2018 | 2017 | % | 2018 | 2017 | % | 2017 |+-------------+-------+-------+--------+-------+-------+--------+--------+|Cloud Revenue| | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|SaaS  | 10 177| 8 903| 14.3| 29 416| 25 276| 16.4| 34 808 |+-------------+-------+-------+--------+-------+-------+--------+--------+|Transaction | 11 029| 9 875| 11.7| 32 405| 28 919| 12.1| 39 689 ||services  | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Other cloud | 1 233| 1 274| -3.2| 3 744| 4 525| -17.3| 5 835 ||revenue  | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Cloud Revenue|22 440 |20 052 | 11.9 | 65 566| 58 720| 11.7| 80 332 ||total | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Non-Cloud | | | | | | | ||Revenue  | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Maintenance | 6 150 | 8 965 | -31.4 | 20 212| 28 170| -28.3| 37 026 |+-------------+-------+-------+--------+-------+-------+--------+--------+|License sales| 401 | 790 | -49.3 | 1 589| 2 810| -43.4| 4 192 |+-------------+-------+-------+--------+-------+-------+--------+--------+|Consulting | 4 966 | 6 063 | -18.1 | 17 504| 20 299| -13.8| 27 746 ||services | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Other non | 34 | -42 | | 59| -74| | -129 ||-cloud | | | | | | | ||revenue | | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Non-Cloud |11 551 |15 776 | -26.8 | 39 364| 51 204| -23.1| 68 836 ||Revenue total| | | | | | | |+-------------+-------+-------+--------+-------+-------+--------+--------+|Group Total | 33 991| 35 827| -5.1|104 929|109 924| -4.5|149 167 |+-------------+-------+-------+--------+-------+-------+--------+--------+ CLOUD ORDER INTAKE Basware’s total cloud annual recurring revenue (ARR) gross order intake in the third quarter amounted to EUR 4.5 million, up from EUR 3.5 million in the third quarter of 2017, an increase of 29.0 percent. This equated to 35.0 percent growth on an organic constant currency basis. There will be a time lag before order intake is visible in net sales. Typically, around one quarter of new ARR order intake converts into revenues in the year that it is won, with roughly fifty to sixty percent converting to revenues in the second year and the remainder thereafter. Further information on the definition of annual recurring revenue gross order intake is included in the section on Definition of Alternative Performance Measures. +-------------------+-----+-----+---------+------+------+---------+------+|Annual recurring |7-9/ |7-9/ |Change,  | 1-9/ | 1-9/ |Change,  |1-12/ ||revenue gross order| | | | | | | ||intake | | | | | | | |+-------------------+-----+-----+---------+------+------+---------+------+|EUR thousand  |2018 |2017 | % | 2018 | 2017 | % | 2017 |+-------------------+-----+-----+---------+------+------+---------+------+|Cloud |4 483|3 475| 29.0|15 531|12 995| 19.5|17 943|+-------------------+-----+-----+---------+------+------+---------+------+|Purchase-to-Pay |3 130|1 988| 57.5| 9 321| 8 303| 12.3|11 246||subscriptions | | | | | | | |+-------------------+-----+-----+---------+------+------+---------+------+ FINANCIAL PERFORMANCE Basware’s adjusted EBITDA was EUR -877 thousand (EUR 3 661 thousand) in the third quarter. The adjustments to EBITDA totalled EUR 187 thousand (EUR 156 thousand) in the quarter. Basware’s operating profit/loss for the quarter amounted to EUR -3 787 thousand (EUR 1 205 thousand). Basware’s adjusted EBITDA was EUR -3 538 thousand (EUR 2 386 thousand) year-to-date. The operating profit/loss for the first three quarters amounted to EUR 2 379 thousand (EUR -6 648 thousand). Basware’s profitability year-to-date and particularly in the third quarter of 2018 has been impacted by the disposals that closed in the first quarter, increased spending on sales and marketing and increased share-based compensation, all of which are in line with Basware’s strategy. The disposed businesses were contributing roughly EUR 8 million of EBITDA in 2017. In line with the strategy we have spent an additional EUR 3 million on sales and marketing in the third quarter of 2018 compared to the third quarter of 2017. As we further align our employees with shareholders, the costs related to share-based compensation increased by roughly EUR 1 million compared to the comparison period. The company’s cost of sales was EUR 16 101 thousand (EUR 16 966 thousand) and total operating expenses including depreciation and amortization EUR 21 361 thousand (EUR 17 400 thousand) in the third quarter. Out of total operating expenses, sales and marketing expenses were EUR 10 759 thousand (EUR 7 809 thousand), research and development expenses EUR 6 599 thousand (EUR 6 539 thousand) and general and administration expenses EUR 4 003 thousand (EUR 3 052 thousand). Other operating income and expenses were EUR -316 thousand (EUR -257 thousand). Research and development expenses in the income statement totalled EUR 6 599 thousand (EUR 6 539 thousand). Of this, EUR 1 535 thousand related to depreciation (EUR 1 126 thousand). Research and development expenses capitalized during the quarter amounted to EUR 1 751 thousand (EUR 2 192 thousand). Basware’s research and development investments totalled EUR 6 815 thousand (EUR 7 606 thousand), or 20.0 percent (21.2 %) of net sales during the quarter. The company’s net finance expenses were EUR -487 thousand (EUR -401 thousand) for the quarter.Basware’s profit/loss before tax was EUR -4 274 thousand (EUR 688 thousand) and profit/loss for the quarter EUR -3 299 thousand (EUR 694 thousand). Taxes for the quarter impacted the profit/loss by EUR 1 045 thousand (EUR 7 thousand). Diluted earnings per share were EUR -0.22 (EUR 0.05) for the quarter. FINANCING AND INVESTMENTS Cash flows from operating activities were EUR -2 676 thousand in the third quarter (EUR -4 840 thousand) and year-to-date EUR -3 421 thousand (EUR -2 206 thousand). Basware’s operating cash flows are seasonal as a relatively large part of payments for annual maintenance are made in the first quarter. Basware’s cash and cash equivalents including short-term deposits totalled EUR 46 235 thousand (EUR 25 275 thousand) at the end of the quarter. In addition to cash and cash equivalents, Basware has an undrawn revolving credit facility of EUR 10 million, bringing total available liquidity at the end of the quarter to EUR 56 235 thousand (EUR 35 275 thousand). In the third quarter of 2018, the company participated in a new fixed rate bond with a loan share totalling EUR 10 million. The bond’s maturity is five years. Basware’s total assets on the balance sheet at the end of the quarter were EUR 219 252 thousand (EUR 220 439 thousand). Net cash flows from investments were EUR -1 489 thousand (EUR -2 453 thousand) in the quarter. The equity ratio was 52.3 percent (53.4 %) and gearing 9.6 percent (20.4 %). The company’s interest-bearing liabilities totalled EUR 57 202 thousand (EUR 49 282 thousand), of which current liabilities accounted for EUR 17 089 thousand (EUR 1 996 thousand). The return on investment was -9.2 percent (2.8 %) and return on equity -11.2 percent (2.3 %) in the quarter. PERSONNEL Basware’s personnel expenses were EUR 22 045 thousand (EUR 21 370 thousand) in the quarter. Basware employed 1 727 (1 826) people on average during the quarter and 1 736 (1 827) at the end of the quarter. Following the partnership with Xerox announced in the third quarter, 387 employees will transfer from Basware to Xerox in the fourth quarter. Geographical division of personnel: +---------------------+------+------+-------+-----+-----+---------+------+|Personnel   |7-9/  |7-9/  |Change,|1-9/ |1-9/ |Change,  |1-12/ |+---------------------+------+------+-------+-----+-----+---------+------+|Employed, on average | 2018 | 2017 | % |2018 |2017 | % | 2017|+---------------------+------+------+-------+-----+-----+---------+------+|Americas  | 138 | 130 | 6.2| 137| 131| 4.8 | 131|+---------------------+------+------+-------+-----+-----+---------+------+|Europe   | 457 | 463 | -1.2| 461| 479| -3.8 | 475|+---------------------+------+------+-------+-----+-----+---------+------+|Nordics  | 473 | 555 | -14.7| 497| 562| -11.6 | 558|+---------------------+------+------+-------+-----+-----+---------+------+|APAC  | 658| 678| -2.9| 673| 668| 0.8| 673|+---------------------+------+------+-------+-----+-----+---------+------+|Group total  |1 727 |1 826 | -5.4|1 768|1 840| -3.9 | 1 838|+---------------------+------+------+-------+-----+-----+---------+------+ In accordance with the new organisational structure announced on June 1, 2018, at the end of the quarter 12.4 percent of the personnel worked in sales and marketing, 48.6 percent in R&D and production and products, 31.0 percent in customer services and 8.0 percent in administration. The average age of employees is 35.4 (35.2) years. Women account for 28.0 percent (27.5 %) of employees, men for 72.0 percent (72.5 %). OTHER EVENTS OF THE PERIOD Composition of the Audit Committee  David Bateman, member of the Board of Directors of Basware Corporation, joined the Board’s Audit Committee as of July 1, 2018. All other members of the Audit Committee remain unchanged. Changes in Basware’s Executive Team Klaus Andersen was appointed as Chief Technology Officer (CTO) and as a member of the Executive Team at Basware. Andersen joined Basware in September and reports to the CEO. Basware launches new Matching Share Plan for key employeesThe Board of Directors of Basware Corporation resolved in its meeting on July 17, 2018 to establish a new Matching Share Plan 2018-2020 for the Group’s key employees. The aim of the plan is to further align the objectives of shareholders and key employees, to retain key employees at the company, and to offer them competitive reward plans based on acquiring and holding the company’s shares.The potential rewards from the plan will be paid partly in Basware shares and partly in cash. The cash proportion is intended to cover taxes and tax-related costs arising from the reward to the employee.The prerequisite for receiving reward on the basis of the Matching Share Plan is that the plan member acquires Basware shares. The plan member will, as a reward, receive matching shares for each share subject to the share ownership prerequisite after a matching period of three (3) years. Receipt of matching shares is contingent on the continuation of employment or service and on the plan member holding the acquired shares upon reward payment.The rewards to be paid in aggregate to plan members on the basis of the Matching Share Plan correspond to the value of a maximum total of 77,714 Basware Corporation shares, including also the proportion to be paid in cash. The plan as a whole entails an aggregate share ownership interest of approximately 116,571 shares for the plan members, via personal share acquisitions and the right to future share ownership through the Matching Share Plan. EVENTS AFTER THE PERIOD Basware announces EUR 1 billion revenue growth vision Basware’s vision is to deliver the best global solution for networked purchasing, invoicing and paying. All organisations need to manage their purchasing processes from procurement through to handling invoices and paying them. Currently many organisations only have unsophisticated or partial tools to manage these processes and as a result many are faced with unmanaged spending, inefficient manual and paper-based processes and poor visibility of cashflows. Basware offers a uniquely complete solution for these challenges that is differentiated by the Basware Network, the largest e-invoicing network in the world. This enables customers to manage 100 percent of their spending, make their purchasing processes completely digital, and improve their carbon footprint by reducing paper usage. As every organization in the world can benefit from our solutions, the market opportunity is huge, worth EUR 15 billion per year. Growth in demand for our solutions is underpinned by several megatrends, including digitalization, automation, and artificial intelligence. Basware’s ambition is to be the number one by market share in the networked source-to-pay industry in the large European countries and a leader in the US market. As a result, we today announce that our growth vision is to become an EUR 1 billion revenue company. At the end of the second quarter 2018 Basware announced that it has moved to a growth phase after almost two years of simplifying and improving its operations. We are now focused fully on cloud revenue growth and will make the necessary investments to accelerate this growth. Undisputed market leader Basware has four sources of cloud revenue growth: new customer acquisitions, customer expansions, customer transformations, and partnering. New customer acquisitions: Basware’s key growth markets are the US, UK, Germany and France. These continue to be the areas where we see the greatest opportunity to win new customers, and this is where we will continue to invest the majority of our new sales and marketing spending and where the “hunters” in our sales force will focus. Customer expansions: We have a fantastic existing cloud customer base with approximately 200 key customers for whom the average annual recurring cloud revenue is approximately EUR 200 thousand. We want to support each of our customers across the full spectrum of networked source to pay cloud solutions and in all jurisdictions where they operate. We are the best placed in our industry to do so given the global reach of our network, the largest e-invoicing network in the world. By investing in account management, serving our customers more intimately and more globally, and by improving customer satisfaction, we believe that we can significantly increase the average revenues from our key customers. Customer transformations: We are focused on actively transforming the largest of our on-premise customers to our cloud solutions. When our customers transform to the cloud they benefit from a modern, more useable, constantly updated solution and as a result typically the revenues from each of these customers more than doubles. Partnering: In the past Basware has focused more on direct sales than partner sales with the share of cloud revenues in 2017 from partners being approximately 5 percent. Reaching more end customers via partners is a scalable way to grow both in our existing key markets and in the future in new geographies, and therefore a dedicated partnering function was created as part of the move to a functional organisation structure announced in May 2018. The goal is to increase the percentage of cloud revenues from partners to 20 percent in the long run. Increasing investments into sales and marketing Basware will increase its investments significantly into sales and marketing during the strategy period 2019 to 2022 in order to grow cloud order intake. We are confident that this will be a good investment, because our historical ratio of customer life time value to customer acquisition cost has been 7 times. This means that for every one Euro invested in sales and marketing a return of seven Euros will be generated. In fact, with a gross renewal rate of 95 percent and a net renewal rate of 106 percent, a typical customer lifetime is 19 years. Simplify global trade interactions We have a powerful cloud platform which enables customers to manage all source-to-pay processes. We have the largest open e-Invoicing network in the world. These assets combined put us in a unique position to leverage the rapid technological developments in the industry to bring more value to our customers by simplifying global trade interactions. The role of analytics solutions will be increasingly more important to increase the value of our offering to customers - from getting actionable insights to making strategic business decisions. We will selectively consider partnering and acquisitions to complement our technology portfolio. Customer value beyond expectations We strive to provide an excellent customer experience and maximize customers’ service adoption and benefits so that they want to purchase even more of our solutions. We will make our consulting and customer service organization more scalable. A scalable business model The cloud business model that Basware is transforming to, now accounting for 66 percent of revenues, is very scalable. This means that as revenues grow, the cost of sales does not grow as quickly, improving our gross margin over time. Whilst we will invest more in sales and marketing during the strategy period, underlying profitability will improve as cost of sales declines as a percentage of sales and we exercise discipline in research and development and general and administrative spending. As a general cost philosophy, we will continuously reallocate spending from less productive to more productive areas. Basware’s priority is cloud revenue growth. In addition to the long-term growth vision to become a EUR 1 billion revenue company, Basware today announces a mid-term target to replace any previous targets: Basware will accelerate annual organic cloud growth to more than 20 percent by 2022. There is a huge market opportunity ahead of Basware which requires ambition to capture. That is why we today announce our EUR 1 billion revenue growth vision. We believe that Basware has the building blocks to be the leader in our industry and with these actions are confident that we can further strengthen our global position and drive cloud revenue growth. Definitions related to cloud metrics included in EUR 1 billion vision statement: Cloud gross churn rate is defined as the total amount of cloud revenues lost during the period, divided by the total cloud revenues at the beginning of the period. Cloud net churn rate is defined as the total amount of cloud revenues lost during the period minus the new cloud ARR won from add-on sales to existing customers during the period, divided by the total cloud revenues at the beginning of the period. Cloud gross renewal rate is defined as 100 percent minus the cloud gross churn rate. Cloud net renewal rate is defined as 100 percent minus the cloud net churn rate. Customer lifetime is defined as 1 divided by the cloud gross churn rate. Lifetime value of the order intake won during the period is calculated by multiplying Cloud ARR order intake during the period by the cloud gross margin and dividing by the cloud gross churn rate. The customer acquisition cost is defined as the total expenditure on sales and marketing for the 12 months prior to the period (to account for the lead time between new sales and marketing expenditure converting to order intake). RISKS AND UNCERTAINTY FACTORS     Basware has a growth strategy with high net sales growth expectations for the cloud business. Executing the strategy requires significant investments in sales and marketing and related resources as well as continued investments in product development. At the same time, the industry transformation from an on-premise license-based business model to a SaaS model will accelerate the decline of certain Basware revenue streams, including license sales and maintenance. The transformation will also make consulting revenues more volatile. Until the transformation is complete, this will act as a drag on Group net sales growth. Additionally, even higher than expected pace in the license to SaaS transformation would have a negative impact on expected net sales in the short term. In addition to SaaS, Basware expects high growth rates in its network-based transaction services which will, besides successful sales effort, also require an efficient supplier onboarding process. Sales from Value Added Services, including Financing Services, are dependent on Basware’s ability to bring innovative and attractive products to the market according to its planned timetable and move customers quickly to a phase where they are using the services extensively enough to provide meaningful revenue to Basware. The fact that more than 50 percent of the company’s sales are expected to come from non-euro countries exposes the Group’s net sales growth to foreign exchange rate movements. In case there is a significant movement of GBP, USD, NOK, SEK or AUD against the euro, reported net sales may be affected. In addition, a proportion of Basware’s costs are denominated in INR and RON. Execution of the growth strategy and going through constant change puts new demands on the organization as well as its management and leadership capabilities. The company’s ability to attract, retain and develop the right type of talent to deliver on its strategy is critical as well as management focus and ability to drive change. Basware considers acquisitions as part of its strategy. Acquisitions entail risks, such as failure in integrating acquisitions or in ensuring that the planned financial benefits and synergies of the acquisitions materialize. The cloud transformation process requires cash investment. The company’s ability to secure financing for this transformation may affect its ability to deliver on the strategy. Basware’s biggest operational risks relate to service disruption as a result of for example data centre failures, various data security threats and non-compliance risks related to Basware’s solutions and services, the company’s activities or its employees’ behaviour. Operational risks are actively managed by continuous improvement in risk monitoring and protection practices as well as internal training of Basware’s personnel. Basware operates in a market where technological and business model innovation play a key role. While Basware is recognized as a leader within its segments by independent analysts, it is critical that Basware continues to innovate and develop its offering. FUTURE OUTLOOKOperating environment and market outlook All organisations need to manage their purchasing processes from procurement through to handling invoices and paying them. Currently many organisations only have unsophisticated or partial tools to manage these processes and as a result many are faced with unmanaged spending, inefficient manual and paper-based processes and poor visibility of cashflows. Basware offers a uniquely complete solution for these challenges that is differentiated by the Basware Network, the largest e-invoicing network in the world, and enables customers to manage 100 percent of their spending and make their purchasing processes completely paperless. Basware expects the demand for networked purchase-to-pay services to continue to grow. The total potential market for networked purchase-to-pay services is estimated to be worth EUR 15 billion in annual revenues. Outlook for 2018 Basware is the global leader in providing networked source-to-pay, e-invoicing and value-added services. Basware’s key strategic priority for the strategy period 2018-2022 is cloud revenue growth. The company continues to strengthen its leading market position in order to grow cloud revenue. Themes affecting cloud revenues in 2018: · SaaS revenues anticipated to continue to grow strongly on an organic basis · Transaction services revenues growth anticipated to accelerate as growth initiatives take effect · Other cloud revenues continue to be impacted by UK public sector revenues · Cloud revenues have a higher proportion of US dollar and Sterling and so are disproportionately affected by foreign exchange movements Themes affecting non-cloud revenues in 2018: · Maintenance and licence revenues will continue to decline as Basware transitions existing customers to cloud services · Consulting revenues are also affected by the cloud transition and more standardised implementations · Non-cloud revenues are disproportionately affected by the divestments completed in February 2018 For 2018 Basware expects the following on an organic basis at constant currencies: · Cloud revenues to be between EUR 90 and 95 million  · Total costs excluding amortization, depreciation and adjustments to be slightly above 2017 levels Constant currencies means that the effects of any changes in currencies are eliminated by calculating the figures for the period using 2017 exchange rates. Organic means that the figures are adjusted to remove the effects of any acquisitions or disposals within the past 12 months. Espoo, Finland, Tuesday, October 16, 2018 BASWARE CORPORATIONBoard of Directors Vesa Tykkyläinen, CEO, Basware Corporation For more information, please contact:Niclas Rosenlew, CFO, Basware CorporationTel. +358 50 480 2160, niclas.rosenlew@basware.comDistribution:Nasdaq HelsinkiKey mediainvestors.basware.com/en SUMMARY OF FINANCIAL STATEMENTS AND NOTES TO THE FINANCIAL STATEMENTS JANUARY 1 – SEPTEMBER 30, 2018    CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME +--------------------+------+------+-------+------+------+-------+-----+|EUR thousand  |7-9/20|7-9/20|Change,|1-9/20|1-9/20|Change,|1-12/|| |18  |17  |% |18 |17 |%  |2017 |+--------------------+------+------+-------+------+------+-------+-----+|NET SALES  | 33| 35| -5.1 | 104| 109| -4.5 | 149|| | 991| 827 | | 929 | 924 | | 167|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Cost of sales | -16| -16| -5.1 | -52| -56| -7.4 | -75|| | 101 | 966 | | 595 | 804 | | 891|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|GROSS PROFIT | 17| 18| -5.2 | 52| 53| -1.5 | 73|| | 890 | 862 | | 335 | 120 | | 276|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Sales and marketing | -10| -7| 37.8 | -31| -26| 17.2 | -36|| | 759 | 809 | | 072 | 508| | 455|+--------------------+------+------+-------+------+------+-------+-----+|Research and | -6| -6| 0.9 | -20| -22| -7.5 | -29||development | 599 | 539 | | 374 | 026| | 629|+--------------------+------+------+-------+------+------+-------+-----+|General and | -4| -3| 31.2 | -12| -9| 26.3 | -14||administration | 003 | 052 | | 185 | 645 | | 110|+--------------------+------+------+-------+------+------+-------+-----+|Total operating | -21| -17| 22.8 | -63| -58| 9.4 | -80||expenses | 361 | 400 | | 631 | 179| | 194|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Other operating | -316 | -257 | 22.7 | 13| -1| | -2||income and expenses | | | | 675 | 589 | | 593|+--------------------+------+------+-------+------+------+-------+-----+|OPERATING | -3|1 205 | |2 379 | -6| | -9||PROFIT/LOSS | 787 | | | | 648 | | 509|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Finance income and | -487 | -401 | 21.5 | -1| -1| 7.3 | -1||expenses | | | | 470 | 370 | | 719|+--------------------+------+------+-------+------+------+-------+-----+|Share of profit/loss| 0 | -117 |-100.0 | -153 | -995 | -84.6 | -1||of a joint venture | | | | | | | 048|+--------------------+------+------+-------+------+------+-------+-----+|PROFIT/LOSS BEFORE | -4| 688 | | 756 | -9| | -12||TAX | 274 | | | | 013 | | 276|+--------------------+------+------+-------+------+------+-------+-----+|Income tax |1 045 | 7 | | -3| 920 | | 752|| | | | | 314 | | | |+--------------------+------+------+-------+------+------+-------+-----+|PROFIT/LOSS FOR THE | -3| 694 | | -2| -8| 68.4 | -11||PERIOD | 229 | | | 558 | 093 | | 524|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Other comprehensive | | | | | | | ||income | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Other comprehensive | | | | | | | ||income that will not| | | | | | | ||be reclassified to | | | | | | | ||profit or loss | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Remeasurement of | 0 | -25 | | 18 | -87 | | 155||employee benefits | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Other comprehensive | | | | | | | ||income that may be | | | | | | | ||reclassified | | | | | | | ||subsequently to | | | | | | | ||profit or | | | | | | | ||loss | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Exchange differences| 350 | -1| |1 502 | -5| | -6||on translating | | 118 | | | 395 | | 743||foreign operations | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Income tax relating | -11 | 69 | | -60 | 255 | | 290||to components of | | | | | | | ||other comprehensive | | | | | | | ||income | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Cash flow hedges | -112 | 0 | | -76 | 0| | 0|+--------------------+------+------+-------+------+------+-------+-----+|Other comprehensive | 227 | -1| |1 384 | -5| | -6||income for the year | | 074 | | | 277 | | 299||net of tax | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|TOTAL COMPREHENSIVE | -3| -380 |-691.0 | -1| -13| 91.2 | -17||INCOME | 002 | | | 175 | 320 | | 823|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Profit/loss | | | | | | | ||attributable to:  | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Equity holders of | -3| 694 | | -2| -8| 68.4 | -11||the parent company | 229 | | | 558 | 093 | | 524|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Total comprehensive | | | | | | | ||income attributable | | | | | | | ||to: | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Equity holders of | -3| -380 |-691.0 | -1| -13| 91.2 | -17||the parent company | 002 | | | 175 | 320 | | 823|+--------------------+------+------+-------+------+------+-------+-----+| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|Earnings per share | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|undiluted, EUR |-0.22 | 0.05 | |-0.18 |-0.56 | 68.6 |-0.80|| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+|diluted, EUR |-0.22 | 0.05 | |-0.18 |-0.56 | 68.7 |-0.80|| | | | | | | | |+--------------------+------+------+-------+------+------+-------+-----+  CONSOLIDATED STATEMENT OF FINANCIAL POSITION +-------------------+---------------+---------------+----------+-------------+|EUR thousand  |Sept. 30, 2018 |Sept. 30, 2017 |Change, % |Dec. 31, 2017|+-------------------+---------------+---------------+----------+-------------+|ASSETS  | | | | |+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|Non-current assets | | | | |+-------------------+---------------+---------------+----------+-------------+|Intangible assets  | 45 299 | 48 980 | -7.5 | 49 039|+-------------------+---------------+---------------+----------+-------------+|Goodwill  | 79 129 | 92 826 | -14.8 | 91 961|+-------------------+---------------+---------------+----------+-------------+|Tangible assets  | 923 | 1 480 | -37.6 | 1 291|+-------------------+---------------+---------------+----------+-------------+|Share of investment| 0 | 207 | | 153||in a joint venture | | | | |+-------------------+---------------+---------------+----------+-------------+|Non-current | 38 | 38 | | 38 ||financial assets  | | | | |+-------------------+---------------+---------------+----------+-------------+|Trade and other | 3 530 | 3 109 | 13.6 | 3 617||receivables  | | | | |+-------------------+---------------+---------------+----------+-------------+|Contract assets | 1 404 | 2 651 | -47.0 | 2 450|+-------------------+---------------+---------------+----------+-------------+|Deferred tax | 7 821 | 10 982 | -28.8 | 10 362||assets  | | | | |+-------------------+---------------+---------------+----------+-------------+|Non-current assets | 138 144 | 160 271 | -13.8 | 158 910|+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|Current assets  | | | | |+-------------------+---------------+---------------+----------+-------------+|Trade receivables  | 24 617 | 23 839 | 3.3 | 24 534|+-------------------+---------------+---------------+----------+-------------+|Other receivables  | 6 820 | 6 901 | -1.2 | 6 880|+-------------------+---------------+---------------+----------+-------------+|Contract assets | 3 076 | 3 536 | -13.0 | 3 446|+-------------------+---------------+---------------+----------+-------------+|Income tax | 361 | 616 | -41.4 | 358||receivables  | | | | |+-------------------+---------------+---------------+----------+-------------+|Cash and cash | 46 235 | 25 275 | 82.9 | 20 683||equivalents  | | | | |+-------------------+---------------+---------------+----------+-------------+|Current assets  | 81 108 | 60 167 | 35.5 | 55 900|+-------------------+---------------+---------------+----------+-------------+| |   |   | | |+-------------------+---------------+---------------+----------+-------------+|ASSETS  | 219 252 | 220 439 | -0.5 | 214 811|+-------------------+---------------+---------------+----------+-------------+  CONSOLIDATED STATEMENT OF FINANCIAL POSITION +-------------------+---------------+---------------+----------+-------------+|EUR thousand |Sept. 30, 2018 |Sept. 30, 2017 |Change, % |Dec. 31, 2017|+-------------------+---------------+---------------+----------+-------------+|EQUITY AND | | | | ||LIABILITIES  | | | | |+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|Shareholders' | | | | ||equity  | | | | |+-------------------+---------------+---------------+----------+-------------+|Share capital  | 3 528 | 3 528 | | 3 528 |+-------------------+---------------+---------------+----------+-------------+|Share premium | 1 187 | 1 187 | | 1 187 ||account  | | | | |+-------------------+---------------+---------------+----------+-------------+|Treasury shares  | -638 | -841 | -24.2 | -841|+-------------------+---------------+---------------+----------+-------------+|Invested | 110 928 | 111 132 | -0.2 | 111 132||unrestricted equity| | | | ||fund   | | | | |+-------------------+---------------+---------------+----------+-------------+|Other reserves | 516 | 540 | -4.4 | 592|+-------------------+---------------+---------------+----------+-------------+|Translation | -9 781 | -9 917 | -1.4 | -11 229||differences  | | | | |+-------------------+---------------+---------------+----------+-------------+|Retained earnings  | 8 868 | 12 014 | -26.2 | 8 920|+-------------------+---------------+---------------+----------+-------------+|Shareholders' | 114 609 | 117 643 | -2.6 | 113 289||equity  | | | | |+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|Non-current | | | | ||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Deferred tax | 4 734 | 5 647 | -16.2 | 4 569||liability  | | | | |+-------------------+---------------+---------------+----------+-------------+|Interest-bearing | 40 113 | 47 286 | -15.2 | 47 286||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Other non-current | 127 | 1 319 | -90.4 | 1 693||financial | | | | ||liabilities | | | | |+-------------------+---------------+---------------+----------+-------------+|Contract | 2 996 | 3 005 | -0.3 | 2 374||liabilities | | | | |+-------------------+---------------+---------------+----------+-------------+|Liabilities from | 361 | 616 | -41.4 | 434||employee benefits  | | | | |+-------------------+---------------+---------------+----------+-------------+|Non-current | 48 331 | 57 874 | -16.5| 56 357||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|Current | | | | ||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Interest-bearing | 17 089 | 1 996 | 756.2 | 1 996||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Trade payables and | 23 276 | 24 635 | -5.5 | 31 409||other liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Contract | 15 575 | 16 918 | -7.9 | 10 656||liabilities | | | | |+-------------------+---------------+---------------+----------+-------------+|Income tax | 109 | 132 | -17.3 | 177||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+|Current provisions | 264 | 1 241 | -78.7 | 928|+-------------------+---------------+---------------+----------+-------------+|Current | 56 313 | 44 922 | 25.4| 45 165||liabilities  | | | | |+-------------------+---------------+---------------+----------+-------------+| | | | | |+-------------------+---------------+---------------+----------+-------------+|EQUITY AND | 219 252 | 220 439 | -0.5| 214 811 ||LIABILITIES  | | | | |+-------------------+---------------+---------------+----------+-------------+  CONSOLIDATED STATEMENT OF CHANGES IN EQUITY   +-------------+-------+--------+--------+-----------+---------+------------+---------+------+|EUR thousand |Share |Share |Treasury|Inv. un |Other |Translation |Retained |Total || |capital|premium |shares  |-restricted|reserves |differences |earnings | || | |account | | | | | | || | | | | | | | | || | | | |equity  | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528 | 1 187 | -841 | 111 131 | 592 | -11 229 | 8 920 | 113||EQUITY | | | | | | | | 289 ||Jan. 1, 2018 | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Effect of | | | | | | | -128 | -128 ||IFRS 9 | | | | | | | | ||restatement –| | | | | | | | ||bad debt | | | | | | | | ||provision | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Effect of | | | | | | | 1 043 |1 043 ||IFRS 2 | | | | | | | | ||amendment | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528 | 1 187| -841| 111 131| 592 | -11 229 | 9 835| 114||EQUITY | | | | | | | | 204 ||Jan. 1, 2018 | | | | | | | | ||(restated)  | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Comprehensive| | | | | | 1 442  | -2 564 | -1||income | | | | | | | | 123 |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Share based | | | 204| -204| | | 1 580 |1 580 ||payments  | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Defined | | | | | | 6| 18| 24||benefit plan | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Cash flow | | | | | -76| | | -76||hedges | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528| 1 187| -638| 110 928| 516| -9 781| 8 868| 114||EQUITY | | | | | | | | 609||Sept. 30, | | | | | | | | ||2018  | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+| | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+| | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+| | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|EUR thousand |Share |Share |Treasury|Inv. un |Other |Translation |Retained |Total || |capital|premium |shares  |-restricted|reserves |differences |earnings | || |  |account | | | | | | || | | | | | | | | || | | | |equity  | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528 | 1 187 | -1 043 | 111 333 | 540 | -4 863 | 22 182| 132||EQUITY | | | | | | | | 864||Jan. 1, 2017 | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Effect of | | | | | | 86| -2 495|-2 409||IFRS 15 | | | | | | | | ||restatement | | | | | | | | ||to revenue | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528 | 1 187| -1 043| 111 333| 540| -4 776 | 19 687| 130||EQUITY | | | | | | | | 455||Jan. 1, 2017 | | | | | | | | ||(restated) | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Effect of | | | | | | | 7| 7||IFRS 15 | | | | | | | | ||restatement | | | | | | | | ||to revenue | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Comprehensive| | | | | | -5 140| -8 100| -13||income  | | | | | | | | 240|+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Share based | | | 202 | -202 | | | 507| 507||payments  | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|Defined | | | | | | | -87| -87||benefit plan | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+|SHAREHOLDERS’| 3 528| 1 187| -841| 111 132| 540| -9 917| 12 014| 117||EQUITY | | | | | | | | 643||Sept. 30, | | | | | | | | ||2017 | | | | | | | | ||(restated)  | | | | | | | | |+-------------+-------+--------+--------+-----------+---------+------------+---------+------+ CONSOLIDATED STATEMENT OF CASH FLOWS  +-----------------------------+--------+--------+--------+--------+---------+|EUR thousand |7-9/2018|7-9/2017|1-9/2018|1-9/2017|1-12/2017|+-----------------------------+--------+--------+--------+--------+---------+|Cash flows from operating | | | | | ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Profit/loss for the period  | -3 229| 694| -2 558| -8 093| -11 524 |+-----------------------------+--------+--------+--------+--------+---------+|Adjustments for profit:  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Depreciation and amortisation| 2 723| 2 300| 8 095| 7 361| 10 108 |+-----------------------------+--------+--------+--------+--------+---------+|Share of profit/loss of a | 0| 117| 153| 995| 1 048 ||joint venture | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Gain (-) / loss (+) on | 0| 0| -16 276| 0| 0 ||disposals of assets | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Unrealised foreign exchange | 176| 158| 141| 773| 764 ||gains and losses | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Financial income and expenses| 354| 207| 1 276| 621| 1 002 |+-----------------------------+--------+--------+--------+--------+---------+|Tax on income from operations| -1 045| -7| 3 314| -920| -752 |+-----------------------------+--------+--------+--------+--------+---------+|Other adjustments | 542| -60| 1 271| 412| 642 |+-----------------------------+--------+--------+--------+--------+---------+|Total adjustments | 2 750| 2 715| -2 026| 9 243| 12 812 |+-----------------------------+--------+--------+--------+--------+---------+|Changes in working capital:  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Increase (-) / decrease (+) | 4 651| -2 030| 1 860| -2 351| -3 123||in trade and other | | | | | ||receivables | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Increase (+) / decrease (-) | -5 490| -4 805| 1 932| 4 958| 4 766||in trade and other payables | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Increase (+) / decrease (-) | -618| -979| -683| -3 831| -4 141||in provisions | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Total changes in working | -1 457| -7 813| 3 108| -1 224| -2 499||capital | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Financial items in operating | -505| -163| -1 378| -579| -958 ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Income taxes paid (-) / | -235| -273| -567| -1 553| -1 832 ||received (+)  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash flows from operating | -2 676| -4 840| -3 421| -2 206| -4 001 ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash flows used in investing | | | | | ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Purchase of tangible and | -2 174| -2 453| -8 689| -9 714| -12 485 ||intangible assets  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Net proceeds from sale of | 686| 0| 29 641| 0| 0 ||tangible and intangible | | | | | ||assets* | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash flows from investing | -1 489| -2 453| 20 952| -9 714| -12 485 ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash flows from financing | | | | | ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Repayment of current | -998| -20 998| -1 996| -27 998| -27 998 ||borrowings | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Proceeds from non-current | 9 923| 30 000| 9 923| 30 000| 30 000 ||borrowings  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash flows from financing | 8 925| 9 002| 7 927| 2 002| 2 002 ||activities  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Net change in cash and cash | 4 760| 1 708| 25 458| -9 918| -14 484 ||equivalents  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+| | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash and cash equivalents at | 41 413| 23 610| 20 683| 35 755| 35 755 ||the beginning of period  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Net foreign exchange | 63| -43| 94| -562| -588 ||difference  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+|Cash and cash equivalents at | 46 235| 25 275| 46 235| 25 275| 20 683 ||the end of period  | | | | | |+-----------------------------+--------+--------+--------+--------+---------+ *Includes proceeds and disbursements directly attributable to the divestments made in Q1 2018 ACCOUNTING PRINCIPLES This interim report has been prepared in accordance with IAS 34. The same accounting principles have been followed as in the annual financial statements except for the adoption of new standards and amendments effective as of January 1, 2018.  Preparation of financial statements in accordance with IFRS requires Basware’s management to make estimates and assumptions that have an effect on the amount of assets and liabilities on the balance sheet at the closing date as well as the amounts of income and expenses for the financial period. In addition, the management must exercise its judgment regarding the application of accounting policies. Since the estimates and assumptions are based on the views at the date of the financial statements, they include risks and uncertainties. The actual results may differ from the estimates and assumptions. The amounts presented in the income statement and balance sheet are Group figures. The amounts presented in the release are rounded, so the sum of individual figures may differ from the sum reported. Percentage changes for net figures are shown on an absolute basis. New and amended IFRS standards Basware has adopted IFRS 15 Revenue from Contracts with Customers as of January 1, 2018 (mandatory application), with full retrospective application. Revenue for different revenue types are recognized over time except for licenses which is recognized at a point in time. As the new standard affects only a minority of the Group’s customer contracts, the impact of the standard on the Group’s 2017 restated total revenue is not material, being EUR -74 thousand in total. However, as a result of the application of the standard, part of Cloud revenue will be recognized later and part of Non-cloud revenue earlier compared to the previous revenue recognition standard. Due to this, 2017 restated IFRS 15 Cloud revenue is EUR 1 667 thousand lower and Non-cloud revenue EUR 1 596 thousand higher compared to the reported revenue. In connection with the IFRS 15 application, the Group has made certain changes in the revenue allocation between Cloud and Non-cloud. Revenues related to dedicated customer services as part of SaaS subscriptions will now be allocated as Cloud revenues. This reallocation does not impact total Group revenue. However, for 2017 a total of EUR 2 830 thousand of revenues reported as part of Non-cloud is now recorded as Cloud revenue. The total net impact of IFRS 15 restatements and the changes in revenue allocation between Cloud and Non-cloud for full year 2017 is EUR -74 thousand on Group level, with Cloud revenue increasing EUR 1 163 thousand and Non-cloud revenue decreasing EUR 1 236 thousand. As a result, the share of Cloud revenue of the Group’s total 2017 revenue has increased slightly. Net sales by revenue type after IFRS 15 restatements and changes in revenue allocation +--------------------------+-------+-------+-------+------+|Net sales by revenue type | 1-3/| 4-6/| 7-9/|10-12/|+--------------------------+-------+-------+-------+------+|EUR thousand  | 2017| 2017| 2017| 2017|+--------------------------+-------+-------+-------+------+|Cloud Revenue | | | | |+--------------------------+-------+-------+-------+------+|SaaS | 8 002| 8 372| 8 903| 9 532|+--------------------------+-------+-------+-------+------+|Transaction services  | 9 471| 9 573| 9 875|10 770|+--------------------------+-------+-------+-------+------+|Other cloud revenue  | 1 444| 1 807| 1 274| 1 310|+--------------------------+-------+-------+-------+------+|Cloud Revenue total |18 917 |19 752 |20 052 |21 612|+--------------------------+-------+-------+-------+------+|Non-Cloud Revenue  | | | | |+--------------------------+-------+-------+-------+------+|Maintenance | 9 849 | 9 357 | 8 965 | 8 856|+--------------------------+-------+-------+-------+------+|License sales | 900 | 1 120 | 790 | 1 383|+--------------------------+-------+-------+-------+------+|Consulting services | 7 071 | 7 165 | 6 063 | 7 447|+--------------------------+-------+-------+-------+------+|Other non-cloud revenue | 73 | -105 | -42 | -54|+--------------------------+-------+-------+-------+------+|Non-Cloud Revenue total |17 893 |17 536 |15 776 |17 631|+--------------------------+-------+-------+-------+------+|Group Total | 36 810| 37 287| 35 827|39 243|+--------------------------+-------+-------+-------+------+ IFRS 15 restatements increased the Group’s non-current assets on December 31, 2017 by EUR 2 082 thousand, current assets by EUR 1 181 thousand, non-current liabilities by EUR 2 374 thousand, current liabilities by EUR 3 525 thousand, and decreased equity by EUR 2 636 thousand. IFRS 15 restatements had no material impact on basic or diluted EPS, and no impact on cash flows. IFRS 15 restatements and the changes in revenue allocation between Cloud and Non-cloud also affect the subscription annual recurring revenue gross order intake reported in 2017. The restated numbers are outlined below also adjusting for the effect of the divested businesses. The annual recurring revenue gross order intake related to the divested businesses was EUR 1.3 million in 2017. Purchase-to-pay subscription annual recurring revenue gross order intake after IFRS 15 restatements and changes in revenue allocation, and adjusting for divestments:  +-------------------+-----+-----+-----+-------+-----+-----+-----+|Annual recurring | 7-9/| 4-6/|1-3/ |10-12/ |7-9/ | 4-6/| 1-3/||revenue gross order| | | | | | | ||intake  | | | | | | | |+-------------------+-----+-----+-----+-------+-----+-----+-----+|EUR thousand  | 2018| 2018|2018 | 2017 |2017 | 2017| 2017|+-------------------+-----+-----+-----+-------+-----+-----+-----+|Purchase-to-Pay |3 130|3 449|2 742| 2 943|1 988|3 809|2 506||subscriptions   | | | | | | | |+-------------------+-----+-----+-----+-------+-----+-----+-----+ Basware has adopted IFRS 9 Financial Instruments (effective date January 1, 2018), which replaces the previous IAS 39 Financial Instruments: Recognition and Measurement. The main impact of IFRS 9 concerns the timing of recording expected credit losses. IFRS 9 has not been applied retrospectively. The Group has adopted the amendment to IFRS 2 Share-based Payment (effective date January 1, 2018). The amendment concerns incentive schemes with “net settlement” features to cover withholding tax obligations and where the employer has an obligation to withhold tax from the received benefit of the share-based payment in the country in question. From 2018 onwards, a compensation cost pursuant to IFRS 2 will be recognized for such payments, based on the entire scheme being an equity-settled payment. DEFINITION OF ALTERNATIVE PERFORMANCE MEASURES Basware presents the following financial measures to supplement its consolidated financial statements which are prepared in accordance with IFRS. These measures are designed to measure growth and provide insight into the company’s underlying operational performance. The Group has applied the guidance from the European Securities and Markets Authority (ESMA) on Alternative Performance Measures which is applicable as of July 3, 2016, and defined alternative performance measures as follows: Cloud revenue includes net sales from SaaS and other subscription types, transaction services and financing services excluding alliance fees. Non-cloud revenue includes net sales from licences, maintenance and consulting, as well as alliance fees. Organic revenue growth is calculated by comparing net sales between comparison periods in constant currencies excluding alliance fees as well as net sales from acquisitions or disposals that have taken place in the past 12 months. Net sales in constant currencies is calculated by eliminating the impact of exchange rate fluctuations by calculating the net sales for the current period by using the comparable period’s exchange rates. Gross investments are total investments made to non-current assets including acquisitions and capitalized research and development costs. Other capitalized expenditure consists of investments in property, plant & equipment and intangible assets excluding acquisitions and capitalized research and development costs. EBITDA is calculated as operating profit/loss plus depreciation and amortization. Adjusted EBITDA is calculated from EBITDA excluding any adjustments related to alliance fees, acquisitions and disposals, restructuring and efficiency measures, impairment losses and litigation fees and settlements. Adjusted operating profit/loss (Adjusted EBIT) is calculated from operating profit/loss excluding any adjustments related to alliance fees, acquisitions and disposals, restructuring and efficiency measures, impairment losses and litigation fees and settlements. Adjusted earnings per share (Adjusted EPS) is calculated by excluding from the profit/loss any adjustments related to alliance fees, acquisitions and disposals, restructuring and efficiency measures, impairment losses and litigation fees and settlements. Annual recurring revenue gross order intake is calculated by summing the total order intake in the period expressed as an annual contract value. For cloud order intake this includes all SaaS and Network recurring revenues including transaction revenues. For the subscription order intake this includes SaaS and other purchase-to-pay subscription types and excludes transaction revenue. Gross order intake covers new cloud customers, add-ons and renewal uplifts but excludes churn. There will be a time lag before this order intake is visible in net sales. Historical quarterly order intake for cloud and purchase-to-pay subscriptions is shown below: +-------------------+-----+-----+-----+-------+-----+-----+-----+|Annual recurring | 7-9/| 4-6/|1-3/ |10-12/ |7-9/ |4-6/ |1-3/ ||revenue gross order| | | | | | | ||intake | | | | | | | |+-------------------+-----+-----+-----+-------+-----+-----+-----+|EUR thousand | 2018| 2018|2018 | 2017 |2017 | 2017| 2017|+-------------------+-----+-----+-----+-------+-----+-----+-----+|Cloud |4 483|6 392|4 657| 4 948|3 475|5 496|4 024|+-------------------+-----+-----+-----+-------+-----+-----+-----+|Purchase-to-Pay |3 130|3 449|2 742| 2 943|1 988|3 809|2 506||subscriptions | | | | | | | |+-------------------+-----+-----+-----+-------+-----+-----+-----+ Adjusted operating profit/loss and adjusted EBITDA +--------------------------+-----+------+-------+------+------+---------+------+| |7-9/ | 7-9/ |Change,| 1-9/ | 1-9/ |Change,  |1-12/ || | | |  | | | | |+--------------------------+-----+------+-------+------+------+---------+------+|EUR thousand     |2018 | 2017 | % | 2018 | 2017 | % | 2017 |+--------------------------+-----+------+-------+------+------+---------+------+|Operating profit/loss | -3| 1 205| | 2 379|-6 648| |-9 509|| | 787| | | | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Adjustments: | | | | | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Acquisition, disposal and |-553 | | | -17| -133| | -133||restructuring income (-) | | | | 758 | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Acquisition, disposal and | 625 | 108| 478.7 |2 707 | 246| | 416||restructuring expenses (+)| | | | | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Efficiency related | 115 | -65 | |1 039 |1 445 | -28.1| 2 023||expenses | | | | | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Settlements | 0 | 114| | 0 | 114| | 389|+--------------------------+-----+------+-------+------+------+---------+------+|Total adjustments | 187 | 156| 19.9| -14| 1 672| | 2 695|| | | | | 012 | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Adjusted operating | -3|1 361 | | -11|-4 976| -133.8|-6 814||profit/loss  | 600 | | | 633 | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Depreciation and | -2| -2| 18.4 | -8|-7 361| 10.0|10 108||amortization | 723 | 300| | 095 | | | |+--------------------------+-----+------+-------+------+------+---------+------+|Adjusted EBITDA |-877 | 3 661| | -3| 2 386| | 3 294|| | | | | 538 | | | |+--------------------------+-----+------+-------+------+------+---------+------+ DIVESTMENTS Basware signed an agreement on February 2, 2018 to sell its Financial Performance Solutions and Banking businesses to Verdane Capital. The divestments were completed on February 28, 2018 and starting from March 1, 2018 Basware Group has not consolidated these businesses in its consolidated financial statements. In 2017, the combined net sales of Financial Performance Solutions and Banking businesses were approximately EUR 15 million and combined direct costs approximately EUR 7 million. The combined sale price of the two businesses was EUR 35.0 million, and after purchase price adjustments related mainly to net working capital, the net cash proceeds from the divestments are estimated to be EUR 30.1 million. In addition, EUR 14.0 million of consolidated goodwill has been allocated to the divested businesses, and EUR 4.8 million of fixed assets, mainly capitalized research and development expenses, was written down. In total, the Group recognized a gain on sale of assets amounting to EUR 16.3 million in the first quarter as a result of the divestments. Tax impact of the divestments will be covered by deferred tax assets recognized for accumulated tax losses. SEGMENT REPORTING Basware reports one operating segment. The reported segment is comprised of the entire Group, and the segment figures are consistent with the Group figures. INFORMATION ON PRODUCTS AND SERVICES Basware reports revenues by type. Cloud revenue includes SaaS, Transaction services (consisting of e-invoicing, scan and capture services, printing services and network start-up fees) and Other cloud revenue. Non-cloud revenue includes Maintenance, License sales, Consulting services (consisting of professional services and customer services management) and Other non-cloud revenue. +-------------+-------+-------+---------+--------+--------+---------+-------+|Net sales by | 7-9/ | 7-9/ |Change,  | 1-9/ | 1-9/ |Change,  | 1-12/ ||revenue type | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|EUR thousand | 2018 | 2017 | % | 2018 | 2017 | % | 2017 |+-------------+-------+-------+---------+--------+--------+---------+-------+|Cloud Revenue| | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|SaaS |10 177 | 8 903 | 14.3 | 29 416 | 25 276 | 16.4 |34 808 |+-------------+-------+-------+---------+--------+--------+---------+-------+|Transaction |11 029 | 9 875 | 11.7 | 32 405 | 28 919 | 12.1 |39 689 ||services  | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Other cloud | 1 233 | 1 274 | -3.2 | 3 744 | 4 525 | -17.3 | 5 835 ||revenue  | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Cloud Revenue|22 440 |20 052 | 11.9 | 65 566 | 58 720 | 11.7 |80 332 ||total | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Non-Cloud | | | | | | | ||Revenue  | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Maintenance | 6 150 | 8 965 | -31.4 | 20 212 | 28 170 | -28.3 |37 026 |+-------------+-------+-------+---------+--------+--------+---------+-------+|License sales| 401 | 790 | -49.3 | 1 589 | 2 810 | -43.4 | 4 192 |+-------------+-------+-------+---------+--------+--------+---------+-------+|Consulting | 4 966 | 6 063 | -18.1 | 17 504 | 20 299 | -13.8 |27 746 ||services | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Other non | 34 | -42 | | 59 | -74 | | -129 ||-cloud | | | | | | | ||revenue | | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Non-Cloud |11 551 |15 776 | -26.8 | 39 364 | 51 204 | -23.1 |68 836 ||Revenue total| | | | | | | |+-------------+-------+-------+---------+--------+--------+---------+-------+|Group Total |33 991 |35 827 | -5.1 |104 929 |109 924 | -4.5 |149 167|+-------------+-------+-------+---------+--------+--------+---------+-------+ GEOGRAPHICAL INFORMATION From Q1 2018, the company has changed the presentation of its geographical information. Basware reports geographical areas Americas, Europe, Nordics and APAC. Americas includes business operations in North and South America. Europe includes operations in Europe and Russia, excluding the Nordic countries (Denmark, Finland, Norway and Sweden), which are reported separately. APAC includes operations in Asia and the Pacific region. +----------------+------+-------+---------+-------+--------+---------+-------+|Net sales by the| 7-9/ | 7-9/ |Change,  | 1-9/ | 1-9/ |Change,  | 1-12/ ||location of | | | | | | | ||customer  | | | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+|EUR thousand  | 2018 | 2017 | % | 2018 | 2017 | % | 2017 |+----------------+------+-------+---------+-------+--------+---------+-------+|Americas  |6 954 | 5 945| 17.0 | 19 661| 18 307 | 7.4| 24 403|| | | | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+|Europe   | 11|11 529 | 1.3 | 35 268| 33 361 | 5.7| 45 401|| | 673 | | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+|Nordics  | 13|16 410 | -17.6| 44 771| 52 608 | -14.9| 71 818|| | 526| | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+|APAC  |1 838 | 1 944 | -5.5 | 5 228| 5 648 | -7.4| 7 545|| | | | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+|Group total  | 33| 35 827| -5.1 |104 929|109 924 | -4.5|149 167|| | 991 | | | | | | |+----------------+------+-------+---------+-------+--------+---------+-------+ +---------------------+-----+------+---------+-----+-----+-------+------+|Personnel   |7-9/ | 7-9/ |Change,  | 1-9/| 1-9/|Change,|1-12/ |+---------------------+-----+------+---------+-----+-----+-------+------+|Employed, on average |2018 | 2017 | % | 2018| 2017| % | 2017|+---------------------+-----+------+---------+-----+-----+-------+------+|Americas  | 138 | 130 | 6.2 | 137| 131 | 4.8 | 131|+---------------------+-----+------+---------+-----+-----+-------+------+|Europe   | 457 | 463 | -1.2 | 461| 479| -3.8 | 475|+---------------------+-----+------+---------+-----+-----+-------+------+|Nordics  | 473 | 555 | -14.7 | 497| 562| -11.6 | 558|+---------------------+-----+------+---------+-----+-----+-------+------+|APAC  | 658| 678| -2.9 | 673| 668| 0.8 | 673|+---------------------+-----+------+---------+-----+-----+-------+------+|Group total  |1 727|1 826 | -5.4 |1 768|1 840| -3.9% | 1 838|+---------------------+-----+------+---------+-----+-----+-------+------+ FAIR VALUES OF FINANCIAL ASSETS AND LIABILITIES +-----------------------------+------+-----+------+------+----------+----------+| |Sept. |Sept. |Dec. 31, 2017 || |30, |30, | || |2018  |2017  | |+-----------------------------+------+-----+------+------+----------+----------+|EUR thousand  |Book |Fair |Book |Fair |Book value|Fair value|| |value |value|value |value | | |+-----------------------------+------+-----+------+------+----------+----------+|Financial assets  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Non-current: | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Non-current financial assets | 38 | 38| 38 | 38 | 38| 38|+-----------------------------+------+-----+------+------+----------+----------+|Non-current trade and other | 911 | 911|1 498 |1 498 | 1 400| 1 400||receivables | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Current: | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Current trade receivables | 24| 24| 23| 23| 24 534| 24 534|| | 617 | 617| 839 | 839 | | |+-----------------------------+------+-----+------+------+----------+----------+|Current other receivables | 165| 165| 146 | 146 | 182| 182|+-----------------------------+------+-----+------+------+----------+----------+|Cash and cash equivalents | 46| 46| 25| 25| 20 683| 20 683|| | 235 | 235| 275 | 275 | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Financial liabilities  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Non-current: | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Financial liabilities valued | | | | | | ||at amortized acquisition | | | | | | ||cost:  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Loans from financial | 40| 40| 47| 47| 47 286| 47 286||institutions, interest | 113 | 113 | 286 | 286 | | ||-bearing  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+| | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Current:  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Loans from financial | 17| 17|1 996 |1 996 | 1 996| 1 996||institutions, interest | 096 | 096| | | | ||-bearing  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+|Trade payables and other |9 952 |9 952|8 262 |8 262 | 12 532| 12 532||liabilities  | | | | | | |+-----------------------------+------+-----+------+------+----------+----------+ Financial liabilities arising from derivative financial instruments of EUR 76 thousand are classified as level 2 and unquoted equity shares of EUR 38 thousand as level 3 in the fair value measurement hierarchy. COMMITMENTS AND CONTINGENT LIABILITIES +-----------------------------+--------------+--------------+-------------+|EUR thousand  |Sept. 30, 2018|Sept. 30, 2017|Dec. 31, 2017|+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Own guarantees  | | | |+-----------------------------+--------------+--------------+-------------+|Business mortgages of own | 0| 1 200| 1 200||debts | | | |+-----------------------------+--------------+--------------+-------------+|Guarantees  | 605| 218| 202|+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Commitments on behalf of | | | ||subsidiaries and group | | | ||companies  | | | |+-----------------------------+--------------+--------------+-------------+|Guarantees | 327| 100| 100|+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Other own guarantees  | | | |+-----------------------------+--------------+--------------+-------------+|Lease liabilities  | | | |+-----------------------------+--------------+--------------+-------------+|Current lease liabilities  | 930| 864| 850|+-----------------------------+--------------+--------------+-------------+|Lease liabilities maturing in| 909| 698| 847||1–5 years  | | | |+-----------------------------+--------------+--------------+-------------+|Total  | 1 839| 1 562| 1 697|+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Other rental liabilities  | | | |+-----------------------------+--------------+--------------+-------------+|Current rental liabilities  | 6 554 | 5 753 | 6 424|+-----------------------------+--------------+--------------+-------------+|Rental liabilities maturing | 8 749 | 10 880 | 11 368||in 1–5 years  | | | |+-----------------------------+--------------+--------------+-------------+|Rental liabilities maturing | 33 | 230 | 180||later  | | | |+-----------------------------+--------------+--------------+-------------+|Total  | 15 336| 16 863| 17 973|+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Other own contingent | 17 174| 18 425| 19 670||liabilities, total  | | | |+-----------------------------+--------------+--------------+-------------+| | | | |+-----------------------------+--------------+--------------+-------------+|Total commitments and | 18 106| 19 943| 21 172||contingent liabilities  | | | |+-----------------------------+--------------+--------------+-------------+ RELATED PARTY TRANSACTIONS Loans from related parties +--------------------------+---------------+--------------+-------------+|EUR thousand  |Sept. 30, 2018 |Sept. 30, 2017|Dec. 31, 2017|+--------------------------+---------------+--------------+-------------+|Arrowgrass Master Fund LTD| 10 000 | 0 | 10 000|+--------------------------+---------------+--------------+-------------+ Loans from related parties includes the share of Arrowgrass Master Fund LTD of the Group’s term loan financing signed in September 2017 and totaling EUR 30 million. The other lenders are Nordea Bank AB, OP Corporate Bank Plc and Ilmarinen Mutual Pension Insurance Company. Loans from related parties have been provided at commercial interest rates.  GROUP QUARTERLY INCOME STATEMENT +------------------+-----+-----+--------+----------+--------+--------+--------+|EUR thousand  |7-9/2|4-6/2|1-3/2018|10-12/2017|7-9/2017|4-6/2017|1-3/2017|| |018 |018 | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|NET SALES  | 33| 34| 35 969| 39 243 | 35 827 | 37 287 | 36 810 || | 991 | 969| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Cost of sales  | -16| -18|-17 913 | -19 087 |-16 966 |-19 363 |-20 476 || | 101 | 580| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|GROSS PROFIT/LOSS | 17| 16| 18 056 | 20 156 | 18 862 | 17 924 | 16 334 || | 890 | 389| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Sales and | -10| -10| -9 879 | -9 947| -7 809| -9 304| -9 395||Marketing  | 759| 434| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Research and | -6| -6| -6 811 | -7 603| -6 539| -7 657| -7 830||Development  | 599| 964| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|General and | -4| -4| -3 868 | -4 465| -3 052| -3 335| -3 257||Administration  | 003| 315| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Total operating | -21| -21|-20 558 | -22 015| -17 400| -20 296| -20 483||expenses  | 361| 712| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Other operating | -316| -1| 14 997 | -1 003| -257| -397| -934||income and | | 006| | | | | ||expenses  | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|OPERATING | -3| -6| 12 495 | -2 862| 1 205| -2 769| -5 084||PROFIT/LOSS  | 787| 329| | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|% of net sales  | | | 34.7 %| | 3.4 %| | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Finance income and| -487|-382 | -600| -349 | -401 | -457 | -512 ||expenses  | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Share of results | 0| 0 | -153| -53 | -117 | -396 | -482 ||of a joint | | | | | | | ||venture  | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Profit/loss before| -4| -6| 11 741| -3 264 | 688 | -3 623 | -6 077 ||tax  | 274| 712 | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|% of net sales  | | | 32.6 %| | 1.9 % | | |+------------------+-----+-----+--------+----------+--------+--------+--------+| | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|Income taxes  |1 045| 966 | -5 325| -168 | 7 | 207 | 706 || | | | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|PROFIT/LOSS FOR | -3| -5| 6 416| -3 431 | 694 | -3 416 | -5 371 ||THE PERIOD  | 229| 746 | | | | | |+------------------+-----+-----+--------+----------+--------+--------+--------+|% of net sales  | | | 17.8 %| | 1.9 % | | |+------------------+-----+-----+--------+----------+--------+--------+--------+ GROUP KEY INDICATORS  +----------------------------------------------+---------+---------+----------+|EUR thousand |1-9/2018 |1-9/2017 |1-12/2017 |+----------------------------------------------+---------+---------+----------+|Net sales  | 104 929 | 109 924 | 149 167 |+----------------------------------------------+---------+---------+----------+|Growth of net sales, %  | -4.5 % | 1.4 %* | 0.4 %* |+----------------------------------------------+---------+---------+----------+|Organic revenue growth | 5.8 %| 2.2 %*| 1.5 %*|+----------------------------------------------+---------+---------+----------+|EBITDA  | 10 474| 714 | 599 |+----------------------------------------------+---------+---------+----------+|% of net sales | 10.0 %| 0.6 % | 0.4 % |+----------------------------------------------+---------+---------+----------+|Adjusted EBITDA | -3 538| 2 386| 3 294|+----------------------------------------------+---------+---------+----------+|% of net sales  | | 2.2 %| 2.2 % |+----------------------------------------------+---------+---------+----------+|Operating profit/loss  | 2 379| -6 648 | -9 509 |+----------------------------------------------+---------+---------+----------+|% of net sales | 2.3 % | | |+----------------------------------------------+---------+---------+----------+|Adjusted operating profit/loss | -11 633| -4 976| -6 814 |+----------------------------------------------+---------+---------+----------+|% of net sales | | | |+----------------------------------------------+---------+---------+----------+|Profit/loss before tax  | 756 | -9 013 | -12 276 |+----------------------------------------------+---------+---------+----------+|% of net sales  | 0,7 % | | |+----------------------------------------------+---------+---------+----------+|Profit/loss for the period  | -2 558 | -8 093 | -11 524 |+----------------------------------------------+---------+---------+----------+|% of net sales  | | | |+----------------------------------------------+---------+---------+----------+| | | | |+----------------------------------------------+---------+---------+----------+|Return on equity, %  | -3.0 % | -8.6 % | -9.4 % |+----------------------------------------------+---------+---------+----------+|Return on investment, %  | 1.8 % | -5.4 % | -5.8 % |+----------------------------------------------+---------+---------+----------+|Interest-bearing liabilities  | 57 202 | 49 282 | 49 282 |+----------------------------------------------+---------+---------+----------+|Cash and cash equivalents  | 46 235 | 25 275 | 20 683 |+----------------------------------------------+---------+---------+----------+|Gearing, %  | 9.6 % | 20.4 % | 25.2 % |+----------------------------------------------+---------+---------+----------+|Equity ratio, %  | 52.3 % | 53.4 % | 52.7 % |+----------------------------------------------+---------+---------+----------+|Total assets  | 219 252 | 220 439 | 214 811 |+----------------------------------------------+---------+---------+----------+| | | | |+----------------------------------------------+---------+---------+----------+|Gross investments  | 8 656| 9 670 | 12 498 |+----------------------------------------------+---------+---------+----------+|% of net sales  | 8.2 % | 8.8 % | 8.4 % |+----------------------------------------------+---------+---------+----------+| | | | |+----------------------------------------------+---------+---------+----------+|R&D investments, expensed**  | 15 882| 18 285| 24 372|+----------------------------------------------+---------+---------+----------+|R&D costs, capitalised   | 6 643| 7 558| 9 879|+----------------------------------------------+---------+---------+----------+|R&D investments, total  | 22 526 | 25 844 | 34 251 |+----------------------------------------------+---------+---------+----------+|% of net sales  | 21.5 % | 23.5 % | 23.0 % |+----------------------------------------------+---------+---------+----------+| | | | |+----------------------------------------------+---------+---------+----------+|Depreciation and amortization | 8 095| 7 361| 10 108|+----------------------------------------------+---------+---------+----------+|Other capitalised expenditure  | 1 983| 2 113| 2 620|+----------------------------------------------+---------+---------+----------+| | | | |+----------------------------------------------+---------+---------+----------+|Personnel expenses  | 72 053 | 73 204 | 99 083 |+----------------------------------------------+---------+---------+----------+|Personnel on average during the period  | 1 768 | 1 840 | 1 838 |+----------------------------------------------+---------+---------+----------+|Personnel at end of period  | 1 736 | 1 827 | 1 829 |+----------------------------------------------+---------+---------+----------+|Change in personnel from comparison period, % | -5.0 % | -2.9 % | -3.2 % |+----------------------------------------------+---------+---------+----------+ * Based on IFRS15 restated revenue including reallocations for 2017 and reported revenue for 2016 ** R&D expenses excluding depreciation +----------------------+------------+------------+-----------+|Group Share | 1-9/2018| 1-9/2017 | 1-12/2017||Indicators  | | | |+----------------------+------------+------------+-----------+|Earnings per share, | -0.18| -0.56 | -0.80 ||undiluted (EUR) | | | |+----------------------+------------+------------+-----------+|Earnings per share, | -0.18 | -0.56| -0.80 ||diluted (EUR) | | | |+----------------------+------------+------------+-----------+|Adjusted earnings per | -1.15| -0.45| -0.61 ||share, undiluted (EUR)| | | |+----------------------+------------+------------+-----------+|Adjusted earnings per | -1.14| -0.45| -0.61 ||share, diluted (EUR) | | | |+----------------------+------------+------------+-----------+|Equity per share (EUR)| 7.94| 8.19 | 7.89 |+----------------------+------------+------------+-----------+|Price per earnings | 200.88| -70.96 | -59.18 ||(P/E) | | | |+----------------------+------------+------------+-----------+|Share price | | | ||performance (EUR) | | | |+----------------------+------------+------------+-----------+|- lowest price | 30.20 | 31.96 | 31.96|+----------------------+------------+------------+-----------+|- highest price | 47.60| 42.47 | 47.50|+----------------------+------------+------------+-----------+|- average price | 40.88| 39.68 | 38.84|+----------------------+------------+------------+-----------+|- closing price | 35.60| 40.00 | 47.50|+----------------------+------------+------------+-----------+|Market capitalization |513 828 898 |574 388 120 |682 085 892||at end of period* | | | ||(EUR) | | | |+----------------------+------------+------------+-----------+|Share issue adjusted | | | ||number of | | | |+----------------------+------------+------------+-----------+|traded shares | 1 545 773 | 1 299 650 | 1 681 791|+----------------------+------------+------------+-----------+|% of average number of| 10.7 % | 8.6 % | 11.7 % ||shares | | | |+----------------------+------------+------------+-----------+|Number of shares* | | | |+----------------------+------------+------------+-----------+|- at end of the period| 14 433 396 | 14 359 703 | 14 359 703|+----------------------+------------+------------+-----------+|- average during the | 14 436 935 | 14 356 548 | 14 357 343||period | | | |+----------------------+------------+------------+-----------+|- average during the | 14 436 935 | 14 395 519 | 14 406 674||period, diluted | | | |+----------------------+------------+------------+-----------+ * Excluding treasury shares SHARE AND SHAREHOLDERS Basware Corporation’s share capital totalled EUR 3 528 369 (3 528 369) at the end of the quarter and the number of shares was 14 433 396 (14 359 703). Basware Corporation holds 31 460 (42 233) of its own shares, corresponding to approximately 0.2 percent (0.3 %) of the total number of shares. Basware had 11 467 (11 992) shareholders at the end of the quarter, including 11 nominee-registers (9). Nominee-registered holdings accounted for 51.8 percent (44.7 %) of the total number of shares. The company’s Annual General Meeting of March 15, 2018 authorized the Board of Directors to decide on the repurchase of the company’s own shares and on share issue as well as on the issuance of options and other special rights entitling to shares.Additional information on shareholdings of major shareholders is available on the company’s investor website at investors.basware.com/en.

myFC develops technology that secures the company’s recurring revenues from fuel, and protects users and manufacturers from counterfeit fuel cards

myFC today announces it has a patent pending that protects the fuel chemistry of its PowerCard. Specifically, the patent covers the technology allowing the device to immediately recognize if a power card is in fact a myFC original PowerCard, safe for the intended use, and ensuring the device does not accept any uncertified or counterfeit versions. Sales of fuel cards is a significant potential source of recurring revenue for myFC and therefore an integral part of the company’s business model. Previously communicated calculations by myFC state that under the assumption that that users would use one to two fuel cards a month, the company’s potential annual revenues for the sale of fuel cards could be five to ten times higher than the revenues for the fuel cell. This technology is also significant for the users. A prerequisite for myFC’s offering is that fuel cards are readily and conveniently available, and that consumers can trust the quality of the fuel. Smartphone manufacturers integrating myFC’s technology into their devices likewise need to be certain their products aren’t compromised by counterfeit or non-certified fuel cards. “This is a significant breakthrough for myFC, which I am happy to finally be able to share. This innovation ensures that no counterfeit cards will be accepted by our system. That means consumers can trust the cards they use are certified and safe, manufacturers can be confident the warranties of their products won’t be compromised, and we at myFC are assured our potential recurrent revenue from PowerCards is protected,” says Björn Westerholm, CEO of myFC. “Developing the system that protects our own, patented fuel is highly complex in itself. But I also want to underline that we have managed to do it very cost-effectively with high scalability and usability, ensuring that it is ultimately commercially viable to include it in thousands of power cards,” adds Westerholm. This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 07:55 CET on 17 October 2018.

MAG Interactive AB (publ) presents interim report Sep 2017 – Aug 2018

COMMENT FROM DANIEL HASSELBERG, CEO Revenue growth thanks to new games “Revenues in the reporting period June-August increased compared to the previous quarter thanks to our two new games Paint Hit and Word Domination. During the reporting period we saw an average of 15 million active players on a monthly basis, which is up significantly compared to the previous quarter and more than double the amount compared to the same period previous year. The contribution from games increased 20% compared to previous year. During the reporting period, we were able to significantly increase our investments in marketing compared to the previous quarter thanks to our new games, which in the short term puts pressure on the profit margin. As we are applying our ROI focused and data driven performance marketing models we expect good returns on these investments over time. The main focus for MAG is to create games with strong long term player commitment. Our multiplayer games Ruzzle, Quiz Duel and Word Domination are all great examples of games that are able to create robust underlying profitability over a long period of time. While the recent quarters have shown declining revenues from our single player games due to difficulties in maintaining marketing volumes, it is positive to see that our multiplayer portfolio has continued to develop favorably. Multiplayer and strong social game design are the keys to success for MAG both historically and in the future." SUMMARY OF THE PERIOD JUNE UNTIL AUGUST 2018 ·  The Group's Net sales for the period were 53,740 KSEK (57,916 KSEK), a decrease of 7% compared to the same period previous year. Net sales adjusted for currency effects is 51,305 KSEK ·  The Group's Net sales for the period corresponds to an increase of 5% compared to the previous reporting period, March-May ·  The Group's game contribution for the period was 22,849 KSEK (19,001 KSEK), an increase of 20% compared to the same period the previous year ·  Daily and monthly active users (DAU and MAU) were 2.8 million and 15.3 million respectively during the quarter, an increase of 73% and an increase of 107% compared with the same period last year ·  The Group's EBITDA for the period was -796 tkr (4,420 tkr) SIGNIFICANT EVENTS SINCE THE END OF THE REPORTING PERIOD · No significant events after the end of the reporting period Full interim report is available at http://www.maginteractive.com/investor-relations/. Further reporting dates  Annual General Meeting            18 December 2018                                 Interim report September-November 23 January 20192018/2019Interim report September-February 10 April 20192018/2019Interim report September-May 26 June 20192018/2019Interim report September-August 23 October 20192018/2019   TWITCH CAST The 17th of October at 10:00, CEO Daniel Hasselberg and CFO Magnus Wiklander will hold a Twitch video cast call to present the interim report. Link to the Twitch feed www.twitch.com/maginteractive. More information is available at www.maginteractive.se/investor-relations. This announcement contains inside information pursuant to Article 7 of the EUMarket Abuse Regulation relating to MAG Interactive AB (publ). The informationwas submitted for publication through the agency of the contact persons setout below, on October 17th, 2018 at 08.00 CET.For additional information,please contact: Daniel Hasselberg / VD / +46 (0)8 644 35 40 /daniel@maginteractive.com Magnus Wiklander / CFO / +46 (0)8 644 35 40 /magnus.wiklander@maginteractive.com About MAG InteractiveMAG Interactive is a leading developer and publisher of casual mobile gamesfor a global audience. MAG Interactive reaches over 10 million active playersevery month and the game portfolio consists of ten successful games with over250 million downloads, including successful titles Ruzzle, Word Domination andWordBrain, all of which have reached #1 spots on the App Store and GooglePlay. With offices located in Stockholm and Brighton, MAG Interactive’s gamesare distributed through virtual app stores allowing for global reach withminimum effort. MAG Interactive is listed on Nasdaq First North Premier withticker MAGI. Avanza Bank AB is acting as MAG Interactive's Certified Adviser.For more information visit www.maginteractive.com.                  

Mycronic receives order for advanced maskwriter

Mycronic has received an order for a Prexision-800 from a customer in Asia. The system is configured with limited functionality and is scheduled for delivery in the second quarter of 2019. The order, which was booked in the fourth quarter, is valued at between USD 30-35 million and also includes certain upgrades to the customer’s existing system. Mycronic’s Business Area Pattern Generators provides mask writers for manufacturing photomasks in several fields of application. These mainly consist of display manufacturing (TV, smartphones and tablets) and applications in the multi-purpose market, a broad segment that includes applications such as electronic packaging, microelectromechanical systems (MEMS) and touchscreen functions. A fully optioned Prexision-800 can – while maintaining productivity – produce patterns that are almost 25 percent more compact than previously possible. This ensures efficient production of the most advanced and critical photomasks for displays, such as 4K smartphones and advanced AMOLED displays. “It is gratifying to secure another order for a system based on the Prexision-800 platform. The customer can upgrade the functionality at a later date to a Prexision-800 system that fully meet the industry’s high standards for manufacturing of new, innovative display applications while maintaining productivity,” says Charlott Samuelsson, Sr VP Business Area Pattern Generators, Mycronic. For further information, please contact: Charlott SamuelssonSr VP Business Area Pattern GeneratorsTel: +46 709 844 282, e-mail: charlott.samuelsson@mycronic.com Tobias BülowDirector IR & Corporate CommunicationsTel: +46 734 018 216, e-mail: tobias.bulow@mycronic.com The information in this press release was published on October 17, 2018, at 08:00 am CET. About MycronicMycronic AB is a Swedish high-tech company engaged in the development, manufacture and marketing of production equipment with high precision and flexibility requirements for the electronics industry. Mycronic’s headquarters are located in Täby, north of Stockholm and the Group has subsidiaries in France, Japan, China, the Netherlands, Singapore, the United Kingdom, South Korea, Germany and the USA. Mycronic (MYCR) is listed on Nasdaq Stockholm. www.mycronic.com

Hansa Medical Receives FDA Fast Track Designation for Imlifidase for Transplantation

Imlifidase (IdeS) is an enzyme in late-stage clinical development that specifically cleaves IgG antibodies, thereby inhibiting the IgG-mediated immune response. Hansa Medical is initially developing imlifidase as a proprietary treatment to enable kidney transplantation in sensitized patients previously unable to undergo transplant surgery due to the presence of donor-specific antibodies (DSAs). In addition, imlifidase is being evaluated in a Phase 2 study in anti-GBM antibody disease, a rare and acute autoimmune disorder, and imlifidase has potential applications in other solid organ transplants and in a variety of additional acute autoimmune indications. “This Fast Track Designation is validation of imlifidase’s potential to address the significant unmet medical need for highly sensitized patients, a patient population for which transplantation is extremely difficult or impossible,” said Søren Tulstrup, President and Chief Executive Officer of Hansa. “Our two recently reported Phase 2 studies demonstrate imlifidase’s ability to enable kidney transplantation for these patients, who otherwise face high mortality rates associated with long-term dialysis. We continue to actively engage with the regulatory agencies and anticipate submitting a Biologic License Application (BLA), as well as a Marketing Authorisation Application (MAA), in either the fourth quarter of this year or the first quarter of 2019.” The imlifidase Fast Track Designation is supported by efficacy data reported from four successfully completed Phase 2 studies that demonstrate imlifidase’s ability to rapidly and significantly reduce Donor Specific Antibodies (DSAs), thereby enabling kidney transplantation. The FDA's Fast Track program is designed to facilitate the development and expedite the review of new drugs to treat serious or life-threatening conditions that demonstrate the potential to address an unmet medical need. Fast Track designation provides a company more frequent communication with the FDA regarding the investigational drug’s development plan and also provides eligibility for priority review if certain criteria are met. This is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 08:00am CEST on October 17, 2018.

Castellum’s Interim Report January-September 2018: A record strong quarter – 13% growth in income from property management

“For Castellum, this resulted in a new record quarter - income from property management rose 13%. The strong earnings after the third quarter mean that I am now even more convinced that in 2018, Castellum will be able to meet its overall target: an increase in income from property management (and thus the dividend) of 10%,” says CEO Henrik Saxborn. “New profitable development opportunities arise through continued high demand for modern, sustainable office spaces. Over the last few years, Castellum has taken a leading role in the expansion of Nyhamnen in central Malmö by constructing a new Swedish National Courts Administration and a new Nordic head office for E.ON. The investment totals SEK 2.3 billion and is one of the largest in the company’s history. This further reinforces Castellum’s position as a community-builder in the Öresund region,” concludes Saxborn.    Enclosure: Interim Report January-September 2018 This information is information that Castellum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on October 17, 2018. For additional information, please contact:Henrik Saxborn, CEO, Phone +46-31 60 74 50Ulrika Danielsson, CFO, Phone +46-706 47 12 61www.castellum.com Castellum is one of the largest listed real estate companies in Sweden. Property values amount to SEK 87.5 billion and holdings comprise office, warehousing/logistics and public sector properties, covering a total leasable area of 4.4 million square metres. The real estate portfolio is owned and managed under the Castellum brand through a decentralized organization with strong and clear local presence in 20 cities in Sweden and also in Copenhagen and Helsinki.   In 2018, Castellum received two awards for sustainability efforts; designated Number One in the world by GRESB for the offices-and-logistics sector, as well as the Level Gold award for sustainability reporting from the EPRA (European Public Real Estate Association). In addition, Castellum is the only Nordic real-estate and construction company elected to the Dow Jones Sustainability Index (DJSI), joining a select group of companies in the world who perform best on sustainability issues.   The Castellum share is listed on Nasdaq Stockholm Large Cap. Castellum AB (publ), Box 2269, SE-403 14 Gothenburg | Corp Id no SE 556475-5550 | Phone +46 31 60 74 00

Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast

Oslo, Norway, 17 October 2018 Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be announced nearer the time). During this presentation, the Company will present updated clinical results from the LYMRIT 37-01 trial with Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma patients. These results will be published on 1 November in an abstract* that will be presented in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018). As a consequence of the change in date of the third quarter 2018 results presentation, the Company will enter its two-week ‘quiet period’ starting on the 23 October 2018. In addition, the Company has decided it will not continue hosting separate presentations of the results in Norwegian. *ASH abstract Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month follow-up Authors: A. Kolstad, et al. The abstract will be published on 1 November 2018 at 09:00am Eastern time at http://www.hematology.org/Annual-Meeting/ For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

Interim Management Statement January-September 2018

Highlights during the third quarter · Adjusted net asset value, based on estimated market values for the major subsidiaries and partner-owned investments within Patricia Industries, amounted to SEK 420,572 m. (SEK 550 per share) on September 30, 2018. Adjusted net asset value increased by SEK 26,402 m., or 7 percent during the quarter. · Reported net asset value amounted to SEK 372,371 m. (SEK 487 per share) on September 30, 2018, an increase of SEK 24,514 m., or 7 percent, during the quarter. · Listed Core Investments generated a total return* of 9 percent. · Based on estimated market values, the value of Patricia Industries, excluding cash, increased by 2 percent during the quarter. · Reported sales growth for the major subsidiaries (including Piab and Sarnova pro forma) amounted to 14 percent, of which 3 percent organic in constant currency. Reported EBITA grew by 13 percent. · The value of Investor’s investments in EQT decreased by 2 percent in constant currency. Net cash flow to Investor amounted to SEK 338 m. Financial information, year to date 2018 · Adjusted net asset value growth and reported net asset value growth, including dividend added back, amounted to 12 percent and 13 percent, respectively. · Contribution to reported net asset value amounted to SEK 36,109 m. (35,504), of which; Listed Core Investments SEK 40,583 m. (43,602), Patricia Industries SEK 4,700 m. (-121) and EQT SEK 2,358 m. (1,774). Investor’s total dividend amounted to SEK 9,178 m. · Leverage* (net debt/reported total assets) was 4.9 percent on September 30, 2018 (3.5). · Consolidated net sales for the period was SEK 30,510 m. (25,430). Consolidated profit/loss was SEK 42,816 m. (SEK 56.01 basic earnings per share), compared to SEK 45,314 m. (SEK 59.28 basic earnings per share) for the same period 2017.

Nordic Nanovector – Financial Calendar

Oslo, Norway, 17 October 2018 FINANCIAL YEAR 2018 Quarterly Report - Q3   06.11.2018 (changed from 21.11.2018) Quarterly Report - Q4   27.02.2019 FINANCIAL YEAR 2019 Annual General meeting 25.04.2019 Quarterly Report - Q1   23.05.2019 Half-yearly Report        22.08.2019 Quarterly Report - Q3   21.11.2019 The dates are subject to change. The time and location of the presentations will be announced in due time. This information is published pursuant to the requirements set out in the Continuing obligations. For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

Medivir scales back research costs to focus on clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects. As part of this plan, Medivir will notify the Public Employment Office of potential employee redundancies impacting approximately 60 positions, mainly within pre-clinical research and administration. Medivir will also call for consultations with the trade unions regarding the possible consequences for the employees. The plan is to reduce Medivir’s annual running cost base, excluding the clinical project costs, by approximately two thirds. Medivir is also exploring strategic alternatives for the research stage projects and organization. “The focus on the clinical portfolio, together with the associated cost reduction within pre-clinical research, are necessary steps for us to continue to develop the value of our clinical stage projects in an optimal way,” said Dr. Uli Hacksell, acting chief executive officer at Medivir. Medivir's clinical pipeline consists of four projects; remetinostat for cutaneous T-cell lymphoma (phase II), birinapant in combination with Keytruda® for solid tumors (phase I), MIV-818, a nucleotide prodrug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, an osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Tomorrow, Thursday October 18, at 2.00 pm (CET) Medivir will host a conference call for investors, analysts and the media where Uli Hacksell presents and comments the recent days’ development and the way forward for the company. Phone numbers for participants from:Sweden + 46 8 566 426 64Europe + 44 20 3008 9802US + 1 855 753 2237 The conference call will also be streamed via a link on the website: www.medivir.comThe presentation will be available on Medivir’s website after completion of the conference. For further information, please contact:For media information:Cord Communications, Lars Wahlström, phone: +46 734 340771. lars.wahlstrom@cordcom.se Uli Hacksell, acting CEO, Medivir AB, phone: +46 (0)8 546 831 00. Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on October 17, 2018. About MedivirMedivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda® for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco, USA

For more than 68 years, the ASA Annual Meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine. Numerous presenters discussed patient safety initiatives and necessary steps to reduce adverse events in the perioperative period. Hundreds of technical, scientific and educational exhibits displaying and demonstrating the latest products, services and industry research. During the exhibition Senzime had the opportunity to address a worldwide audience of Key opinion leaders and demonstrate the TetraGraph, as well as formally launch the TetraGraph Viewer. This software allows the user to easily export patient data. “The anesthesia discussions today is all about having the patient in focus. The ability to digitally present data and analyze trends is a key component,” says Lena Söderström, CEO of Senzime. Senzimes distributors from Australia & New Zealand and South Korea also attended the event to meet with local customers visiting the conference. For further information, please contact:  Lena Söderström, CEO Tel: +46-708 16 39 12. Email: lena.soderstrom@senzime.com TO THE EDITORS   About Senzime   Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com   

CLS signs agreement with IGT for development and commercialization of product for MR generated temperature monitoring

Clinical Laserthermia Systems AB (publ) and Image Guided Therapy SA (IGT)  have signed an agreement, in line with the ”term sheet” previously communicated. The purpose of the agreement is to develop and commercialize a software product offering doctors MR-generated, optimal conditions for viewing, measuring and controlling tissue temperatures during treatment with laser ablation and CLS’ immune stimulating imILT® procedure. The objective is to make the product compatible with MR systems from all leading vendors. With this new product offering CLS will strengthen its position in establishing the TRANBERG® product portfolio for image guided laser ablation and imILT® treatments within the market for interventional MR procedures. -  Our main goal is to offer the doctors, choosing to use the products of CLS, an improved workflow where they in the best way possible can monitor the treatment procedure. With this new software we will offer the hospital a more complete solution, said Lars-Erik Eriksson, CEO at CLS. In brief, the collaboration means that IGT will provide the core technology for the development of the new product, while CLS will bring the know-how of thermal therapies and the regulatory process that is required for EC approval in Europe and FDA clearance in the U.S. The new product will will be registered in CLS’ quality assurance system. CLS and IGT each covers its own costs within the project, said Lars-Erik Eriksson.  - We are aiming at having the new software product approved and ready to launch during the second half of 2019. Already today we have hospitals waiting to test the product, said Dan Mogren, CCO at CLS. The commercial part of the agreement includes joint sales and marketing of the product and with an exclusive right for CLS to sell the software together with our products for soft tissue ablation and imILT® treatments, said Dan Mogren. IGT is a French medtech company that, utilising research work from the university in Bordeaux, has developed products in the field of MR guided, minimally invasive cancer treatments. IGT has also been involved with two main developments: MR guidance for RF ablation procedures and MR guided focused ultrasound ablation devices (MRgFUS). More about Image Guided Therapy   About the CLS TRANBERG®|Thermal Therapy System CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories. CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times. This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. 

Nomination Committee for Securitas’ Annual General Meeting 2019

The following representatives of Securitas AB’s shareholders will be members of the Nomination Committee for the Annual General Meeting 2019: - Carl Douglas, Investment AB Latour, [Chairman of the Nomination Committee]- Mikael Ekdahl, Melker Schörling AB- Maria Nordqvist, Lannebo Fonder- Johan Sidenmark, AMF Försäkring och Fonder- Jan Andersson, Swedbank Robur Fonder The Chairman of the Board, Marie Ehrling, shall convene the Nomination Committee to its first meeting and shall also be co-opted to the Nomination Committee. The Nomination Committee shall prepare proposals for the Annual General Meeting in 2019 regarding the election of Chairman of the General Meeting, members of the Board of Directors, Chairman of the Board, Vice Chairman of the Board, auditor, fees for the members of the Board including division between the Chairman, the Vice Chairman, and the other Board members, as well as fees for committee work, fees to the company’s auditor and, if necessary, changes of the instructions for the Nomination Committee. The Annual General Meeting will be held on May 6, 2019 at 4 p.m. CET, at Courtyard Marriott Hotel in Stockholm, Sweden. Shareholders who wish to submit proposals to the Nomination Committee should send an email to valberedningen@securitas.com. This press release is also available at: www.securitas.com Information: Micaela Sjökvist, Head of IR and Acting SVP Corporate Communications and Public Affairs, Securitas AB, mobile +46 76 116 7443 or email micaela.sjokvist@securitas.com

Asetek Presents Third Quarter 2018 Results on Wednesday, 24 October

October 17, 2018 – Asetek will release its financial results for the third quarter 2018 on Wednesday, 24 October at 7:00 AM CEST. This is followed by a presentation by CEO André Sloth Eriksen and CFO Peter Dam Madsen at 8:00 AM CEST. Asetek invites investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed through live webcast or by conference call. Conference call – audio only:Please dial in 5-10 minutes prior using the phone numbers and confirmation code below: +--------------------------------------+-----------------------+|Copenhagen, Denmark: |+45 3515 8049   |+--------------------------------------+-----------------------+|Oslo, Norway: |+47 2100 2610 |+--------------------------------------+-----------------------+|London, United Kingdom: |+44 (0) 330 336 9127   |+--------------------------------------+-----------------------+|Paris, France: |+33 (0)1 76 77 22 74 |+--------------------------------------+-----------------------+|New York, United States of America:   |+1 929 477 0402 |+--------------------------------------+-----------------------+|Confirmation code:   7993172 |+--------------------------------------+-----------------------+ Webcast – audio and slide presentation:Please join the Q3 2018 Results webcast by clicking here . The third quarter report and presentation will also be made available on www.asetek.com  and www.newsweb.no, as well as through news agencies. A recorded version of the presentation will be made available on www.asetek.com  approximately two hours after the broadcast has concluded. For further information, please contact:Peter Dam MadsenChief Financial OfficerMobile: +45 2080 7200investor.relations@asetek.com

Archer commences Equinor Drilling Services Fixed Platforms contract

Stavanger, Norway (October 17, 2018) On October 1st 2018 Archer successfully transitioned over four new and nine existing operations to the “Drilling Services Fixed Platforms” contract with Equinor previously awarded on 3rd April this year. Archer now provides integrated drilling, engineering, rentals and well services on 13 of the 20 Equinor production drilling and quarters (PDQ) platforms on the Norwegian Continental Shelf. “Following contract award in April, both our onshore and offshore teams have worked relentlessly to ensure a safe and effective start up and transition on all platforms. We have cross trained Archer and service contractor personnel, whilst also increasing our workforce by over 400 personnel. I would like to take this opportunity to express my gratitude to the team for their professionalism and commitment”, says Joachim Bengtsson - Archer’s Operations Manager for Equinor. The new contract work scope, coupled with the four additional platforms (Grane, Gullfaks A,B,C), has increased the Archer employee family significantly, and we now have over 1,000 personnel dedicated to delivering operational excellence and ensuring maximum value through reducing total well cost for Equinor. Archer will continue to grow our organization over the coming months as we integrate and deliver additional services. The contract ensures Archer’s continued operations for Equinor in the Norwegian continental shelf until at least October 1, 2022, with a value of more than NOK 6 billion based on the current drilling schedule. There are further contractual options which can secure operations until 2028. “This contract represents a new chapter in the delivery of platform drilling services to Equinor, whereby the drilling contractor, service contractors and Equinor will collaborate as one team, and jointly deploy resources and skills to optimize well deliveries. Our main objectives are improved efficiency, reduced POB and cost per well, reduced carbon foot print and reduced risk exposure for personnel with no harm to people as our first priority. We will accomplish this through close collaboration, continuous improvement through effective recording and sharing of lessons learned, and a win-win performance culture. We firmly believe this is and will be the future operational model in Norway” continues Mr. Bengtsson. For additional information please contact: Joachim Bengtsson, Operations Manager for EquinorM: +47 41291929joachim.bengtsson@archerwell.com #wearearcher #oneteam

CLS Signs Agreement with Image Guided Therapy to Develop and Commercialize Product for MR-Generated Temperature Monitoring

Framingham, MA – October 17, 2018 - CLS AB in Lund, Sweden, with the subsidiary Clinical Laserthermia Systems Americas, Inc . (CLS Americas), today announced it has signed an agreement with Image Guided Therapy SA (IGT) to develop and commercialize a software product offering doctors MR-generated, optimal conditions for viewing, measuring and controlling tissue temperatures during precision laser ablation and CLS’s immune stimulating imILT®treatment. The objective is to make the jointly-developed product compatible with MR systems from all leading vendors. With this new product offering CLS will strengthen its position in establishing CLS’s product portfolio for precision image guided laser ablation and imILT® treatments within the market for interventional MR procedures. “Our main goal is to offer the doctors, choosing to use the products of CLS, an improved workflow where they can monitor the treatment procedure in the best way possible.  With this new software, we will be able to offer the hospital a more complete solution,” said Lars-Erik Eriksson, CEO at CLS. “In brief, the collaboration means that IGT will provide the core technology for the development of the new product, while CLS will bring the know-how of thermal therapies and the regulatory process that is required for EC approval in Europe and FDA clearance in the U.S. The new product will be registered in CLS’ quality assurance system. CLS and IGT will each covers its own costs within the project.“ “We are aiming at having the new software product approved and ready to launch during the second half of 2019. Already today we have hospitals waiting to test the product,” said Dan Mogren, Chief Commercial Officer at CLS. “The commercial part of the agreement includes joint sales and marketing of the product and with an exclusive right for CLS to sell the software together with our products for soft tissue ablation and imILT® treatments.”  About Image Guided Therapy IGT is a French medtech company that, utilizing research work from the University in Bordeaux, has developed products in the field of MR guided, minimally invasive cancer treatments. IGT has also been involved with two main developments: MR guidance for RF ablation procedures and MR guided focused ultrasound ablation devices (MRgFUS). For more information, visit: www.imageguidedtherapy.com. About the CLS TRANBERG®|Thermal Therapy System CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories. CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.

Kährs Group recruits Chief Marketing Officer

[Charlotta Fellman CMO Khrs Group 1 Januari 2019]Photo: Roger Nellsjö  As part of strengthening Kährs Group's market position with focus on brand and product development, the company has recruited Charlotta Fellman as new CMO. In addition to working with the company's marketing strategy, Charlotta will play an important role in developing Kährs' sales channels to best meet customer needs. "We are very happy that Charlotta has chosen to join us. She possesses the market competence we seek in order to strengthen our offering to our different customer segments in line with Kährs strategy. As CMO, Charlotta plays an important role in driving the company's market and brand-related issues forward", said Christer Persson, President and CEO, Kährs Group. "I am very excited about becoming part of Kährs as the entire company breathes design and innovation. Together with my future colleagues, my aim is to take the next step in offering flooring products at the forefront in the market. I am also looking forward to developing Kährs' different sales channels to meet the demand from our target groups and reach them in a desirable way", said Charlotta Fellman. Charlotta joins from the position as Vice President Sales at Perstorp Group, in charge of the business areas Europe, Middle East and Africa, and has simultaneously driven Perstorp's digital transformation programs. She has a long background at Unilever where she worked with brand building and acted as Country Manager in Norway. Charlotta Fellman begins her new position at Kährs on January 1, 2019. For further information, please contact:  Helén Johansson, Corporate Communication, Kährs GroupTel: +46 70 364 60 30      About Kährs GroupKährs Group is a Europe-leading flooring manufacturer in hardwood and resilient flooring with several strong brands in its product portfolio, including Kährs, Karelia and Upofloor. Kährs’ innovations have shaped the industry throughout history and the company is dedicated to providing private, commercial and public spaces with environmentally sound and long-lasting flooring solutions. Kährs Group, which delivers products to more than 70 countries, is the market leader in Sweden, Finland and Russia and holds a strong position in other key markets, such as Norway, the UK and Germany. The Group has approximately 1,700 employees and annual sales of more than SEK 3 billion. www.kahrsgroup.com

Clinical Laserthermia Systems (CLS) and MRI Interventions Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery

Irvine, CA and Lund, Sweden – October 17, 2018 – MRI Interventions, Inc. (OTCQB:MRIC) and Clinical Laserthermia Systems AB  (NASDAQ FIRST NORTH:CLS B), today entered into a collaborative license and co-development agreement to provide next-generation navigation and precision laser ablation platforms for use in Spine and Neurosurgery. Under the terms of the agreement, CLS will provide an exclusive, worldwide license to current and future products and IP to MRI Interventions and will act as the exclusive manufacturer of those products. CLS will retain the rights for all fields outside of Neuro and Spine. “This agreement is a truly exciting step towards execution of our growth strategy,” commented Joe Burnett, President and CEO of MRI Interventions. “Historically we have been the company that helps deliver other company’s therapeutic products to deep structures of the brain in the most precise manner possible. Now we have the opportunity to deliver our own therapies, which will improve efficiency, workflow and procedure times for our hospital customers, and expand revenue and per-procedure profitability for our investors. Now in partnership with CLS, we can truly be a leader in the movement toward minimally-invasive neurosurgery because we can offer both navigation and laser ablation therapy, all under the watchful eye of a single clinical specialist to help support the procedure. The objective is to offer a platform that provides accuracy and workflow advantages to our customers and meets our requirements of being able to do multiple procedures in the same day. We estimate a formal launch of this combined platform during 2020.”  “We are delighted to find a partner to bring our advanced laser ablation platform to the neurosurgery space,” said Lars-Erik Eriksson, CEO of CLS. “The agreement covers our existing products as well as our new software product that will be developed in collaboration with our partner Image Guided Therapy, and that allows MR-guided temperature measurement and control during the laser ablation procedure.The neurosurgery market is an incredibly challenging market to enter and build from the ground up. We are thrilled to be able to find a partner in MRI that already has years of experience in the space, a large and growing installed base at some of the most prestigious neurosurgery centers in the U.S. They also have a team of clinical specialists already participating in the guidance of these laser surgeries today, that I see will bring great value to this collaboration,” said Lars-Erik Eriksson.  CLS’ technology is the core in the TRANBERG® | Thermal Therapy System, a laser system with USFDA 510 (k) clearance for soft tissue ablation and in Europe (CE mark) for soft tissue ablation and immunostimulatory interstitial laser thermotherapy (imILT®). About MRI Interventions, Inc. Building on the power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com. The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).  Media Contact CLS TopSpin Communications Joe Waldygo P: 480-363-8774 Contact Information Clinical Laserthermia Systems AB: Lars-Erik Eriksson +46 70 290 33 00 lee@clinicallaser.se E: joe@topspinpr.com

CLS Signs Exclusive Distribution Agreement with MRI Interventions for USA and Canada

Clincial Laserthermia Systems AB (publ) (CLS) and MRI Interventions (MRIC), today announced that the companies have signed an agreement granting MRI Interventions the exclusive right to distribute and sell CLS’s portfolio of products, including its TRANBERG® product line for high precision ablation, in the USA and Canada. This new two-year agreement includes all interventional MR-guided procedures beyond the previously announced license agreement for spine and neurosurgery. “In line with CLS’s ambition to continue building its precision ablation business within interventional MR, MRI Interventions Inc has been selected as CLS’s distribution partner for USA and Canada. MRI Interventions is well-established, with a long and deep experience in marketing and sales of their ClearPoint® product portfolio to hospitals and clinicians, active within this space. We are excited about the immediate potential in this partnership and look forward to teaming up with this great company,” stated Dan Mogren, Chief Commercial Officer of CLS.  “The distribution agreement expands the partnership beyond the license and collaboration agreement our two companies recently entered into, and it gives CLS immediate access to a team of +20 commercial managers and clinical specialists and their extensive business network,” says Lars-Erik Eriksson, CEO of CLS. “This is an exciting collaboration for MRI,” commented Joe Burnett, President and CEO of MRI Interventions. “In addition to our previously announced co-development partnership and license for neurosurgery and spine, this agreement allows us to support the CLS platform beyond neurosurgery. MRI will leverage its existing commercial infrastructure to achieve scale and represent a great technology with our very capable team. This collaboration is a terrific tool to continue both parties path to profitability.”  In collaboration with its customers and partners, CLS intends to continue expanding its product portfolio and offer unique products that will advance image guided ablation into a more precise, predictable, safe and effective therapy. This will help improve outcomes through better procedure planning and execution, and also allow for new innovative approaches, such as the immune stimulatory interstitial laser thermotherapy treatment (imILT®) of CLS, aimed for the interventional oncology market. About MRI Interventions, Inc.Building on the power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com. This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Clinical Laserthermia Systems (CLS) Signs Exclusive Distribution Agreement with MRI Interventions for USA and Canada

Framingham, MA – October 17, 2018 - CLS AB (NASDAQ FIRST NORTH: CLS B)in Lund, Sweden, with the subsidiary Clinical Laserthermia Systems Americas, Inc . (CLS Americas), and MRI Interventions (MRIC), today announced that the companies have signed an agreement granting MRI Interventions the exclusive right to distribute and sell CLS’s portfolio of products, including its TRANBERG® product line for high precision ablation, in the USA and Canada. This new, two-year agreement includes interventional MR-guided procedures beyond the previously announced license agreement for spine and neurosurgery. “In line with CLS’s ambition to continue building its precision ablation business within interventional MR, MRI Interventions Inchas been selected as CLS’s distribution partner for USA and Canada. MRI Interventions is well-established with a long and deep experience in marketing and selling their ClearPoint® product portfolio to hospitals and clinicians active within this space. We are excited about the immediate potential in this partnership and look forward to teaming up with this great company,” stated Dan Mogren, Chief Commercial Officer of CLS.  “The distribution agreement expands the partnership beyond the license and collaboration agreement our two companies recently entered into, and it gives CLS immediate access to a team of +20 commercial managers and clinical specialists,” says Lars-Erik Eriksson, CEO of CLS. In collaboration with its customers and partners, CLS intends to continue expanding its product portfolio and offer unique products that will advance image guided ablation into a more precise, predictable, safe and effective therapy. This will help improve outcomes through better procedure planning and execution, and also allow for new innovative approaches, such as the immune stimulatory interstitial laser thermotherapy treatment (imILT®) of CLS, aimed for the interventional oncology market. “This is an exciting collaboration for MRI to execute on our four-pillar growth strategy,” commented Joe Burnett, President and CEO of MRI Interventions. “In addition to our previously announced co-development partnership and license for neurosurgery and spine, this agreement allows us to support the CLS platform beyond neurosurgery and leverage our existing commercial infrastructure to achieve scale. This collaboration is a terrific tool to continue our path to profitability and represents a great technology with our very capable team.”  About MRI Interventions, Inc.Building on the power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com. The TRANBERG® |Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).  Media Contact CLS: TopSpin Communications Joe Waldygo P: 480-363-8774 E: joe@topspinpr.com  Company Contact Clinical Laserthermia Systems AB:  Lars-Erik Eriksson, CEO  +46 70 290 33 00 lee@clinicallaser.se  Contact Information MRI Interventions Inc: Matt Kreps, Darrow Associates Investor Relations +1 (214) 597-8200 mkreps@darrowir.com 

Arjo to divest low-spec medical beds business

Arjo, a market-leading supplier of medical devices and solutions, today signed an agreement to divest Acare – the group’s low-spec medical beds business – to China-based CBL Group. The divestment is a key part of the group’s action plan to improve profitability in the medical beds product category. Arjo acquired the Chinese company Acare Medical Science Ltd. in 2012 to expand its presence in emerging markets. Arjo has now decided to focus on the premium segment for medical beds where the company already has strong market positions and where the profitability is significantly better. “The divestment of Acare is part of the action plan that we have prepared to improve the group’s gross margin in the medical beds category. Our strength is found outside the value segment and that is also the area on which we will focus to maintain and further strengthen our leading positions in the market,” says Joacim Lindoff, President and CEO of Arjo. CBL Group has its head office situated in Guangzhou, China, and has about 1,200 employees. Acare is deemed to have better conditions for developing with CBL, which already has an extensive offering in the low and mid-price segment and thus will be able to add the know-how and the synergies required for continuing to develop the operations. The divestment encompasses a production and sales unit in Zhuhai, China, that has 186 employees and generated sales of about SEK 80 M in 2017. The divestment is expected to be completed at the end of 2018. The divestment has no considerable effect on cash flow or results 2018 but is expected to have a positive annual effect of approximately SEK 25 M on operating profit from 2019. About Acare Acare Medical was founded in 1999 and acquired by Getinge Group in 2012. Product development and production of simple low-price beds take place at Acare’s facility in Zhuhai, China, and sales amounted to about SEK 80 M in 2017. Acare Medical’s products are sold through Arjo’s in-house sales organisation and via distributors. The primary markets are China and India. Acare Medical has 186 employees. For further information, please contact: Kornelia Rasmussen, EVP Marketing Communications & Public RelationsTel: +46 (0)10 335 4810E-mail: kornelia.rasmussen@arjo.com This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 14:15 CET on October 17, 2018. About Arjo  At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has approximately 6,000 employees worldwide and customers in over 100 countries. In 2017, Arjo sales amounted to approximately SEK 7.7 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.com

Extended notice: Noreco acquires Shell’s Danish upstream assets

Norwegian Energy Company ASA's (“Noreco” or the “Company”) wholly owned subsidiary, Altinex AS (“Altinex”) has entered into an agreement to acquire Royal Dutch Shell Plc’s (“Shell”) upstream assets in Denmark (the “Acquisition”). Through the transaction, Noreco becomes the second largest oil and gas producer in Denmark and a considerable E&P company. Establishing Noreco as a considerable independent E&P company This acquisition will establish Noreco as an E&P company on the Danish Continental Shelf (“DCS”), and position it as the second largest oil and gas producer in the country. Noreco will post completion have a 36.8% non-operated interest in the Danish Underground Consortium (“DUC”) with assets that comprise 15 fields in four producing hubs; Halfdan, Tyra, Gorm and Dan. DUC is a joint venture between Total (31.2%), Shell (36.8%), Chevron (12.0%) and Nordsøfonden (20.0%) cooperating to recover oil from the Sole Concession holder’s area of the Danish North Sea. Total recently announced the acquisition of Chevron’s (12.0%) interest, which remains subject to approval of partners and relevant authorities. The Sole Concession covers 1,635.7 km² of the DCS. DUC is operated by Total which has extensive offshore experience in the region and worldwide. The transaction The transaction will be structured as a sale to Altinex of all shares in Shell Olie- Og Gasudvinding Danmark B.V. (“SOGU”), which in turn owns a 36.8% interest in DUC and a 100% interest in Shell Olie- Og Gasudvinding Denmark Pipelines ApS (“SOGUP”), which will own a proportionate interest in the F3 gas pipeline. Included in the transaction are proven and probable (2P) reserves of 209 million barrels of oil equivalent (mmboe) based on an independent CPR assessment as per year-end 2017, of which 65% are liquids. Further, Noreco estimates significant reserves and production growth coming from existing resources (discoveries, EOR initiatives & new projects). Shell’s share of production from DUC in 2017 was 67 thousand barrels of oil equivalent per day (mboepd). Noreco expects to maintain strong production in the years to come. The DUC portfolio has attractive economics, with 2017 opex of USD 13 per boe. As the Tyra hub is being redeveloped, the portfolio will be revitalised and offer improved economics accompanied by prolonged field life. Liquids production volumes are protected through a guarantee lasting from signing of the Acquisition through 2020. Local SOGU staff mostly dedicated to the DUC will pass to Noreco along with the business with their existing contracts of employment intact and full continuity of service. In total ca. 8 employees will follow from Shell, which will bring additional competences to the Noreco organisation. Following the transaction, Noreco will have 15 employees, and does not plan to make any organisational reductions. The SOGU organisation is based in Copenhagen, and Mr. Lee James Hodder serves as managing director. The Board of Directors of SOGU currently consists of Mr. Lee James Hodder and Mr. Michael Lund Jensen. Completion of the transaction is subject to: receipt of all mandatory consents, approvals and clearances from governmental authorities, including the Danish Energy Agency; that no party relevant to the joint operating agreements invokes option rights to purchase Shell’s SOGU interest; and other conditions customary for a transaction of this nature. Subject to fulfilment of applicable conditions, completion is targeted for H1 2019. Noreco will, to the extent required by section 3.5 of the Oslo Stock Exchange Continuing Obligations, prepare an information memorandum with further information on the Acquisition and Noreco’s operations following completion of the Acquisition. Transaction consideration and financing The consideration of the transaction is USD 1.9 billion with effective date as of 1 January 2017, with pro contra adjustment currently estimated by Noreco to USD 0.7 billion. The transaction will be financed through a new seven year Reserve Based Lending bank facility provided by BMO Capital Markets, Deutsche Bank and Natixis of up to USD 900 million with a sub-limit of USD 100 million for letters of credit, by the issuance of a convertible bond of up to USD 160 million (the “Convertible Bond”), issuing new ordinary shares (the “Shares”) through a USD 352 million private placement (the “Private Placement”) and USD 40 million through a subsequent offering (the “Subsequent Offering”). USD 30 million of the Subsequent Offering has been underwritten (further details follow below). In order to fund part of the initial payment to Shell, Noreco will enter into a short-term funding agreement of USD 35 million (the “Deposit Loan”). The deposit loan including accrued interest will upon closing of the Transaction be rolled into the Convertible Bond at par, increasing the size of the Convertible Bond to up to USD 160 million. The Convertible Bond, Private Placement, and Deposit Loan will be directed towards and subscribed by Noreco’s largest shareholders CQS (UK) LLP (“CQS”), Kite Lake Capital Management (UK) LLP (“Kite Lake”), Taconic Capital Advisors UK LLP (Taconic), and by funds managed or advised by York Capital Management Europe (UK) Advisors LLP (“York”) (together, the “Investors”). The subscription price per Share in the Private Placement is set to USD 22.62 (NOK 185) per Share, and will result in the issuance 15.6 million Shares. The Convertible Bond will have a tenor of eight years. The convertible element will have a duration of five years and have a strike price of 29.73% above the share price in the private placement. This gives a conversion price of USD 29.34 (NOK 240) per Share, subject to customary adjustment mechanisms. Interest will be payment-in-kind with additional bonds at 8.0% with the possibility for Noreco to choose to pay cash interest of 6.0%. Following expiry of the conversion period, the bond will carry an interest of 0.0%. The Convertible Bond will be non-callable during the first 30 months. It will thereafter be callable at par if the mean volume weighted average price of the shares over a period of 20 consecutive dealing days exceed 130.0% of the then current conversion price, to the extent not converted by the holders thereof. The Convertible Bond will be mandatory redeemable upon the expiry of the conversion period. The Deposit Loan will carry a fixed interest of 12.0% annually, and will be rolled into the Convertible Bond upon completion of the Transaction no later than 15 October 2019. The Deposit loan is secured by an initial deposit payment to Shell amounting to USD 40 million. If completion of the Transaction does not occur, the Loan shall be rolled into the current NOR10 bond issue at par and be repaid together with accrued interest in cash on 31 March 2020. Noreco intends in connection with completion of the Acquisition to call NOR10 at the applicable call price (101.5% of par). The Convertible Bond, the Private Placement and the Subsequent Offering are subject to approval from the Company’s shareholders. An extraordinary general meeting of shareholders in Noreco will be called on or about 17 October 2018 (the “EGM”). Subject to completion of the Private Placement, a Subsequent Offering of around 1.8 million shares, amounting to up to USD 40 million will be made towards existing shareholders as of 16 October 2018, as registered in the VPS on 18 October 2018, who were not allocated Shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful or, for jurisdictions other than Norway, would require any prospectus, filing, registration or similar action. Such shareholders will be granted transferable preferential rights to subscribe for, and, upon subscription, be allocated new Shares. The preferential rights will be listed and tradeable on Oslo Børs. Over-subscription will be allowed. The Company's Shares will accordingly trade ex. right to participate in the Subsequent Offering as of 17 October 2018. The subscription price per Share in such Subsequent Offering will be the same as the subscription price in the Private Placement. USD 30 million of the Subsequent Offering will be underwritten by CQS, Kite Lake and Taconic (each an "Underwriter" and, together, the "Underwriters"). Each of the Underwriters have, severally, and not jointly, undertaken to subscribe for the new Shares not subscribed for during the subscription period of the Subsequent Offering. The underwriting obligation of each Underwriter does not include a guarantee for the payment by any subscriber or any other Underwriter of their subscription amount in the Subsequent Offering. The Underwriters will receive a guarantee commission of 2.0% of their guaranteed amount, subject to completion of the subsequent Offering or, as the case may be, certain other events. In connection with the transaction, Noreco will implement a new share incentive program for its key management as well as Board of Directors. Current options in the money (100,000) will be settled with cash at NOK 240 per share amounting to a total of NOK 19.8 million, while options out of the money will be cancelled (subject to option-holders’ approval). The new program consists of 1,510,000 new options. Existing management and board of directors will be allotted 715,000 options which will have a strike price of NOK 240 per share and a vesting period of three years as well as 170,000 options with a strike price determined by the VWAP 30 days after completion of the Transaction. The remaining 625,000 options will be intended for new employees and will have a strike price based on board policies. The EGM will be called on or about 17 October 2018 where the Company’s board will propose that the shareholders approve the Private Placement, the Convertible Bond, the Subsequent Offering, as well as the new share incentive program and associated authorisation to issue new Shares. The board will in addition ask for a new authorisation to issue up to 10.0% new Shares in one or several share issues. The board has obtained voting undertakings from shareholders representing 56% of the outstanding shares of Noreco, who have undertaken to vote in favour of the proposals. Completion of the proposed resolutions will be subject to completion of the Acquisition. Listing of the Shares issued in the Private Placement on Oslo Børs, and execution of the contemplated Subsequent Offering, will require a prospectus pursuant to chapter 7 of the Norwegian Securities Trading Act. It is expected that such prospectus will be published on or about the time of completion of the Acquisition, and that the Subsequent Offering will commence shortly thereafter. ABG Sundal Collier ASA, Arctic Securities AS, BMO Capital Markets Ltd. and Jefferies are engaged as financial advisors to the Company, ABG Sundal Collier ASA and Arctic Securities AS act as joint lead managers for the Private Placement, Convertible Bond, the Deposit Loan, and the Subsequent Offering. BAHR, CMS and Lundgrens act as legal advisors to the Company, PwC acts as tax advisor and Rystad Energy acts as strategic and commercial advisor. Key financials The below table outlines key financials and other selected key metrics for SOGU for the financial periods ended 31 December per respective period. Key financials for period ended 31 December 2014 2015 2016 2017USDm Audited Audited Audited Audited Sales....................................... 2,353 1,241 849 1,149EBITDAX....................................... 1,691 791 421 821Exploration -32 -18 -2 -1expenses.......................................Depreciation & -853 -1,151 -1,088 -1,009amortisation.......................................EBIT....................................... 805 -377 -669 -189Net profit....................................... 17 -272 -148 -188 Total assets 4,860 4,064 3,076 2,246Shareholder's -161 -208 466 230equity.......................................Total 5,021 4,272 2,610 2,016liabilities....................................... Production 79 71 64 67(mboepd)*.......................................* Production sourced from Danish Energy Agency Company presentation Noreco will host a company presentation in Oslo 18 October 2018 at 10:00 CET. Venue: Arctic Securities AS, Haakon Viis Gt 5, 0161 Oslo Noreco will host a company presentation in Stavanger 18 October 15:00 CET: Venue: Norsk Oljemuseum, Kjeringholmen 1 A, 4006 Stavanger Contacts: Riulf Rustad, Chair of the Board +47 900 87 703 ir@noreco.com  About SOGU’s assets Halfdan Halfdan is the largest producing field in Denmark and the most important DUC asset in terms of value and resources. The field came into production in 1999 and consists of two main groups of platforms, Halfdan A and Halfdan B in addition to an unmanned wellhead platform, Halfdan CA (North East). Produced oil is transported in pipeline to shore via Gorm while the gas is transported to the Tyra hub. Gas can also be imported (for injection) and exported to Dan. Injection water is supplied from Dan. SOGU’s share of remaining reserves is estimated to 61 MMstb oil and 163 Bscf gas as of 31.12.2017 based on independent reserves report. Halfdan produced 24 mboepd in 2017 (net to SOGU). Dan hub Dan was the first field in production in Denmark in 1972. Close to 28% of total Danish oil production has been extracted from Dan. The field remains a significant asset within the DUC portfolio. The Dan field has been developed in several phases and now consists of a total of 12 platforms. The oil production from Dan is transported to Gorm while the gas is transported to Tyra East. The Dan hub has two satellite fields, Kraka and Regnar, of which Kraka is currently producing. SOGU’s share of remaining reserves related to the Dan hub is estimated to 28 MMstb oil as of 31.12.2017 based on independent reserves report. The Dan hub produced 10 mboepd in 2017 (net to SOGU). Tyra hub The Tyra field commenced production in 1984. The field installations comprise three platform complexes, Tyra West, Tyra East and Tyra South East. Tyra is the centre for Denmark’s national energy infrastructure, processing ~90% of the nation’s gas production. The oil and condensate production from the Tyra field and its satellite fields are transported to shore via Gorm. Total, as operator is undertaking the full redevelopment of Tyra as Denmark’s major gas hub, and in the process extending the life of the Danish North Sea. The redevelopment of Tyra ensures continued production from Denmark’s largest gas field and will protect important Danish North Sea infrastructure. The Tyra redevelopment was sanctioned in 2017 and is expected to bring the hub on-stream in 2022. As part of the agreement, Noreco will assume all of Shell’s existing commitments and obligations, including the Tyra redevelopment. The Tyra hub also includes the satellite fields Valdemar, Roar, Svend (Svend is shut in), Harald and Lulita (Noreco holds a 10% working interest in producing field Lulita prior to the transaction). SOGU’s share of remaining reserves related to the Tyra hub is estimated to 35 MMstb oil and 263 Bscf gas as of 31.12.2017 based on independent reserves report. The Tyra hub produced 27 mboepd in 2017 (net to SOGU). Gorm hub Gorm production started in 1981, making it the second Danish field in production. Gorm provides processing and utilities support tosatellite fields Skjold, Rolf and Dagmar (Dagmar is shut in)in addition to being the export centre for most of the liquids produced on the Danish Continental Shelf. The oil from Gorm and the rest of the DUC portfolio is transported onhore to the Frederica refinery via pipeline. Gas from Gorm is sent to the Tyra hubfor export. SOGU’s share of remaining reserves related to the Gorm hub is estimated to 11 MMstb oil as of 31.12.2017 based on independent reserves report. The Gorm hub produced 6 mboepd in 2017 (net to SOGU). About Noreco Noreco is a publicly owned company with focus on the oil, gas and offshore industry. The company's shares are listed on the Oslo Stock Exchange (ticker NOR). For further information, please visit: www.noreco.com.This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and section 3.4 of the Oslo Stock Exchange’s Continuing Obligations. IMPORTANT INFORMATION This release does not constitute an offer, invitation or solicitation of an offer to buy, subscribe or sell any shares in the Company. The distribution of this release in certain jurisdictions is restricted by law. This release is not for distribution or release, directly or indirectly, in or into any jurisdiction in which the distribution or release would be unlawful. Matters discussed in this release may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates, Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”, “anticipates”, “targets”, and similar expressions. Any forward-looking statements contained in this release, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its subsidiary undertakings or any such person’s affiliates, officers or employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors, nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this release or the actual occurrence of the forecasted developments. The Company assume no obligation to update any forward-looking statements or to confirm these forward-looking statements to our actual results.

Invitation to Saab’s Capital Markets Day 2018

Saab President and CEO Håkan Buskhe and other members of the Group Management will present Saab’s strategy, the company’s view on market trends and growth opportunities as well as provide an overview of Saab’s business area Kockums. The event includes a visit to the Kockums shipyard in Karlskrona. The CMD agenda will start on the evening of 14 November in Stockholm with a reception hosted by Håkan Buskhe at the Saab headquarters. Participants will have the opportunity to discover the new Saab showroom, The Edge, including product simulators.   On 15 November, Håkan Buskhe and other members of Group Management invite all participants to Karlskrona, where the CMD will take place at the Maritime museum. Saab offers participants the possibility to travel on a Saab aircraft from Bromma to Ronneby. Programme 14 November: 18.00 – 20:00          Reception at Saab headquarters and presentation of Saab showroom The Edge by President and CEO Håkan Buskhe. Olof Palmes Gata 17C, Stockholm 15 November: 07:30                      Saab aircraft leaves from Grafair Jet Center, Bromma 08:30                      Arrival at Ronneby airport, chartered bus to Karlskrona 10:00                      Welcome and presentation, Maritime Museum, Stumholmen 14:10                      Bus to Kockums shipyard, Amiralitetsgatan 25 15:15                      Bus to Ronneby airport 16:30                      Saab aircraft leaves from Ronneby airport 17:30                      Saab aircraft arrives at Grafair Jet Center, Bromma Please consider that the visit to the shipyard at Kockums will be outside and therefore dress warmly. R.S.V.P. 30 October 2018 to email: cmd.2018@saabgroup.com In the response, please include the following information: · Which parts of the programme you will attend. · If you have any special food requirements (allergies, etc.). · Preferred travel arrangements. If travelling with Saab to Ronneby, please provide information about invoicing details. · ID number (Swedish citizens) or passport number (non-Swedish citizens). Live webcast The CMD will be webcasted live. The presentation material and the webcast will be available on http://www.saabgroup.com/investor-relations For further information, please contact: Ann-Sofi Jönsson, Head of Investor Relations Phone number: +46 (0)734 187214 Ann-sofi.jonsson@saabgroup.com Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Cherry acquires remaining shares in Game Lounge

Cherry currently owns 95 percent of Game Lounge, which in turn owns 100 percent of Game Lounge Ltd. Cherry has today signed an agreement to acquire the remaining 5 percent of Game Lounge. The purchase consideration consists of three parts and can amount to a maximum SEK 260 million. The first part of the purchase consideration is fixed and amounts to SEK 100 million to be paid in cash when Cherry gains control of the shares. The second part of the purchase considerations amounts to SEK 60 million and is conditional on Game Lounge’s consolidated EBITDA for the period 1 January 2019 to 30 June 2019 exceeding SEK 90 million. In the event that the target of SEK 90 million is not reached as per 30 June 2019, the measurement period will be extended until 30 September 2019, at which time, Game Lounge’s consolidated EBITDA shall amount to at least SEK 150 million. The third part of the purchase consideration amounts to SEK 100 million and requires Game Lounge’s consolidated EBITDA to exceed SEK 300 million for any consecutive four calendar quarter period between 1 July 2019 and 31 December 2021, or between 1 October 2019 and 31 December 2021 in the event that the measurement period for the second part of the purchase consideration is extended in accordance with the above. Cherry is entitled to pay all or part of the second and third parts of the purchase consideration in Class B shares in Cherry. The sellers are employees of Game Lounge. Against this background, the acquisition constitutes a so-called related-party transaction and must therefore be approved by a general meeting in Cherry. Cherry’s Board of Directors will prepare a written account of the acquisition and obtain an independent valuation statement (fairness opinion) regarding Game Lounge. The operations in Game Lounge have developed well and Cherry’s Board of Directors makes the assessment that the company will continue to enjoy favourable market conditions into the future and that it is therefore desirable to increase Cherry’s holding to 100 percent. The sellers will remain in their senior positions, are shareholders in Cherry and also participate in incentive program within the Cherry Group. Accordingly, the Board of Directors assesses that the terms of the acquisition, including the purchase consideration, are in line with the market and will therefore recommend that Cherry’s Annual General Meeting approve the acquisition in accordance with the principal terms above. For further information, please contact: Gunnar Lind, Acting President and CEO, gunnar.lind@cherry.seChristine Rankin, CFO, Tel.: +46 765 399 492, christine.rankin@cherry.seAnders Antonsson, IR & Communications: +46 709 994 970, anders.antonsson@cherry.se This information is such that Cherry AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication under the auspices of the contacts detailed above on 17 October 2018, at 3:50 p.m. CET. CHERRY IN BRIEF Cherry is an innovative and fast-growing gaming company with operations in gaming, media and entertainment.The company was founded in 1963 and today, Cherry operates through five diversified business areas: Online Gaming, Game Development, Online Marketing, Gaming Technology, and Restaurant Casino. The Group’s objective is to grow organically in combination with strategic acquisitions of fast-growing companies. Cherry employs some 1,400 people and has about 9,250 shareholders. The company’s class B share is listed on the Nasdaq Stockholm exchange, Mid Cap segment. More information is available at www.cherry.se.

Nederman acquires Luwa Air Engineering AG, a global market leader in fibre and textile air engineering

Luwa, founded in 1935, is a global market leader in textile air engineering and a quality and performance leader with a global brand in the fibre and textile industry. The Luwa Group’s activities include the design and engineering of single components and whole systems as well as manufacturing, assembly, installation and after sales services. Manufacturing and assembly facilities are situated in India and China and the group has a significant global installed base that is the source of Luwa’s deep understanding of the technical demands as well as the local requirements of customers.  The acquisition price amounts to CHF 28.5 million under a locked box mechanism, based on consolidated equity capital as of December 31, 2017.   The acquisition is funded by a combination of cash and existing bank facilities. The acquisition price will be paid in two instalments, the first instalment today on completion, and the second instalment of CHF 5.7 million two calendar years after completion. The Luwa Group, with approximately 350 employees, had a turnover in 2017 of CHF 66 million. Luwa will be part of the Nederman Mikropul organisation. The Luwa brand and team will continue to operate as before, and their high quality solutions will add to the Nederman Group’s capabilities in the strategically important global fibre and textile market. “Luwa is an excellent complimentary fit for the Nederman Group. Combining Luwa’s strong market presence, particularly in the Asia Pacific region, and their proven world leading technical capabilities and strong brand name and installed base within the strategically important fibre and textile markets, with Nederman’s global organisation and presence will make the Nederman Group a more complete partner for our customers,” says President and CEO, Sven Kristensson.   On behalf of the sellers and owners for the past 11 years, Gruenwald Equity Group, Dr Raimund Koenig, founder and managing partner says: “The perfect fit of Luwa with Nederman again shows the success of the long term strategic and operational investment approach of Gruenwald Equity in developing businesses.”  For further information,please contact:Sven Kristensson, CEO          Matthew Cusick, CFO                              Telephone: +46 42 18 87 00    Telephone +46 42 18 87 00 e-mail: e-mail: matthew.cusick@nederman.com sven.kristensson@nederman.com      This information is information that Nederman Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 04:30 p.m. CET on October 17, 2018.        Facts about NedermanThe Nederman Group is a world-leading supplier and developer of products and solutions within the environmental technology sector. We filter, clean and recycle in demanding industrial environments. Clean air is a cornerstone for sustainable production and Nederman’s products and solutions improve production efficiency, reduce environmental impact and protect employees from harmful dust, smoke and fumes. The Nederman Group is listed on Nasdaq Stockholm. The Group has 1800 employees and presence in more than 50 countries. Learn more at nedermangroup.com  Nederman Holding AB (publ), P.O. Box 602, SE-251 06 Helsingborg, Sweden. Corporate registration number: 556576-4205

QuickCool AB (publ): QuickCool calls for the Extraordinary General Meeting and Rights Issue

The Board proposes that the EGM: -               Decides to reduce the share capital of the Company with 4.224.789,60 kronor, without reducing the number of shares. Thereby, the share capital of the Company will be reduced to 12.674.368,80 kronor and the quota value of the share to 0,6 kronor. The reason for the proposal is to align the quota value to the terms and conditions of the financing agreement that was entered with European High Growth Opportunities Securitization Fund through its advisor Alpha Blue Ocean (for more information, please refer to the press release of 21 June 2018). -               Decides on a rights issue of 6.2 MSEK, comprising Units that if fully subscribed brings circa 6,2 MSEK before issuance costs. Summary: · The one who is a registered shareholder on 23 November 2018 in QuickCool has preferential rights to Units in this Rights Issue, where every existing share entitles to one (1) Unit Right (UR) and ten (10) URs entitle to subscribe to one (1) Unit at a subscription rate of 3,00 SEK per Unit. · One Unit comprises three (3) shares and one (1) warrant TO2.   · The subscription period starts on 27 November and ends on 11 December 2018. · The rights issue is guaranteed through guarantee commitments to about 50% of the rights issue, amounting to circa 3 MSEK. · The rights issue will primarily be used to improve the financial flexibility in conjunction with the production of the 0-series and the third party testing.   · The terms and conditions of the rights issue are aligned with the terms and conditions that were agreed with European High Growth Opportunities Securitization Fund.   Indicative Timeplan   +---------------+-----------------------------------------------------------+|15 November |Extraordinary General Meeting to decide on rights issue ||2018 | |+---------------+-----------------------------------------------------------+|21 November |Last day for trading of QuickCool share, including the ||2018 |preferential right to participate in the Rights Issue |+---------------+-----------------------------------------------------------+|22 November |First day for trading of QuickCool share, excluding the ||2018 |preferential right to participate in the Rights Issue |+---------------+-----------------------------------------------------------+|23 November |Day for recording the ones who are entitled to the ||2018 |preferential right to participate in the Rights Issue |+---------------+-----------------------------------------------------------+|About 23 |Memorandum is published ||November 2018 | |+---------------+-----------------------------------------------------------+|27 November – |Subscription period ||11 December | ||2018 | |+---------------+-----------------------------------------------------------+|27 November – 7|Trading period of URs on Spotlight Stock Market ||December 2018 | |+---------------+-----------------------------------------------------------+|27 November |Trading period of BTAs until the rights issue is registered||2018 (onwards) |with the Swedish Companies Registration Office |+---------------+-----------------------------------------------------------+|About 13 |Publication of final outcome in the Rights Issue ||December 2018 | |+---------------+-----------------------------------------------------------+ The Board of Directors’ proposal will be presented and decided upon at the Extraordinary General Meeting on 15 November 2018. The EGM is called for in a separate press release today. Lund, 17 October 2018QuickCool AB (publ)Board of Directors Fredrik RadencrantzCEO QuickCool AB Ideon Science ParkBeta 6, Scheelevägen 17 - SE-223 70 Lund - SwedenE-mail: fredrik.radencrantz@quickcool.se Web: www.quickcool.seMobile +46 (0)73 834 1188 This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made publicly available by the Company’s contact person on 17 October, 2018. Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se

EQL Pharma resolves on a rights issue of approximately SEK 24.9 million and announces changed date for publication of the Q2 interim report to 18th October, 2018

The rights issue in brief Pursuant to the authorization resolved by the annual general meeting on August 22nd, 2018, the board of directors of EQL Pharma has today resolved on a rights issue of shares (the “Issue”). Through the Issue, EQL Pharma will get a capital injection of approximately SEK 24.9 million before issue costs. The issue costs are estimated to amount to approximately SEK 1.7 million, of which underwriting costs represent SEK 0.3 million. Each existing share entitles to one (1) subscription right and six (6) subscription rights entitle to subscription of one (1) new share. The subscription price amounts to SEK 6.00 per share. The subscription period in the Issue will run during the time period October 30th, 2018 – November 13th, 2018. Motive for the Issue and use of proceeds EQL Pharma has laid the foundation for future growth and currently markets 10 niche generics and have a total pipeline of 36 products. The Company also has a well-functioning cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China. In addition, the Company has identified a range of new products that may be launched in the next few years. This development will be capital intensive and to enable the pipeline expansion, a capital injection is needed. The proceeds of the Issue will be used exclusively for studies and applications of new generics. Christer Fåhraeus, CEO of EQL Pharma comments: EQL Pharma is about to take the next step in the Company’s development. The Company’s ambition is to expand the current portfolio of pharmaceutical projects. Even if EQL Pharma, at an operating level is internally financed and in addition has agreed on new bank financing, a capital injection will be needed in order to realize the expansion of our pipeline. Terms for the Issue and indicative timetable: · Each existing share entitles to one (1) subscription right · Six (6) subscription rights entitle to subscription of one (1) new share · The subscription price is determined to SEK 6.00 per share · In total, 4,151,944 new shares may be issued at the highest in the Issue. If fully subscribed, the number of shares will thus increase from 24,911,666 to 29,063,610 and the share capital will increase with SEK 186,837.48 from SEK 1,121,024.97 to SEK 1,307,862.45, corresponding to a dilution of approximately 14.3 percent for shareholders not participating in the Issue · The record date for the Issue is October 24th, 2018 · Last day of trading in the EQL Pharma share with right to participate in the Issue is October 22nd, 2018 · The subscription period will run from October 30th to November 13th, 2018 · Subscription by exercise of subscription rights shall be made through simultaneous cash payment. Subscription without exercise of subscription rights shall be made through subscription on a special application form. Payment for shares subscribed for without exercise of subscription rights shall be made in cash in accordance with the specific instruction in the promissory note · The board of directors shall have the right to prolong the time period for subscription and payment · Trading in subscription rights will take place from October 30th to November 9th, 2018 · Trading in paid subscribed shares will take place from October 30th, 2018 until the Issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) · An information memorandum will be published in conjunction with the commencement of the subscription period Preferential rights If not all shares are subscribed for by exercise of subscription rights, allotment of the remaining shares shall be made within the highest amount of the Issue: (i)                  firstly, to those who have subscribed for shares by exercise of subscription rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro-rata in relation to the number of subscription rights that each and every one of those, who have applied for subscription of shares without exercise of subscription rights, have exercised for subscription of shares; (ii)                 secondly, to those who have subscribed for shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro-rata in relation to the number of shares the subscriber in total has applied to subscribe for; and (iii)               thirdly, to those who have provided underwriting commitments with regard to subscription of shares, in proportion to such underwriting commitments. To the extent that allotment in any section above cannot be done pro-rata, allotment shall be determined by drawing of lots. Subscription undertakings and underwriting commitments The Company has obtained subscription undertakings from existing shareholders of approximately SEK 15 million (corresponding to approximately 60 percent of the Issue). In addition, the Company has obtained underwriting commitments from Christer Fåhraeus through company and the board member Lars Holmqvist through company, for a total amount of approximately SEK 9.9 million (corresponding to approximately 40 percent of the Issue). Consequently, the Company has received subscription undertakings and underwriting commitments corresponding to 100 percent of the Issue. Information memorandum  The Company will publish an information memorandum in conjunction with the Issue. In the information memorandum, there will be additional information about subscription undertakings, underwriting commitments etc. The complete memorandum will be available on the Company’s website (www.eqlpharma.com), Spotlight Stock Market’s website (www.spotlightstockmarket.com), Västra Hamnen Corporate Finance website (www.vhcorp.se) and Aqurat Fondkommission’s website (www.aqurat.se) in conjunction with the commencement of the subscription period. Financial and legal advisors Västra Hamnen Corporate Finance AB is financial advisor and Setterwalls Advokatbyrå AB is legal advisor to EQL Pharma in connection with the Issue. Changed date for Q2 interim report To ensure that investors in conjunction with the Issue have access to the latest financial information about the Company, the date for publication of the Q2 interim report has been changed to the 18th October, 2018. Previously announced date for publication of the Q2 interim report was 15th November, 2018. This information is information which EQL Pharma AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2018. 

Daniel Harding renews contract with the Swedish Radio Symphony Orchestra until 2023 - named Artistic Director

Daniel Harding conducting the Swedish Radio Symphony Orchestra. Photo: Arne HyckenbergIn addition to renewing his role, Daniel Harding will become the orchestra’s first ever Artistic Director, giving him overall responsibility for the orchestra’s artistic vision, allowing him to create new programme formats and to help build new audiences. “It is increasingly rare to find that a conductor’s relationship with an orchestra not only survives more than a decade but also continues to deepen and grow. It is also rare to find an orchestra that has the highest musical intelligence and quality and the determination to continue to thrive. I’m thrilled to belong to this musical family.”, says Daniel Harding about the Swedish Radio Symphony Orchestra.  “We are so proud to have Daniel Harding leading our orchestra.  His passion and his energy and his creativity challenge us and our audience every single day.  He is also a brilliant ambassador for Swedish Radio which is a luxury that very few broadcasting corporations enjoy.  With Daniel Harding, the Swedish Radio Symphony Orchestra plays a crucial role in musical life both in Sweden and abroad”, says Cilla Benkö, Director General of Swedish Radio. “We are fortunate to have the backing of an enormous and extensive media organisation. We must work as closely as possible with the Swedish Radio to tell Sweden and the rest of the world about all the wonderful things we’re doing; something I’m excited to do in my new role as Artistic Director”, Daniel Harding adds. As part of the celebration of this exciting news, the Swedish Radio Symphony Orchestra and Daniel Harding will go on an extensive 11-stop European tour next month including concerts at the Concertgebouw Amsterdam, Konzerthaus Vienna, Elbphilharmonie Hamburg and Philharmonie am Gasteig in Munich with Janine Jansen and Alina Ibragimova as soloists. “A tour as important and prestigious as this one is the result of years of hard work and extraordinary music making under Daniel Harding’s leadership.  His stock is so high all around the world and so we are very proud to travel with him to the musical meccas of Europe. This tour is THE perfect way to affirm our very special bond and relationship.” says Helena Wessman, General Manager of the Swedish Radio Symphony Orchestra and Berwaldhallen in Stockholm. Daniel Harding continues to work regularly with the Berliner Philharmoniker, Vienna Philharmoniker,  Symphonieorchester des Bayerischen Rundfunks, Royal Concertgebouw Orchestra, Dresden Staatskapelle and the London Symphony Orchestra. He has recently been appointed Artistic Director of the Anima Mundi Festival in Pisa. He is perhaps the only conductor on earth to have qualified as an Airbus A320 pilot. The Swedish Radio Symphony Orchestra has an extraordinary history and has received worldwide acclaim for its concerts, radio broadcasts, recordings and international tours. It is resident at Berwaldhallen in Stockholm, alongside the renowned Swedish Radio Choir. Concerts on the European tour, november 2018Antwerpen, 12 november – Koningin ElisabethzaalEindhoven, 13 november – Muziekgebouw EindhovenAmsterdam, 14 november – Concertgebouw AmsterdamKöln, 15 november – Kölner PhilharmonieHamburg, 16 november – ElbphilharmonieWien, 18 november – Wiener KonzerthausZürich, 19 november – Tonhalle MaagMünchen, 20 november – Philharmonie am GasteigNürnberg, 21 november – Meistersingerhalle NürnbergBaden Baden, 23 november – Festspielhaus Baden-BadenDortmund, 25 november – Konzerthaus Dortmund Links to biographiesDaniel Harding Swedish Radio Symphony Orchestra  Watch a video about Daniel Harding’s renewed contract . For more information and interview requests, please contact

BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD

Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain. The presentation will be given during the symposium “Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD” where additional data will be highlighted from the BAN2401 Phase 2b study (ClinicalTrials.gov identifier: NCT01767311). Presentation of BAN2401 at CTAD 2018: Product, Title and scheduled presentation dateSession and timeNumberBAN2401 Clinical and Biomarker Updates fromSession no.: BAN2401 Study 201 in EarlySymposium 3 ADSymposium:  October 25 (Thursday), 14:30 – 15:30 CEST  (02:30 – 03:30 p.m. CEST) The BAN2401 Phase 2b study presentation at CTAD will be webcast live on Thursday, October 25 at 14:30 – 15:30 CEST. To access the live webcast, please visit https://www.eisai.com/ir/index.html. BioArctic previously announced results from BAN2401 Phase 2b study presented by Eisai during the Alzheimer’s Association International Conference (AAIC) in July 2018. More information in the press releases: “BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s disease ” and “BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018 ”. BioArctic is striving to develop disease-modifying treatments in order to contribute to addressing unmet medical needs of Alzheimer patients and their families. Today there is no disease-modifying treatment on the market for these patients. This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval. For more information, please contactGunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 Christina Astrén, Director IR & Communications, BioArctic ABE-mail: christina.astren@bioarctic.seTelephone: + 46 70 835 43 36 Notes to editorsPlease note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until after the officially scheduled date and time of presentation, symposia or poster session. About BAN2401BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 selectively binds to neutralize and eliminate soluble, toxic amyloid-beta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007. Eisai is responsible for the Phase 2b study and the development of BAN2401 for Alzheimer’s disease. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401. About the collaboration between BioArctic and Eisai  Since 2005, BioArctic has long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the development and commercialization agreement on the BAN2401 antibody, which was signed in December 2007, and the development and commercialization agreement on the antibody BAN2401 back-up for Alzheimer's disease, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com. About Eisai Co., Ltd.Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai defines their corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which Eisai calls their human health care (hhc) philosophy. With approximately 10,000 employees working across the global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to realize their hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. Leveraging the experience gained from the development and marketing of Aricept®, a treatment for Alzheimer’s disease and dementia with Lewy bodies, Eisai has been working to establish a social environment that involves patients in each community in cooperation with various stakeholders including the government, healthcare professionals and care workers, and is estimated to have held over ten thousand dementia awareness events worldwide. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions. For more information about Eisai Co., Ltd., please visit www.eisai.com. This information was submitted for publication at 01:30 a.m. CET on October 18, 2018.

Atea reports financial results for Q3 2018

Financial highlights are as follows: ·  Revenue: NOK 7.1 billion (NOK 6.7 billion) ·  Gross profit: NOK 1.7 billion (NOK 1.6 billion) ·  EBITDA before share based compensation: NOK 249 million (NOK 272 million) ·  EBIT: NOK 132 million (NOK 176 million) Outside of Denmark, Atea reported revenue growth of 15.7% in Q3 and EBIT growth of 24.2% from last year. In Denmark, Atea reported lower revenue and a EBIT loss of DKK 39 million (NOK 50 million) in Q3, as a court conviction in June continued to negatively impact the business throughout the quarter. Furthermore, Atea incurred operating losses of NOK 8 million in a newly launched start-up venture called AppXite, which was in line with management’s expectations. Adjusted for the cost of a legal penalty in Denmark and the operating losses in the AppXite business venture, Group EBIT was NOK 144 million in Q3 2018. Approval of the self-cleaning program was delayed compared with management’s assumptions during the Q2 report and the company had higher-than-expected share based compensation costs due to a very strong appreciation in the Atea share price during Q3. “I am very pleased with Atea’s continued strong growth in revenue and operating profit in all geographies outside of Denmark,” commented Atea CEO Steinar Sønsteby. “In Denmark, we look forward to returning to normal operations and turning around the business following the acceptance of our self-cleaning program in September.” The interim report and presentation are available at https://www.atea.com/investors/financial-reports/The press conference is available via webcast at https://www.atea.com/investors/financial-reports/2018/webcast-q3-18/   The Stock Exchange Announcement is available at https://www.atea.com/about-atea/news/  For further information, please contact: Steinar Sønsteby, CEO Atea ASA, mobile (+47) 930 55 655 Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188 About Atea Atea is the leading supplier of IT infrastructure and system integration in the Nordic and Baltic regions with 7,200 employees. Atea is present in 87 cities in Norway, Sweden, Denmark, Finland, Lithuania, Latvia and Estonia. Atea delivers IT products from leading vendors and assists its customers with specialist competencies within IT infrastructure services. Atea had revenue of approximately NOK 32 billion in 2017 and is listed on Oslo Stock Exchange https://www.atea.com 

Tele2 AB: Interim Report Third Quarter 2018

CEO comment by Allison Kirkby“The final quarter before the closing of the merger with Com Hem was once again a quarter of solid business trends, allowing us to make another upgrade of our full-year guidance. Mobile end-user service revenue growth was 5 percent and adjusted EBITDA growth was 9 percent, like-for-like. Our investment markets continue to outperform while Sweden remained resilient, returning to mid-single digit EBITDA growth as the drag from Roam Like at Home is now behind us. Operating cash flow for continuing operations grew by 14 percent on a rolling 12-months basis.” Highlights · Revenue growth of 4 percent like-for-like, to SEK 6,538 million · Mobile end-user service revenue growth of 5 percent and adjusted EBITDA growth of 9 percent, like-for-like · Rolling 12 months operating cash flow growth of 14 percent · Sweden returns to growth of 1 percent in mobile end-user service revenue, driven by B2B, and adjusted EBITDA growth of 6 percent · Continued momentum in our investment markets with like-for-like growth in mobile end-user service revenue of 22 percent in Kazakhstan and 12 percent in Croatia  · Extraordinary General Meeting and European Commission approved Com Hem merger, with expected closing on November 5 · Earnings per share, after dilution, was SEK 1.28 · 2018 financial guidance upgraded with adjusted EBITDA between SEK 7.0 and 7.2 billion (previously between SEK 6.8 and 7.1 billion) Presentation of the third quarter 2018Tele2 will host a presentation with the possibility to join through a conference call, for the global financial community at 10:00 am CEST (09:00 am BST, 04:00 am EDT) on Thursday, October 18, 2018. The presentation will be held in English and will also be available as a webcast on Tele2’s website: www.tele2.com   Dial-in informationTo ensure that you are connected to the conference call, please dial in a few minutes before the start of the conference call to register your attendance. Ask for ‘Tele2’.Dial-in numbers:SE: +46 (0)8 5033 6574UK: +44 (0)330 336 9105US: +1 929-477-0324For more information, please contact:Joel Ibson, Head of Public Relations, Tele2 AB, Phone: +46 766 26 44 00Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88This information is information that Tele2 AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CEST on October 18, 2018._________________________________________________________________________ TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We believe the connected life is a better life, and so our aim is to make connectivity increasingly accessible to our customers, no matter where or when they need it. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 offers mobile services, fixed broadband and telephony, data network services, content services and global IoT solutions. Every day our 17 million customers across eight countries enjoy a fast and wireless experience through our award winning networks. Tele2 has been listed on Nasdaq Stockholm since 1996. In 2017, Tele2 generated revenue of SEK 25 billion and reported an adjusted EBITDA of SEK 6.4 billion. For definitions of measures, please see the last pages of the Annual Report 2017. Follow @Tele2group on Twitter for the latest updates.

Ericsson reports third quarter results 2018

Third quarter highlights   · Sales as reported increased YoY by 9% and sales adjusted for comparable units and currency increased by 1%. · Segment Networks showed a sales growth adjusted for comparable units and currency of 5% YoY with strong sales growth in North America as well as in Europe and Latin America. · Gross margin was 36.5% (26.9%). Gross margin excluding restructuring charges improved to 36.9% (28.5%), driven mainly by cost reductions, the continued ramp-up of Ericsson Radio System (ERS) and good progress in reviewing Managed Services contracts. · Operating margin was 6.0% (-7.4%). Operating margin excluding restructuring charges was 7.0% (-1.7%). · Networks operating margin excluding restructuring charges was 16.1% (11.9%) driven by cost reductions and ERS ramp-up, partly offset by increased investments in R&D. · Digital Services operating margin excluding restructuring charges was -15.9% (-29.9%) supported by a gross margin excluding restructuring charges of 36.9% (32.0%). Sequentially, gross margin declined from 42.6% mainly due to increased provisions related to transformation projects. · Managed Services operating margin excluding restructuring charges improved to 6.8% (-9.5%) as a result of cost reductions and customer contract reviews. · Cash flow from operating activities was SEK 2.0 (0.0) b. and free cash flow excluding M&A was SEK 0.7 (-0.8) b. Net cash increased YoY to SEK 32.0 (24.1) b. +----------------------------+------+------+------+------+------+-------+-------+|SEK b. |Q3 |Q3 |YoY |Q2 |QoQ |9 month|9 month|| |2018 |2017 |change|2018 |change|s |s 2017 || | | | | | |2018 | |+----------------------------+------+------+------+------+------+-------+-------+|Net sales |53.8 |49.4 |9% |49.8 |8% |147.0 |147.5 |+----------------------------+------+------+------+------+------+-------+-------+|Sales growth adj. for |-  |-  |1%  |-  |7%  |-  |-  ||comparable units and | | | | | | | ||currency  | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+|Gross margin |36.5% |26.9% |- |34.8% |- |35.2% |24.0% |+----------------------------+------+------+------+------+------+-------+-------+|Operating income (loss) |3.2 |-3.7 |- |0.2 |- |3.1 |-15.5 |+----------------------------+------+------+------+------+------+-------+-------+|Operating margin |6.0% |-7.4% |- |0.3% |- |2.1% |-10.5% |+----------------------------+------+------+------+------+------+-------+-------+|Net income (loss) |2.7 |-3.5 |- |-1.8 |- |0.2 |-13.9 |+----------------------------+------+------+------+------+------+-------+-------+|EPS diluted, SEK |0.83 |-1.09 |- |-0.58 |- |0.01 |-4.31 |+----------------------------+------+------+------+------+------+-------+-------+|EPS (non-IFRS), SEK [1] |1.03 |-0.29 |- |-0.09 |- |1.04 |-2.15 |+----------------------------+------+------+------+------+------+-------+-------+|Cash flow from operating |2.0 |0.0 |- |1.4 |41% |5.1 |-1.6 ||activities | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+|Free cash flow excluding M&A|0.7 |-0.8 |- |-0.2 |- |1.3 |-5.4 ||[2] | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+|Net cash, end of period |32.0 |24.1 |33% |33.1 |-3% |32.0 |24.1 |+----------------------------+------+------+------+------+------+-------+-------+|Gross margin excluding |36.9% |28.5% |-  |36.7% |-  |36.5%  |26.2%  ||restructuring charges  | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+|Operating income (loss) |3.8  |-0.8  |-  |2.0  |85%  |6.7  |-9.4  ||excluding restructuring | | | | | | | ||charges  | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+|Operating margin excluding |7.0%  |-1.7% |-  |4.1%  |-  |4.6%  |-6.4%  ||restructuring charges  | | | | | | | |+----------------------------+------+------+------+------+------+-------+-------+ [1] EPS diluted, excl. amortizations and write-downs of acquired intangible assets, and excluding restructuring charges. Potential ordinary shares are not considered when their conversion to ordinary shares would increase earnings per share. [2] Free cash flow excluding M&A: See Alternative Performance Measures (APM) at the end of the report. Non-IFRS financial measures are reconciled to the most directly reconcilable line items in the financial statements at the end of this report. Comments from Börje Ekholm, President and CEO of Ericsson (NASDAQ:ERIC) "We continue to execute on our focused strategy, tracking well towards our 2020 targets. We see improvements across our businesses resulting in a gross margin[1] of 36.9% (28.5%) and an operating margin[1] of 7.0% (-1.7%). Organic [2] sales growth was 1% for the Group, despite headwind from exited non-strategic contracts. We continue to invest in our competitive 5G-ready portfolio to enable our customers to efficiently migrate to 5G. Operators around the world plan for launching 5G services, led by North America. The strong customer interest in 5G generates a gradual increase in costs for field trials. We expect the costs to remain on high levels, at least for the coming 12-18 months, and they are included in our 2020 profitability target of at least 10%. Networks gross margin[1] improved to 41.5% (34.8%) with an organic[2] sales growth of 5%. The strong sales were mainly driven by a continued high activity level primarily in North America. Due to the strong sequential sales increase in the third quarter we expect lower effects from seasonality than normal in the fourth quarter in Networks. Digital Services gross margin[1] improved to 36.9% (32.0%) YoY, but declined QoQ. We see clear results of our cost-out activities and good progress in large parts of the business. At the same time, provisions related to large digital transformation projects increased in the quarter, explaining the sequential drop in gross margin. We are not satisfied with the development in these digital transformation projects and are thus increasing our efforts to turn them around. In Managed Services, gross margin[1] improved to 12.9% (-4.0%) supported by efficiency gains and customer contract reviews. We have finalized 40 of the targeted 42 contracts, with an annualized profit improvement of SEK 0.9 b. We are increasing our investments in R&D to reshape the offering based on automation and artificial intelligence. We see strong customer interest in the coming solutions, but sales are so far limited as we are in early stages. In segment Emerging Business and Other, sales grew by 22% driven by growth in the iconectiv business. We continue to invest in strategic future growth areas such as Internet of Things (IoT) and saw increasing momentum with one important customer win with our connectivity platform solutions in the quarter. As parts of the portfolio in Emerging Business are in an early phase, sales are so far limited. We will remain disciplined in our investments in Emerging Business by tracking each venture against delivery milestones. Even though the cost reduction program, announced in July 2017, has been completed, we continue our efforts to drive efficiency and cost reductions to further increase competitiveness. Our estimate for restructuring charges of SEK 5-7 b. for the full year remains. Free cash flow excluding M&A improved to SEK 0.7 (-0.8) b. and our cash position remains strong. Our work to further strengthen the balance sheet continues. As previously disclosed, we have been voluntarily cooperating since 2013 with an investigation by the SEC and, since 2015, with an investigation by the DOJ into Ericsson’s compliance with the U.S. FCPA. While we cannot comment in detail we can provide the following update on the process. We have identified facts that are relevant to the investigations and these facts have been shared with the authorities. We continue to cooperate with the SEC and the DOJ and are engaged in discussions with them to find a resolution. While the length of these discussions cannot be determined, based on the facts that we have shared with the authorities, we believe that the resolution of these matters will likely result in monetary and other measures, the magnitude of which cannot be estimated currently but may be material. We continue our efforts to improve on our compliance program. See further details in “Other information”. There is strong momentum in the global 5G market with lead markets moving forward. The global radio access market is recovering from several years of negative growth and our investments in R&D have positioned us well to benefit from this development. More work remains, however, to get all parts of the business to a satisfactory performance level. We remain confident in reaching our long-term target of at least 12% operating margin beyond 2020.” Börje Ekholm President and CEO [1] Excluding restructuring charges [2] Organic sales growth: Sales adjusted for comparable units and currency Planning assumptions going forward Market related                                                                                                                                 · The Radio Access Network (RAN) equipment market is estimated to decline by -2% for full-year 2018 with 2% CAGR for 2017-2022. (Source: Dell’Oro) Currency exposure                                            · Rule of thumb: A weakening by 10% of USD to SEK would have a negative impact of approximately -5% on net sales and approximately -1 percentage point on operating margin (based on 2017 full-year currency exposure). Ericsson related 2018; Sales · Sales growth in 2017 between Q3 and Q4 was 17%. · Due to strong sequential sales increase in the third quarter, lower effects from seasonality than normal are expected in the fourth quarter in Networks. Ericsson related 2018; Operating expenses · Gradually increased cost for field trials. · Operating expenses typically increase between Q3 and Q4 due to seasonality. · To further strengthen technology leadership, R&D expenses will increase primarily in Networks in Q4. · The divestment of Media Solutions is expected to be closed around year-end 2018 with estimated additional expenses of SEK -0.2 b. in Q4. Ericsson related 2018; Other · Restructuring charges for full-year 2018 are estimated to be SEK 5-7 b. · Actual and estimated net impact from amortization and capitalization of development expenses and from recognition and deferral of hardware costs: +--------+-------+--------+-------+--------------+----------------+--------+|SEK b. |Q3 2018|Q4 2018 |Q4 2017|FY 2017 Actual|FY 2018 Estimate|FY 2019 || |Actual |Estimate|Actual | | |Estimate|+--------+-------+--------+-------+--------------+----------------+--------+|Cost of |-0.2 |-0.1 |-0.8 |-2.6 |-0.7 | ||sales | | | | | | |+--------+-------+--------+-------+--------------+----------------+--------+|R&D |-0.5 |-0.5 |-0.6 |-0.3 |-1.7 | ||expenses| | | | | | |+--------+-------+--------+-------+--------------+----------------+--------+|Total |-0.7 |-0.6 |-1.4 |-2.9 |-2.4 |-1 to -2||impact | | | | | | |+--------+-------+--------+-------+--------------+----------------+--------+ NOTES TO EDITORS You find the complete report with tables in the attached PDF or by following this link https://www.ericsson.com/assets/local/investors/documents/financial-reports-and-filings/interim-reports-archive/2018/9month18-en.pdf or on www.ericsson.com/investors The company will hold a press briefing, which will also be available through a live webcast, starting at 09.00 CEST on October 18, 2018 at Ericsson Studio, Grönlandsgatan 8, Kista, Sweden.  A conference call for analysts, investors and media will begin at 14.00 (CEST). Live webcast of the briefing and conference call details, as well as supporting slides, will be available at www.ericsson.com/press and www.ericsson.com/investors  FOR FURTHER INFORMATION, PLEASE CONTACT Contact person Peter Nyquist, Head of Investor RelationsPhone: +46 10 714 64 99E-mail: peter.nyquist@ericsson.com  Additional contacts Helena Norrman, Senior Vice President, Marketing and CommunicationsPhone: +46 10 719 34 72E-mail: media.relations@ericsson.com Investors Åsa Konnbjer, Director, Investor RelationsPhone: +46 10 713 39 28E-mail: asa.konnbjer@ericsson.com Stefan Jelvin, Director, Investor RelationsPhone: +46 10 714 20 39E-mail: stefan.jelvin@ericsson.com  Rikard Tunedal, Director, Investor RelationsPhone: +46 10 714 54 00E-mail: rikard.tunedal@ericsson.com Media Ola Rembe, Vice President, Head of External CommunicationsPhone: +46 10 719 97 27E-mail: media.relations@ericsson.com  Corporate CommunicationsPhone: +46 10 719 69 92E-mail: media.relations@ericsson.com This information is information that Telefonaktiebolaget LM Ericsson is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CEST on October 18, 2018.  

Ahlsell awarded work-site logistics contract for the construction of Karlatornet in Gothenburg

Ahlsell has been awarded the work-site logistics contract for the construction of Karlatornet, the tallest building ever built in the Nordic region. Karlatornet, which is to be built in the new Karlastaden district in Gothenburg, will have 73 floors and be 245 meters high. The tower is expected to be ready for its first residents in 2021 and the new district is planned to be completed a few years later. The contract covers the full logistic solution for the project, and Ahlsell will have some 40 employees involved in the logistics throughout the project time. For Ahlsell, the project will be running at full speed from 2020 onwards, with a ramping up period throughout 2019. The customer is Serneke Bygg AB and for them, it was critical to find a business partner with competence and innovative thinking about complex logistics flows. "It’s a high construction on a very small area. Already at an early stage, we at Serneke identified the logistical challenges in the project. The logistics concept we planned for has now, with help from Ahlsell, been refined further. With their experience of complex flows and commitment to work-site logistics, it was natural to select them as partners in the project.", says Conny Segerdahl, Site manager, Karlatornet, Serneke Bygg AB. Ahlsell has a thorough experience of efficient and sustainable logistics solutions, why efficient work-site logistics has been on the agenda for a long time. For the last three years, the company has worked with an increased focus to define and market the solution. "There are studies showing that installers only work efficiently with installation 30-40% of the time. The rest of the time is spent on waiting, searching for or retrieving material. In current times of resource shortage and requirements for cost-effectiveness, there is a huge upside for customers to get the right products, to the right place at the right time.", says Fredrik Bergegård, Sales Director at Ahlsell Sverige. The service “efficient work-site logistics” only represents a small part of the Group revenues today, but the potential is significant. "We are convinced that efficient work-site logistics is the future way to build, as there are so many benefits. The customer reduces its total cost of the project while reducing the risk of project delays. It also results in a sustainable construction as fewer trucks with a higher filling degree reduces greenhouse gas emissions. Another advantage is that the workplace accidents are reduced too, as construction material is not laying around on the construction site before being used." Fredrik continues. The partners have agreed not to disclose the scope of the contract. For Ahlsell, the profitability level of the agreement is in line with the Group's. For further information please contact:    Karin Larsson, Head of Investor Relations and external communications+46 8 685 59 24, Karin.Larsson@ahlsell.se Ahlsell is the Nordic region’s leading distributor of installation products, tools and supplies for installers, construction companies, facility managers, industrial and power companies and the public sector. The unique customer offer covers more than one million individual products and solutions. The Group has a turnover of just over SEK 29 billion and is listed on Nasdaq Stockholm. About 97% of revenue is generated in the three main markets of Sweden, Norway and Finland. With about 5,800 employees, more than 230 branches and three central warehouses, we constantly fulfil our customer promise: Ahlsell makes it easier to be professional! Press ReleaseStockholm, October 18, 2018

Citycon Oyj’s Interim Report for 1 January – 30 September 2018: Solid operating performance continued and administrative expenses declined significantly.

- Occupancy remained at a high level of 96.1%.- Successful opening of newest asset Mölndal Galleria in Gothenburg Sweden.- Divestments conducted in 2017 and in 2018 as well as weaker currencies impacted net rental income and EPRA Earnings as expected.- Cost savings initiatives progressed well and administrative expenses decreased significantly by 14% year-on-year.- Fair value change of investment properties was EUR -54.2 million mainly driven by secondary assets in Finland and Norway.- Loan-to-value (LTV) increased to 48.2% as a result of fair value changes and higher outstanding debt mainly due to the acquisition of the remaining 50% share in Mölndal Galleria.- Guidance related to Direct operating profit, EPRA Earnings and EPRA Earnings per share specified JULY—SEPTEMBER 2018- Net rental income was EUR 53.6 million (Q3/2017: 58.6). Divestments decreased net rental income by EUR 5.1 million and weaker currencies by EUR 1.3 million.- EPRA Earnings was EUR 36.8 million (39.3) due to lower net rental income following disposals. Lower administrative and direct net financial expenses partly offset this reduction. EPRA Earnings per share (basic) was EUR 0.041 (0.044), negative impact from weaker currencies was EUR 0.001.- IFRS-based earnings per share was EUR -0.01 (0.01) as a result of increase in net financial expenses due to indirect one-off costs of EUR 21.5 million mainly related to the bond tender as well as impacts from divestments and currencies. Bond buy-back will reduce financing costs going forward. JANUARY—SEPTEMBER 2018- Net rental income was EUR 161.2 million (Q1-Q3/2017: 174.6). (Re)development projects and acquisition of Straedet in Denmark increased NRI by EUR 6.2 million, while property divestments decreased net rental income by EUR 14.4 million and weaker SEK and NOK by EUR 4.2 million.- EPRA Earnings was EUR 109.3 million (118.5) due to lower net rental income. Lower administrative expenses as well as direct net financial expenses partly offset this reduction. EPRA Earnings per share (basic) was EUR 0.123 (0.133), negative impact from weaker currencies was EUR 0.004.- IFRS-based earnings per share was EUR 0.01 (0.07) as a result of net fair value losses on investment properties, increase in net financial expenses and impacts from property divestments as well as currencies. KEY FIGURES +-----------+----+-------+-------+-----+-------+-------+------+----------+-------+| | |Q3/2018|Q3/2017|%1)  |Q1-Q3 |Q1-Q3 |%1) |Comparable|2017 || | | | | |/2018 |/2017 | |change | || | | | | | | | |% 3) | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|Net rental |MEUR|53.6 |58.6 |-8.6%|161.2 |174.6 |-7.7% |-5.4% |228.5 ||income | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|Direct |MEUR|47.8 |51.7 |-7.5%|143.6 |154.7 |-7.2% |-4.8% |200.5 ||operating | | | | | | | | | ||profit 2) | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|Earnings |EUR |-0.01 |0.01 |- |0.01 |0.07 |-82.7%|-81.8% |0.10 ||per | | | | | | | | | ||share | | | | | | | | | ||(basic) | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|Fair value |MEUR|4,183.4|4,184.2|0.0% |4,183.4|4,184.2|0.0% |- |4,183.4||of | | | | | | | | | ||investment | | | | | | | | | ||properties | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|Loan to |% |48.2 |47.5 |1.5% |48.2 |47.5 |1.5% |- |46.7 ||Value (LTV)| | | | | | | | | ||2) | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|EPRA based | | | | | | | | | ||key | | | | | | | | | ||figures 2) | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|EPRA |MEUR|36.8 |39.3 |-6.4%|109.3 |118.5 |-7.8% |-6.3% |152.3 ||Earnings | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|EPRA |EUR |0.041 |0.044 |-6.4%|0.123 |0.133 |-7.8% |-6.3% |0.171 ||Earnings | | | | | | | | | ||per | | | | | | | | | ||share | | | | | | | | | ||(basic) | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+|EPRA NAV |EUR |2.66 |2.78 |-4.3%|2.66 |2.78 |-4.3% |- |2.71 ||per share | | | | | | | | | |+-----------+----+-------+-------+-----+-------+-------+------+----------+-------+ 1) Change from previous year. Change-% is calculated from exact figures.2) Citycon presents alternative performance measures according to the European Securities and Markets Authority (ESMA) new guidelines.More information is presented in Basis of Preparation and Accounting Policies in the notes to the accounts.3) Change from previous year (comparable exchange rates). Change-% is calculated from exact figures. CEO MARCEL KOKKEEL:“Our strategic focus is to concentrate on multi-functional shopping centres in growing urban areas. During the third quarter, we continued to execute on our strategy and successfully opened our newest shopping centre Mölndal Galleria in greater Gothenburg in Sweden. The new centre consist of 26,000 square meters of retail, groceries, food and beverage as well as services with excellent connections to public transportation at the heart of the growing city of Mölndal. Mölndal Galleria is a true testimony to Citycon’s strategy to recycle and deploy capital to high quality irreplaceable assets in growing urban areas. We have been very pleased with how Mölndal Galleria has been received by the local community and we are confident that it will be the social and commercial hub of the surrounding community.In January-September 2018 our business developed in line with our expectations. Our operating performance remained solid, but our EPRA earnings declined to EUR 0.123 as a result of disposals and negative currency impact. However, thanks to our strict cost management measures, administrative expenses declined significantly. During the reporting period, net rental income amounted to EUR 161 million and the pro-forma like-for-like net rental income, which includes Iso Omena and Buskerud shopping centres for the April-September period, grew by 0.8%.During the third quarter, we successfully completed the re-financing of a bond expiring in 2020. In August, we issued a EUR 300 million Eurobond to institutional investors and used most of the proceeds to buy back part of a EUR 500 million bond expiring in 2020. As a result, we de-risked the re-financing of a large bond expiring in 2020, whilst the average cost of debt improved to 2.36% and the average loan maturity now clearly exceeds our target of over 5 years.In the retail industry a noticeable divergence between the best and other assets is clearly visible. We continue to see this polarization also in our asset portfolio. The performance in our prime shopping centres in major urban areas remained good during January-September 2018, while the development in secondary shopping centres, particularly in Finland, was softer. As a result, the fair value changes of our investment properties were EUR -54.2 million during January-September 2018 driven by Finland and Norway. Due to negative fair value changes and higher debt, our loan-to-value metric increased to 48.2% at the end of September. Lowering the loan-to-value remains a key priority for management. We aim to divest EUR 200-400 million of assets in the coming few years and use the proceeds to strengthen our balance sheet.With three quarters of the year now behind us and after the announced divestments, we have specified our guidance range. We now expect our EPRA EPS to be in the range of EUR 0.1575-0.1675 for the full year 2018.“ OUTLOOK 2018 SPECIFIED +-------------------------------+-----+---------------+-------------+| | | |Previously |+-------------------------------+-----+---------------+-------------+|EPRA Earnings per share (basic)|EUR |0.1575 – 0.1675|0.155 – 0.170|+-------------------------------+-----+---------------+-------------+|Direct operating profit 1) |MEUR |-14 to -5 |-14 to -1 |+-------------------------------+-----+---------------+-------------+|EPRA Earnings 1) |MEUR |-12 to -3 |-14 to -1 |+-------------------------------+-----+---------------+-------------+ 1) Change compared to the previous year These estimates are based on the existing property portfolio and on the prevailing level of inflation, the EUR–SEK and EUR–NOK exchange rates, and current interest rates. Guidance for 2018 includes around EUR -5 million impact from weaker currencies. Premises taken offline for planned or ongoing (re)development projects reduce net rental income during the year. EVENTS AFTER THE REPORTING PERIODNo material events after the reporting period. AUDIOCASTCitycon's investor, analyst and press conference call and live audiocast will be arranged on Thursday 18 October 2018 at 10 am EEST. The audiocast can be participated by calling in and followed live at: https://citycon.videosync.fi/2018-q3-interim-reportConference call numbers are:Participants from Europe +44 3333 000 804                              PIN: 20016107#Participants from the US +1 6319 131 422                                  PIN: 20016107# For more investor information, please visit the company’s website at www.citycon.com. Espoo, 17 October 2018Citycon OyjBoard of Directors For further information, please contact:Eero SihvonenExecutive VP and CFOTel. +358 50 557 9137eero.sihvonen@citycon.com Mikko PohjalaIR and Communications DirectorTel. +358 40 838 0709mikko.pohjala@citycon.com Citycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic region, managing assets that total approximately EUR 4.5 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark.Citycon has investment-grade credit ratings from Moody's (Baa2) and Standard & Poor's (BBB). Citycon Oyj’s share is listed in Nasdaq Helsinki.www.citycon.com

SYNOSTE Ltd raises €5.1 million to launch its smart skeletal deformation correction technology

(Helsinki, October 18, 2018) – SYNOSTE Ltd, a Finnish medical device company creates smart solutions for patient-friendly bone-lengthening and bone-deformation correction. The company has raised over five million euros to start clinical investigations and to develop new clinical applications. SYNOSTE ’s patented technology platform provides the basis for further disruptive changes in the treatment of congenital, trauma- and tumour-related limb discrepancies, adult and paediatric deformities, and craniomaxillofacial deformations. The new funding was provided by Lifeline Ventures, a specialist early investor in game-changing technologies and AO Invest, an investment fund backed by the AO Foundation, the world’s largest community and network of musculoskeletal surgeons and scientists. “We are excited to gain funding from two complimentary groups – Lifeline’s forward-thinking mindset and strong entrepreneurial experience combined with AO’s expertise and access to a global network of our target surgeons will empower our development of an expanded portfolio of cutting-edge solutions and enable us to transition them into clinical practice faster”, says SYNOSTE’s Managing Director and co-founder Harri Hallila.  “SYNOSTE is exactly the type of company that interests AO Invest; they have created not just a product but a platform that will enable various intelligent solutions from traditional intramedullary nails to flat plates that can be used in the treatment of extremely painful and psychologically debilitating conditions” comments Michel Orsinger, Chairman of AO Invest. The €5.1M Lifeline and AO investment raises the total equity invested in SYNOSTE to ten million euros. SYNOSTE’s other investors include strategic and financial investors: Evonik Venture Capital, a German materials company; High-Tech Gründerfonds, Germany’s largest seed investor; Innovestor Ventures, with the largest portfolio of venture backed companies in Finland; and Mectalent, a partner company that provides SYNOSTE component manufacturing and precision mechanics. For further information about SYNOSTE, this investment, and our market opportunities, please contact Harri Hallila (hallila@synoste.com).  About AO InvestAO Invest  is a newly established investment fund focused on start-ups active in the field of musculoskeletal disorders. The fund is backed by the AO Foundation , a 60-year old non-profit organization, which boasts the world’s largest network of more than 19'000 surgeons and scientists in orthopedics and trauma. The goal of AO Invest is to invest in start-ups related to the AO Foundation's core expertise, and use the Foundation's unique reach and expertise to help their companies achieve their full potential. About Lifeline VenturesLifeline Ventures is a team of serial entrepreneurs who invest in the sectors where they have explicit and comprehensive knowledge, know how, and experiences. As start-up specialists the team at Lifeline start working with a fledgling companies before they have launched their first products. The company credo is to be “FIRST” in the heart and mind of the partnering entrepreneur to support them in both times of trouble and joy. Lifeline’s notable investments include e.g. Supercell (acquired by Softbank), Moves (acquired by Facebook), Oncos Therapeutics, ZenRobotics and Applifier (acquired by Unity). For more information, please visit http://www.lifelineventures.com

Citycon’s Financial Reporting Schedule and AGM 2019

Citycon Oyj’s schedule of the financial reporting in 2019 is the following: Year 2018 full-year Financial Thursday 7 February 2019 at about 9:00 a.m.Report, Financial Statements andthe Report by the Board ofDirectorsYear 2019 three-month Interim Wednesday 17 April 2019 at about 9:00 a.m.ReportYear 2019 six-month Half-Yearly Thursday 11 July 2019 at about 9:00 a.m.ReportYear 2019 nine-month Interim Thursday 24 October 2019 at about 9:00 a.m.Report Citycon Oyj’s Annual General Meeting (AGM) 2019 will be held on Wednesday, 13 March 2019 starting at 12:00 p.m. The notice to the AGM will be disclosed separately at a later date once the Board of Directors has convened the AGM 2019. A shareholder is entitled to demand a matter for discussion at the AGM, if such matter falls under the competence of a General Meeting according to the Finnish Companies Act. A written request shall be provided to Citycon Oyj’s Board of Directors by e-mail at legal@citycon.com or by mail addressed to Citycon Oyj, Legal/AGM, Suomenlahdentie 1, FI-02230 Espoo, Finland by 31 January 2019.CITYCON OYJFor further information, please contact:Marcel KokkeelChief Executive OfficerTel. +358 40 154 6760marcel.kokkeel@citycon.comEero SihvonenExecutive VP and CFOTel. +358 50 557 9137eero.sihvonen@citycon.comCitycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic region, managing assets that total approximately EUR 4.5 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark.Citycon has investment-grade credit ratings from Moody's (Baa2) and Standard & Poor's (BBB). Citycon Oyj’s share is listed in Nasdaq Helsinki. www.citycon.com

Ahlstrom-Munksjö completes the acquisition of Caieiras specialty paper mill in Brazil

AHLSTROM-MUNKSJÖ OYJ PRESS RELEASE OCTOBER 18, 2018 at 9:10 Ahlstrom-Munksjö has completed the acquisition of MD Papéis’ Caieiras specialty paper mill in Brazil for a debt free purchase price of about EUR 98 million*. The acquisition significantly strengthens Ahlstrom-Munksjö’s offering in South America and provides further growth opportunities. The acquired business had net sales of about EUR 76 million and comparable EBITDA of EUR 12 million in 2017. Annual synergy benefits of up to EUR 6 million are estimated, mainly arising from optimization of overlapping businesses. The agreement was announced on April 24, 2018. The Caieiras product offering is an excellent match for Ahlstrom-Munksjö with 80% of sales being in line with the company’s current portfolio. The plant gives access to local production of decor paper, thus strengthening Ahlstrom-Munksjö’s offering and partnership with existing customers, who have so far relied on imports. Ahlstrom-Munksjö is already a global leader in tape materials, serving both local and global customers and this position is further strengthened through the acquisition. In addition, production and delivery capabilities as well as competitiveness are improved by combining Caieiras with the company’s operation in nearby Jacarei. Daniele Borlatto, EVP of Industrial Solutions Business Area, comments: “The Caieiras business is an excellent addition to our global platform, and drives our ambition to maintain a leading position in selected niches of the global fiber-based solutions market that offers growth. Our existing as well as new specialty paper customers will benefit from a stronger offering coupled with our well-established excellent customer service. This transaction is another significant milestone in the execution of our strategy. I welcome the Caieiras employees to Ahlstrom-Munksjö.”Ahlstrom-Munksjö operates three plants near Sao Paolo, employing over 700 people with revenues of approximately of EUR 200 million following the acquisition. *Assuming EUR/BRL exchange rate of 1 to 4.32 For further information, please contact:

Interim Report January-September 2018

Third quarter 2018 compared to third quarter 2017 · Customer growth was strong and 32,200 (31,200) new customers were added · Net inflow improved by 42 per cent to SEK 8,380 million (5,900) · Operating income increased by 18 per cent mainly due to higher fund commissions, although all income streams improved · Operating expenses rose by 9 per cent mainly due to increased personnel costs as a result of larger development efforts. Full-year costs are still expected to grow by nearly 11 per cent compared to 2017 · Tax on profit for the period was affected by the Swedish Tax Agency’s decision in the third quarter to impose a retroactive tax on Avanza related to intermediary commissions in Försäkringsaktiebolaget Avanza Pension, as announced in the interim report for the second quarter. This resulted in an increased tax cost of SEK 6 million for the quarter, of which SEK 2 million relates to the current year. The decision will not be appealed · Net profit amounted to SEK 106 million, an increase of 20 per cent · Avanza Global, the world’s cheapest global index fund, was launched · Avanza ranked as the most reputable bank in Nordic Brands’ survey · Avanza climbed from 26th to 10th place on Lynxeye’s list of Sweden’s most purposeful brands · In early October, the margin loan was improved to allow customers to borrow up to SEK 50,000 at 0% interest Quote from Rikard Josefson, CEO Avanza “A bullish stock market, coupled with new product launches, improved the net inflow and strengthened customer growth in the quarter. The number of new fund owners at Avanza was high. Quarterly operating profit reached a record level despite that – or presumably because – we continue to revolutionise the market with cheaper, better and simpler products and now have free offers in every product area.” Q3 Q2 Change Q3 Change Jan-Sep Jan-Sep Change 2018 2018 % 2017 % 2018 2017 %Operating 267 244 10 227 18 782 705 11income,SEKOperating –135 –153 –12 –123 9 –440 –378 16expenses,SEKOperating 132 90 47 104 27 342 327 4profit,SEKmNet 106 79 34 89 20 289 280 3profit,SEK mEarnings 3.54 2.64 34 2.97 19 9.63 9.40 3pershare,SEKOperating 49 37 13 46 4 44 46 –3margin, Net 8,380 4,840 73 5,900 42 21,200 23,200 –9inflow,SEK mNo. of 32,200 23,300 38 31,200 3 97,900 97,500 0newcustomers(net)Savings 331,000 307,100 8 281,000 18 331,000 281,000 18capitalattheend oftheperiod,SEK This information is information that Avanza Bank Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.15 (CEST) on 18 October 2018. This Interim Report is published in Swedish and English. In the event of any difference between the English version and the Swedish original, the Swedish version shall prevail.

NeuroVive presents first preclinical NV354 efficacy results in a model for mitochondrial disease

The presentation at the CSHL Meeting on October 19 will include in vivo efficacy data from an advanced experimental model for acute energy crisis involving complex I dysfunction. The initial results show that NV354 restores tissue succinate levels and reduces lactate levels. Further NV354 efficacy studies are ongoing using both short- and long-term treatment regimens. A parallel evaluation of NV354 drug properties in a separate set of experiments demonstrated high oral bioavailability and efficient brain delivery. Based on these data, NeuroVive will broaden the further preclinical development of NV354 as a chronic therapy for conditions associated with genetic mitochondrial disease, in addition to a therapy for acute energy crisis. The focus on severe pediatric conditions, such as Leigh syndrome, involving dysfunction of mitochondrial respiratory complex I, will continue.  “This is indeed very promising first efficacy data in a model highly relevant to patients with mitochondrial disease. We expect additional ongoing efficacy studies to provide further guidance for future clinical development, including the extensive studies planned at the Children’s Hospital of Philadelphia,” said Magnus Hansson, NeuroVive’s Chief Medical Officer and Vice President Preclinical and Clinical Development. “The most exciting finding from the ongoing studies is that through its drug properties, NV354 demonstrates potential to treat not only acute, but also chronic conditions in patients with mitochondrial disease, which expands therapeutic opportunities as well as commercial potential,” said NeuroVive’s CEO Erik Kinnman. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 18 October 2018 For more information please contact:Catharina Johansson, CFO, IR & Communications+46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard)info@neurovive.com, www.neurovive.comFor news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/   About NV354One of the most common causes of mitochondrial diseases relates to Complex I dysfunction, i.e. when energy conversion in the first of the five protein complexes in the mitochondrion that are essential for effective energy conversion does not function normally. This is apparent in disorders including Leigh syndrome and MELAS, both of which are very serious diseases with symptoms such as muscle weakness, epileptic fits and other severe neurological manifestations. The NVP015 project is based on a NeuroVive innovation in which the body’s own energy substrate, succinate, is made available in the cell via a prodrug technology. A prodrug is an inactive drug that is activated first when it enters the body by the transformation of its chemical structure. Within the project a lead compound, NV354, has been selected for further development in the program based on tolerability, oral bioavailability, plasma stability and organ delivery, specifically to the brain. In 2017 NeuroVive received a research grant from the Swedish innovation agency, Vinnova, for developing the succinate prodrugs as a new treatment for genetic mitochondrial diseases. About genetic mitochondrial diseasesGenetic mitochondrial diseases are metabolic diseases that affect the ability of cells to convert energy. The disorders can manifest differently depending on the organs affected by the genetic defects and are viewed as syndromes. An estimated 12 in every 100,000 people suffer from a mitochondrial disease. Mitochondrial diseases often present in early childhood and lead to severe symptoms, such as mental retardation, heart failure and rhythm disturbances, dementia, movement disorders, stroke-like episodes, deafness, blindness, droopy eyelids, limited mobility of the eyes, vomiting and seizures. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). 

Eltel signs a high voltage power line agreement with the Polish power grid company PSE S.A. for a value of about EUR 18.5 million

The new overhead power line will run between Ostrołęka and Stanisławów, with a total length of 105 km. The agreement also includes an upgrade of two substations, design works, right of way and documentation of the delivery. The project has started and will be completed by the end of 2023. The two other partners in the consortium are SPIE ELBUD Gdańsk S.A. and ELFEKO S.A., with the latter being the consortium leader. Eltel’s share of the consortium will be equal to the other partners, which means a third of the contract value. For further information:Christian Wittneven, Director, Solution Unit High VoltageTel: +49 173 180 4588, christian.wittneven@eltelnetworks.com Elin Otter, Head of Group CommunicationsTel: +46 72 595 4692, elin.otter@eltelnetworks.se About EltelEltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a growing customer base of large network owners. In 2017, Eltel’s net sales amounted to EUR 1.3 billion. The current number of employees is approximately 7,680. Since 2015, Eltel AB is listed on Nasdaq Stockholm.

Rauma Marine Constructions and Tallink sign letter of intent for a new car and passenger ferry – effect on employment in the region “significant”

The planning of the Tallink Shuttle ship, which will operate on the Helsinki-Tallinn route, will start in spring 2019 and building will commence in 2020. The vessel will be delivered to Tallink at the end of 2021. The new vessel is the biggest newbuild order as of yet for RMC. The passenger capacity of the ship will be 2,800 people. The newest technology and innovative solutions will be utilized in the design phase to ensure that the vessel will be as energy-efficient and environmentally friendly as possible. The letter of intent is significant for RMC, and recruitment of more employees is already underway, says Jyrki Heinimaa, CEO, Rauma Marine Constructions. “This is outstanding news for shipbuilding in Rauma. RMC’s four-year journey has been consistent and the letter of intent with Tallink represents a natural continuation of our development. The order’s impact on employment will total around 1,500 person-years. We will hence recruit a significant amount of new talent to Rauma shipyard in the near future.” Rauma shipyard has built a total of four vessels for Tallink Grupp over the years. In addition, two more vessels have been designed at the shipyard. Baltic Queen, the previous vessel built at Rauma shipyard, was completed in 2009 and operates nowadays on the Tallinn-Stockholm route. “We are very pleased to announce that Rauma shipyard’s shipbuilding tradition, together with Tallink, will continue with RMC's building of a new Shuttle ship. It is a great honor to be signing a letter of intent with our old friends at Tallink who have always shown appreciation for the shipbuilding expertise in Rauma. This is an opportunity for us to utilize our longstanding experience and to help steer the ship traffic between Finland and Estonia in a more environmentally friendly direction,” says Heinimaa. During the upcoming months, Tallink Grupp and RMC will work on finalizing the contract and financial arrangements. RMC’s previous car and passenger ferry m/s Hammershus, built for Danish ferry operator Molslinjen, began operating in Denmark in September. The company is also cooperating with the shipyard in Turku on building ship blocks for a large cruise ship.

Enea Wins Layer123 Network Transformation Award

STOCKHOLM, Sweden, Oct. 18, 2018 – Enea® (NASDAQ Stockholm: ENEA), a global supplier of network software platforms and world class services, today announced that Enea® NFV Access won the prestigious Layer123  Network Transformation Award (NetTA) as the Best NFVi Platform 2018. Enea NFV Access features a lightweight virtualization software runtime platform - without the need for OpenStack - designed for deployment on edge devices at the customer premise. It is streamlined for high networking performance with minimal RAM footprint for both platforms and VNFs. Enea NFV Access provides a foundation for uCPE and SD-WAN agility, reducing cost and complexity for computing at the network edge. "We saw at an early stage that the network edge offered challenges in terms of cost-effectiveness combined with high performance", said Karl Mörner, SVP R&D and Product Management at Enea's NFV Business Unit. "These are problems that Enea has traditionally been really good at solving. Thanks to our experience in providing operating systems for the most demanding environments, we were able to develop Enea NFV Access – a lightweight, high-performance, virtualization software platform for uCPE and SD-WAN use cases." The award was presented on October 10th at the SDN NFV World Congress, one of the largest events in the carrier network transformation industry with more than 2000 executives and decision makers. Awards are judged independently by a panel of leading analysts invited from SDN NFV Congress Analyst Partners. All submissions are assessed against published criteria and graded using a weighted points system to ensure consistency, depth of analysis and rigor. A random matrix process is used to ensure a credible, fair and unbiased assessment of all submissions. For more information, please visit https://www.enea.com/enea-nfv-access Additional Resources NFV Access Datasheet https://www.enea.com/globalassets/downloads/nfvi-platforms/enea-nfv-access/enea-nfv-access-datasheet.pdf Evaluation Request for NFV Access https://www.enea.com/products/nfv-virtualization-platforms/enea-nfv-access/eval-request-enea-nfv-access/ Media Contact Erik Larsson, SVP Marketing & Communication, Enea Phone: +33 1 70 81 19 00 E-mail: erik.larsson@enea.com About NetTA – Network Transformation Awards  Network Transformation Awards recognize achievement in advancing the industry, celebrate innovation founded on SDN and NFV, and inspire determination for future progress. Network Transformation Awards, part of this year's SDN NFV World Congress, highlight the industry's most innovative people and companies by recognizing their most significant achievements in accelerating Network Transformation over the last 12 months. NetTA shortlist and winners are selected using a transparent and robust process, and judged independently by a panel of leading analysts invited from SDN NFV Congress Analyst Partners. NetTA Winners can be confident in receiving an authentic Award that highlights their leadership and achievement, and gives credit to themselves, their work and their company. For more information: https://www.layer123.com/awards About Enea Enea develops the software foundation for the connected society. We provide solutions for mobile traffic optimization, subscriber data management, network virtualization, traffic classification, embedded operating systems, and professional services. Solution vendors, systems integrators, and service providers use Enea to create new world-leading networking products and services. More than 3 billion people around the globe already rely on Enea technologies in their daily lives. Enea is listed on Nasdaq Stockholm. For more information: www.enea.com  Enea®, Enea OSE®, Netbricks®, Polyhedra®, and Enea® Element are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Polyhedra® Lite, Enea® ElementCenter, Enea® On-device Management, Enea® NFV Core, and Enea® NFV Access are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. All rights reserved. © Enea AB 2018.  

Camanio Care executes a rights issue and secures next step in pursued expansion plans

- We have the support from investors to pursue with the strategic and financial growth plans. The investments of SEK 60 million into the company over the past years were made for developing the company with a strong focus on investing into R&D. With this additional funding, we will continue to develop the commercialization of our products. The digital transformation of social care and healthcare has just begun, and we are well positioned to capitalize on this trend, says Catharina Borgenstierna, CEO of Camanio Care. The board of directors of Camanio Care AB has decided to launch a rights issue of SEK 5 million. Existing major shareholders intend to subscribe to 50% in the rights issue. The subscription consists of a unit-emission of four (4) shares and 1 (one) warrant. The unit price 6,80 SEK, e.g. the share price in the offer 1,70 SEK per share. For each (1) share in Camanio Care AB owned by the day of settlement, October 25th 2018, the shareholders receive one (1) unit subscription right. Twenty-two (22) unit subscription rights are required in order to subscribe to one (1) new unit. The price is calculated as a volume weighted average price from 20 days during the past month. The warrant included in the unit is gratuitous and the maturity of the warrant is 12 months. Following this rights issue, the number of shares will increase from 16,674,539 to 19,706,271 which implies a dilution of 15%. If all subscribed warrants are converted into shares, the dilution will be an additional 4%. The subscription period for the rights issue will be 29th October to 19th November 2018. This rights issue is executed by the board based on the entrusted mandate given at the Annual General Meeting on the 23rd of April 2018. In addition to the underwritten SEK 5 million rights issue, the board has decided on an oversubscription tranche, still with preferential rights to the existing shareholders, of up to SEK 2 million. The purpose of the oversubscription tranche is to allow existing shareholders to sign up for their interests above their pro rata share. The implication of the oversubscription tranche is that the number of shares in the rights issues increases with additional 1,176,470 shares to a total of 20,882,741 share excluding the warrants, with a dilution of additional app 6%. By this design of the rights issue the Board aims to invite all existing shareholders that have shown interest in the further growth of the company. This is one of the first steps in the company’s long-term financial strategy. Time plan for the rights issue: Last day for trade in the share including transferable unit subscription rights:              2018-10-23 First day for trade in the share excluding transferable unit subscription rights:             2018-10-24 Record date for participation in rights issue:                                                                                                                2018-10-25 Memorandum is published on Camanio Care website:                                                                                           2018-10-26 First subscription date:                                                                                                                                                        2018-10-29 First day of trading in unit subscription rights and BTU:                                                                                           2018-10-29 Last day for trade in unit subscription rights:                                                                                                               2018-11-15 Last day of subscription:                                                                                                                                                     2018-11-19 Last day of trade with BTU will be communicated through a market announcement after registration at Bolagsverket (Swedish Companies Registration Office). The full terms of the underwritten rights issue and the oversubscription tranche will be available in our memorandum on the 26th October: https://www.camanio.com/en/invest/ For further information, please contact:Catharina Borgenstierna, CEOTelephone: +46733-93 00 07E-mail: catharina.borgenstierna@camanio.com   About Camanio CareCamanio Care is a care tech company that develops smart technologies for an excellent care at home with the individual in focus. Camanio Care offers digital service platforms for digital care, robotics and assistive devices, with products such as VITAL, BikeAround TM, Bestic® and Giraff TM. Through three focus areas; Activation, Mealtime and Digital care, Camanio Care wishes to support people's basic needs and increase accessibility and quality within health care. Headquartered in Stockholm, Camanio Care has a subsidiary in the US, and global reach via distributors in Asia, the Middle East, Hong Kong, Australia and in ten European countries. Subscribe to our press releases and read more about us, Camanio Care at: https://www.camanio.com/en/.This information is information that Camanio Care is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, on October 18th, 2018.  

Getinge publishes Interim Report for January-September 2018

Getinge’s growth is continuing at a high pace – net sales for the quarter increased by close to 15%, almost half of which was organic growth. The order intake increased by slightly more than 8%, of which just under 1% was organic.This was in line with expectations due to a strong third quarter in 2017. Market and product mix effects in the form of robust growth in capital goods and in emerging markets are continuing to have an adverse effect on the gross margin. As stated earlier, these effects were foreseen and are natural in a phase of growth, and they are expected to support future sales of consumables linked to the use of our capital goods. In addition, the gross margin was negatively impacted by Getinge actively securing a number of large business opportunities in emerging markets at lower margins. Cash flow improved significantly, as a result of more efficient management of our working capital. The operating profit for the quarter was strongly negatively affected by a provision of SEK 1.8 billion, intended to cover future costs for claims related to hernia mesh products in North America, which we communicated on October 14. On October 18, 2018, an agreement to divest the surgical mesh business was signed. The biosurgery business has been a relatively small segment within Getinge’s overall portfolio and the only therapeutic asset in the general surgery field. The divestment is a strategic desicion in order to focus on core therapeutic solutions. The deal is expected to close in the fourth quarter of this year subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions.    July – September 2018 in brief ·  Order intake rose organically by 0.9% and net sales increased organically by 7.2% primarily due to the continued favorable trend in capital goods and in emerging markets.   ·  Adjusted EBITA amounted to SEK 438 M (544), negatively affected by a lower gross margin due to the product and market mix.   ·  Currency effects had an impact of SEK +383 M on net sales, SEK +129 M on gross profit and SEK -24 M on EBITA. ·  Adjusted earnings per share amounted to SEK 0.78 (1.20). ·  A provision of SEK 1.8 B was made to cover costs related to lawsuits in North America related to surgical mesh implants. The provision is recognized as items affecting comparability in operating profit. ·  The TSO3 distribution agreement for low temperature sterilization ended, resulting in an item affecting comparability of SEK -126 M in operating profit. ·  Cash flow after net investments amounted to SEK 801 M (182). Conference callA conference call will be held on October 18 at 3:00 – 4:00 p.m. CEST hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO. Please find dial in details to join the conference call here . Media contact:Jeanette Hedén Carlsson, Executive Vice President Communications & Brand ManagementPhone: +46 (0)10 335 1003Email: Jeanette.hedencarlsson@getinge.com Lars Mattsson, Head of Investor RelationsPhone: +46 (0)10 335 0043E-mail: lars.mattsson@getinge.comThis information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on October 18, 2018, at 13:00 CEST. 

BATTLETECH Flashpoint Launching Nov. 27, Pre-Orders Begin Today

STOCKHOLM - Oct. 18, 2018 - Paradox Interactive and Harebrained Schemes today announced that pre-orders for BATTLETECH Flashpoint are now live. Flashpoint is BATTLETECH's first expansion and will launch on November 27th for $19.99 MSRP, on Steam, GOG, and Paradox Plaza. Two new money-saving bundles are also available today - the BATTLETECH Season Pass and the BATTLETECH Mercenary Collection, a super-deluxe edition. Flashpoint features branching multi-mission contracts that will draw players into the machinations and feuds of the Great Houses. New ‘Mechs, a new mission type, a new tropical biome and more are in store in BATTLETECH’s first expansion. Check out this handy new video with more info from Mitch Gitelman, BATTLETECH Game Director and co-founder of Harebrained Schemes: "Four things you need to know about BATTLETECH Flashpoint" https://youtu.be/bSc5GWIRHBU The new Season Pass includes all current game content, plus Flashpoint and the next two planned BATTLETECH Expansions, at a discounted price of $49.99 MSRP. In addition to Flashpoint, the Season Pass contains explosive metropolitan combat in the Urban Warfare expansion plus another unannounced expansion in the works for 2019. This week only, save an additional 20% off the Season Pass with a special launch discount. The super-deluxe Mercenary Collection is the ultimate BATTLETECH bundle, including the Deluxe Digital Edition and the Season Pass, for access to all future expansions, in addition to all current game content. The Mercenary Collection is out now for $89.99 MSRP (a $20 savings over buying the individual products). Here’s the place for Flashpoint pre-orders, both new bundles, and more info: https://store.steampowered.com/app/911930/BATTLETECH_Flashpoint/

Qliro Group sets new financial targets

“Qliro Group has for some time been operating the three subsidiaries as independent units. CDON Marketplace is focusing on external merchants and is phasing out sales from own inventory, mainly consumer electronics with low margin. Qliro Financial Services focuses on attracting new external merchants and utilizing economies of scale. Nelly will benefit from its strong brand and digital marketing to boost its profitable growth in the Nordic,” says Marcus Lindqvist, CEO and President of Qliro Group. Qliro Financial Services focuses on e-commerce volumes and loan book growthQliro Financial Services strategy is to offer an attractive payment solution to merchants and to take advantage of the volumes to offer digital financial services to consumers. Since its inception, the company has built its offering of financial services and will focus on leveraging economies of scale and capitalizing on existing service offerings.   To strengthen its position as an independent company, Qliro Financial Services is increasing its commercial initiatives and recruiting personnel working with attracting and integrating new merchants. The financial development is dependent on the transaction volumes and the recruitment of new external merchants. During 2019 volumes will be negatively affected by the fact that CDON Marketplace is phasing out sales from own inventory as a part of its transformation to a marketplace. Qliro Financial Services new financial target: · Achieve an operating income before depreciation and amortization of SEK 100 – 125 million in 2019 Qliro Financial Services previous long-term financial targets was to achieve an operating income before depreciation and amortization of at least SEK 150 million in 2019. CDON Marketplace focuses on growing with external merchantsCDON Marketplace strategy is to be the leading marketplace in the Nordic region for external merchants. To strengthen its position as an independent company, CDON Marketplace accelerates its transformation by focusing on external merchants while phasing out sales from own inventory, especially within consumer electronics, a segment with low margin. This provides the right long-term conditions for a strong market position and profitable growth. We estimate that operating income before depreciation and amortization will be positive for the full year 2019.  CDON Marketplace new financial targets:  · Achieve a growth rate in external gross merchandize value of above 20 percent per year   · Achieve an operating margin before depreciation and amortization above 3 percent of net sales per year  CDON Marketplace previous long-term financial targets was to attain a level of organic growth in total gross merchandise value of an average of 10 per cent per year (that is, external and own sales) and generate operating income before depreciation and amortization of 1– 2 percent of gross merchandise value (that is, not ordinary operating margin before depreciation, amortization and impairment). Nelly focuses on its own brandsNelly’s strategy is to develop its position as a leader in online fashion for young people in the Nordic region. At its core is its own brands, complemented by a well-curated portfolio of approximately 200 external brands. The company benefits from its strong own brand and digital marketing. An important driver is that a growing proportion of sales comes from clothing and accessory of Nelly’s own design. Based on its strong market position, Nelly’s target for growth is now raised with an unchanged target for operating margin. Nelly’s new financial targets:   · Achieve an organic growth in net sales above 10 percent per year · Achieve an operating margin before depreciation and amortization above 6 percent per year Nelly’s previous long-term financial targets was to attain a level of organic growth of an average of 8 per cent per year and generate an operating margin before depreciation and amortization of at least 6 percent. Qliro Group publishes its interim report for January-September 2018 on Friday, October 19 at 8:00 am. A telephone conference will be held at 10:00 am the same day. The conference call will also be available at www.qlirogroup.com.  This information is information that Qliro Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication by the contact person below for publication on October 18, 2018, at 7.15 pm. For more information, please visit www.qlirogroup.com or contact:Niklas Alm, telephone: +46 70 824 40 88, ir@qlirogroup.com  About Qliro Group Qliro Group is a leading Nordic e-commerce group in consumer goods and related financial services. Qliro Group operates CDON.COM, the leading Nordic online marketplace, the fashion brand Nelly.com and Qliro Financial Services, offering financial services to merchants and consumers. In 2017 the Group had sales of SEK 3.4 billion. Qliro Group’s shares are listed on the Nasdaq Stockholm MidCap segment under the ticker symbol QLRO.

Saab Receives Order from Boeing for the Advanced Pilot Training Aircraft T-X

Saab and Boeing were selected by the U.S. Air Force on 27 September for the T-X programme, a new era in Saab and Boeing’s partnership going forward.    The T-X programme is divided into multiple phases. This order concerns the first phase, EMD, in which Saab and Boeing industrialise the T-X aircraft together with the customer. EMD includes testing, U.S. military flight certification and delivery of five jets. The EMD phase will be followed by a serial production phase.   “This order is an exciting step towards a whole new era when it comes to trainer jets. It lays the foundation for our joint work for many years to come. We look forward to taking these next steps together with Boeing,” says Håkan Buskhe, President and CEO of Saab. Saab and Boeing have developed the T-X aircraft together. Saab is a risk-sharing partner with Boeing in the development. Boeing is the designated prime contractor for the advanced pilot training system acquisition by the U.S. Air Force. For more information on the T-X aircraft, please visit: https://saab.com/tx https://mediaportal.saabgroup.com/ For further information, please contact: Saab Press Centre Ann Wolgers, Press Officer +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Telia Company Interim report January-September 2018

BETTER EARNINGS MOMENTUM     Third quarter summary · Net sales in local currencies, excluding acquisitions and disposals rose 0.1 percent. In reported currency, net sales rose 5.5 percent to SEK 20,685 million (19,614). Service revenues in local currencies, excluding acquisitions and disposals, declined 1.9 percent. · Adjusted EBITDA rose 1.8 percent in local currencies, excluding acquisitions and disposals. In reported currency, adjusted EBITDA rose 6.4 percent to SEK 6,977 million (6,556). The adjusted EBITDA margin rose to 33.7 percent (33.4). · Adjusted operating income rose 5.3 percent to SEK 3,964 million (3,763). · Total net income amounted to SEK 3,026 million (2,585). Total net income attributable to the owners of the parent was SEK 2,825 million (2,310). · Free cash flow from continuing and discontinued operations was SEK 2,963 million (-1,281). Comparable figures were impacted by the payment related to the settlement regarding the Uzbekistan investigations. Operational free cash flow from continuing operations was SEK 2,569 million (2,808). · The acquisition of Get and TDC Norway was completed on October 15. · Outlook for adjusted EBITDA 2018 is revised up. Nine months summary · Net sales in local currencies, excluding acquisitions and disposals increased 0.5 percent. In reported currency, net sales increased 4.6 percent to SEK 61,351 million (58,627). · Adjusted operating income rose 0.5 percent to SEK 11,153 million (11,102). · Total net income amounted to SEK 4,670 million (9,438). Total net income attributable to the owners of the parent declined to SEK 4,275 million (8,913). · Operational free cash flow from continuing operations was SEK 9,399 million (8,883). Comments by Johan Dennelind, President & CEO    “Dear shareholders and Telia followers, the third quarter of 2018 gives us further comfort as our focus and dedication to deliver on our cost agenda and operational free cash flow ambition for the year is paying off. We are clearly on track to deliver the net cost reduction of SEK 1.1 billion that we have set out as a priority for the year. Our operational free cash flow continues to be strong, having generated SEK 10.2 billion over the last 12 months. Our adjusted EBITDA is growing in six out of seven countries, with Finland, Norway as well as our central units being the main drivers. The performance is a combination of strong execution of the cost ambition as well as delivering synergies and stronger propositions to customers from the acquisitions we have done in recent years.     In early October we obtained the approval on our acquisition of TDC Norway and Get. The transaction closed October 15, and I would like to take the opportunity to give a warm welcome to all the customers and staff to the Telia Company family. Together we create a strong convergent operator with a lot of attractive new products and services for both our consumer and enterprise customers. Regarding the Bonnier Broadcasting transaction, we are in dialogue with the EU Commission and aim to complete the merger filings around the end of the first quarter next year. The closing is therefore still expected for the second half of 2019.    Sweden had, as expected, a slower EBITDA quarter compared to previous quarters, partly explained by expected tougher comparisons, but also due to costs related to thunderstorms and negative currency effects. Even though we have reduced costs year-to-date in Sweden under the cost program, we are still not happy with the pace of the turn-around. We know there is clear large potential for improvements over the years to come. The new CEO in Sweden Anders Olsson has taken substantial steps in building a stronger commercial roadmap and improving the efficiency. Part of this will be executed already from January 1, as we go live with our updated operating model. Initially the new model will be implemented between our new unit Common Products and Services (under the Group COO Magnus Zetterberg) and Sweden. The new model includes Sweden's IT and product platforms and around 500 employees being moved into Common Products and Services. The other countries will follow at a later stage, adding further structural efficiencies. Since the transformation is delayed and the real significant benefits are to come in 2020 rather than as expected in 2019, part of the turn-around in Sweden is to tighten the execution of the transformation and also to improve cost efficiency in other areas.    In Finland we reported a mobile B2B growth of 7 percent adding some large wins in the quarter. Our position in this segment has been strengthened during recent years through acquisitions and it is very satisfying that we continue to deliver value from the acquisitions that we have made. Equally satisfying is that the Telia Helsinki Data Center has come out flying from the starting blocks having signed an important agreement with Nokia almost immediately after launch. The Finnish ice hockey league started its season in September. We have had a good start and see the asset as a key differentiator in the market. We see a clear opportunity to further capitalize on these rights.    Our team in Norway has shown excellent execution of the Phonero acquisition and at the same time shown cost control in a flattish market, which resulted in strong EBITDA growth. Our Baltic operations continue with their strong performance.    During the quarter we have launched a pre-commercial 5G network in the city center of Helsinki. Full scale commercial operations will be available in 2019 when we can utilize the spectrum acquired in the recent 3.5 GHz auction. This is in line with our 5G strategy to be early out in understanding what 5G will bring in terms of potential for our customers. We reiterate that 5G related investments will be limited before 2020 and thereafter gradually replace current 4G related investments.    Sustainability is key for our strategy and value creation. We strive to be a transparent, trusted partner for all our stakeholders. To further increase our transparency, we are now publishing the sustainability highlights alongside the quarterly financial reports. Log on to our website and read about Telia Company’s new human rights policy, our work with children’s rights and how we, so far, have engaged half of our employees to volunteer on various projects where digitalization is used to improve lives in our society.    Today our shares will open trading excluding the second part of the 2017 dividend of SEK 1.15, to be distributed in a few days. As of last week, we have bought back shares for SEK 2.7 billion under our current buy-back program. We remain committed to our capital allocation ambitions and balance sheet targets.    No doubt comparisons will continue to be tough in the fourth quarter, especially in Sweden. Still, given the performance so far, with adjusted EBITDA having grown by 4 percent excluding currency effects, we up our full year EBITDA guidance from “in line or slightly above the 2017 level” to “slightly above the 2017 level”. The outlook for operational free cash flow being above SEK 9.7 billion is left unchanged. Finally, I want to thank my team for a solid delivery in the quarter.”    Johan Dennelind, President and CEO       This information is information that Telia Company AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on October 19, 2018.      For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany  .       Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.       We’re Telia Company, the New Generation Telco. Our approximately 20,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com

Volvo Group – the third quarter 2018

· In Q3 2018 net sales increased by 21% to SEK 92.3 billion (76.4). Adjusted for currency movements and acquired and divested units sales increased by 13%. · The adjusted operating income amounted to SEK 10,247 M (6,937), corresponding to an adjusted operating margin of 11.1% (9.1). · Reported operating income amounted to SEK 10,247 M (7,337). · Currency movements had a positive impact on operating income of SEK 423 M. · Diluted earnings per share amounted to SEK 3.67 (2.66). · Operating cash flow in the Industrial Operations amounted to SEK 1.3 billion (0.6). October 19, 2018 Press and Analyst Conference. An on-line presentation of the report, followed by a question-and-answer session will be webcast starting at 09.00 CET. More information under Investors on www.volvogroup.com Aktiebolaget Contact Media Relations: Volvo (publ) 556012-5790           Investor Claes Eliasson +46 765 53 72 29Relations, VHQ  SE-405 08 Göteborg,SwedenTel +46 31 66 00 00 Contacts Investor Relations: www.volvogroup.com Christer Johansson +46 31 66 13 34  Johan Bartler +46 739 02 21 93 Anders Christensson +46 31 66 11 91  This information is information that AB Volvo (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.20 CEST on October 19, 2018. For more information, please visit volvogroup.com/press   The Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. The Volvo Group, which employs almost 100,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2017 the Volvo Group’s sales amounted to about SEK 335 billion (EUR 35 billion). The Volvo Group is a publicly-held company headquartered in Göteborg, Sweden. Volvo shares are listed on Nasdaq Stockholm.

Strong organic sales growth

Third quarter · Net sales increased by 15% to SEK 21,191 M (18,499), with organic growth of 5% (3) and acquired net growth of 2% (2) · Strong sales growth in Global Technologies and Americas and good growth in Entrance Systems. Sales in EMEA and Asia Pacific were stable · Three acquisitions have been signed with combined expected annual sales of about SEK 1,200 M · Operating income (EBIT)amounted to SEK 3,424 M (3,080), with an operating margin of 16.2% (16.7) · Net income amounted to SEK 2,384 M (2,153) · Earnings per share amounted to SEK 2.15 (1.94) · Operating cash flow increased by 13% to SEK 3,004 M (2,654). Sales and income +----------------------------------+------+------++---++------+----------+--+| |Third quarter|| ||January-September| |+----------------------------------+------+------++---++------+----------+--+| | 2017| 2018|| Δ|| 2017| 2018| Δ|+----------------------------------+------+------++---++------+----------+--+|Sales, SEK M |18,499|21,191||15%||56,028| 60,881|9%|+----------------------------------+------+------++---++------+----------+--+|Of which: | | || || | | |+----------------------------------+------+------++---++------+----------+--+|Organic growth | 590| 960|| 5%|| 1,956| 2,620|5%|+----------------------------------+------+------++---++------+----------+--+|Acquisitions and divestments | 373| 446|| 2%|| 1,273| 1,079|2%|+----------------------------------+------+------++---++------+----------+--+|Exchange-rate effects | –488| 1,286|| 8%|| 990| 1,154|2%|+----------------------------------+------+------++---++------+----------+--+|Operating income (EBIT) [1], SEK M| 3,080| 3,424||11%|| 8,982| 9,164|2%|+----------------------------------+------+------++---++------+----------+--+|Operating margin (EBITA) [1], % | 16.9%| 16.6%|| || 16.3%| 15.5%| |+----------------------------------+------+------++---++------+----------+--+|Operating margin (EBIT) [1], % | 16.7%| 16.2%|| || 16.0%| 15.1%| |+----------------------------------+------+------++---++------+----------+--+|Income before tax [1], SEK M | 2,910| 3,221||11%|| 8,447| 8,595|2%|+----------------------------------+------+------++---++------+----------+--+|Net income [1], SEK M | 2,153| 2,384||11%|| 6,250| 6,396|2%|+----------------------------------+------+------++---++------+----------+--+|Operating cash flow, SEK M | 2,654| 3,004||13%|| 6,053| 6,435|6%|+----------------------------------+------+------++---++------+----------+--+|Earnings per share [1], SEK | 1.94| 2.15||11%|| 5.63| 5.76  |2%|+----------------------------------+------+------++---++------+----------+--+ [1]Excluding impairment of goodwill and other intangible assets of SEK -5,595 M in the second quarter of 2018. The effect on net income from the impairment of intangible assets was SEK –5,268 M. Comments by the President and CEOStrong organic sales growth in the quarterThe third quarter continued with strong organic growth of 5%. Organic growth was very strong in Global Technologies (12%) and Americas (10%) and continued to be good in Entrance Systems (4%), while EMEA and Asia Pacific reported stable organic sales growth of 2% and 1% respectively. Accelerated growth in Global Technologies and continued strong growth in AmericasThe demand for our products continued to grow at a good level in most of our markets during the third quarter and in the Global Technologies and Americas divisions in particular. Following a strong start to the year for Global Technologies, the growth accelerated during the third quarter. During the last five years ASSA ABLOY Hospitality’s performance has been very impressive, with innovative new solutions, combined with a solid financial development. The business has expanded from offering solutions for hotels and marine cruise ships into solutions for other verticals such as elderly care, student accommodation and logistics. As a result of this transformation, the Hospitality organization will now evolve under a new name, ASSA ABLOY Global Solutions, where we will develop the existing business and look for new opportunities to build global solutions for our customers. HID Global is also developing positively. Two years ago ASSA ABLOY set a target to double HID’s revenue in five years’ time through organic sales and acquisitions. With the recent announcement of the acquisition of Crossmatch, we are on track to reach this target. Crossmatch allows us to offer biometric identity in critical applications and complements our total offering. In Americas the growth was mainly driven by the development in the US. It is very encouraging that both the commercial and residential markets grew well during the quarter. In both segments our electromechanical products are market leaders and we note a strong demand for our innovative new solutions. Strong operating income and cash flowThe third quarter’s operating income improved strongly by 11% year-on-year to SEK 3,424 M, corresponding to an operating margin of 16.2%. Due to higher raw material costs and negative currency effects the margin declined compared to last year, but we continue to work hard on further offsetting these material price increases. Operating cash flow was strong in the third quarter and increased by 13% to SEK 3,004 M. New CFO appointedLast but not least, we have recently announced that Erik Pieder has been appointed as Chief Financial Officer. He will join ASSA ABLOY in January 2019.I would like to thank Carolina Dybeck Happe for her invaluable contribution to ASSA ABLOY over the last 16 years and wish her great success in her new position. Stockholm, 19 October 2018 Nico DelvauxPresident and CEO Further information can be obtained from:Nico Delvaux,President and CEO, Tel: +46 8 506 485 82 Carolina Dybeck Happe,Chief Financial Officer, Tel: +46 8 506 485 72 ASSA ABLOY is holding a telephone and web conference at 10.00 today which can be followed on the Internet at www.assaabloy.com.It is possible to submit questions by telephone on:+46 8–566 193 53, +44 203 008 9806 or +1 855 831 5945 This information is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 19 October 2018.

Rottneros’ Nomination Committee and AGM 2019

Rottneros’ Annual General Meeting (AGM) will be held on Thursday, 2 May 2019, in Sunne. Nomination Committee has been appointed. In accordance with the guidelines decided at Rottneros’ AGM 2018, the Nomination Committee has been appointed for the AGM 2019. The Nomination Committee comprises: · Julia Onstad, appointed by Arctic Paper S.A. · Stefan Sundh, appointed by PROAD AB · Per Lundeen, Chairman of the Board of Rottneros AB The Nomination Committee has appointed Julia Onstad as its chairwoman. The Nomination Committee's tasks are to, before the AGM 2019, prepare and present proposals for election of the Chairperson and other members of the Board, Board fees to be divided between the chairperson, other members and remuneration for committee work, election and remuneration of the auditor, election of Chairperson of the AGM and, where applicable, changes in the guidelines for Nomination Committee. Shareholders who wish to submit proposals to the Nomination Committee can do this by e-mail to info@rottneros.com or by letter to Rottneros AB, to: Nomination Committee, Box 144, 826 23 Söderhamn, Sweden, no later than 31 January 2019. Shareholders who wish to have a proposal considered at the AGM must submit such a proposal to the Chairman of the Board by email to info@rottneros.com by 14 March 2019, in order for the proposal to be included in the notice convening the meeting. For further information, please contact:Julia Onstad, Chairwoman of the Nomination Committee, mobile +44 79 8039 8314Per Lundeen, Chairman of the Board, mobile +46 70 518 33 47 The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 19 October 2018. Rottneros is an independent producer of market pulp. The Group comprises the parent company Rottneros AB, listed on NASDAQ Stockholm, and its subsidiaries Rottneros Bruk AB and Vallviks Bruk AB with operations involving the production and sale of market pulp. The Group also includes Rottneros Packaging AB, which manufactures fibre trays, and the wood procurement company SIA Rottneros Baltic in Latvia. The Group has about 300 employees and had a turnover of approximately SEK 1.9 billion in the 2017 financial year.

InDex Pharmaceuticals publishes post-hoc analysis of the COLLECT study

In the COLLECT study, 131 patients with moderate to severe active UC and an inadequate response to conventional therapy received either cobitolimod or placebo, in addition to standard of care therapies. The study was conducted at 38 sites in seven European countries. The main results including primary and secondary endpoints were previously published in the Journal of Crohn's and Colitis in November 2016. 104 patients with available e-diary data were included in a post-hoc analysis, out of which 70 had been treated with cobitolimod and 34 with placebo. Symptomatic remission, defined as absence of blood in stool and a mean daily stool frequency <4, based on e-diary records was achieved at week 4 in 17.1% of cobitolimod vs. 5.9% of placebo treated patients (p=0.13), at week 8 in 35.7% of cobitolimod vs. 17.6% of placebo treated patients (p=0.07), and at week 12 in 38.6% of cobitolimod vs. 17.6% of placebo treated patients (p=0.04). As expected, symptomatic remission rates in the cobitolimod and placebo group were smaller for anti-TNFα experienced patients, but with a similar relative effect-size compared to anti-TNFα naïve patients. In addition, clinical efficacy was in general higher in patients with moderate compared to severe disease, which is in line with what has been reported for other therapies in this indication. The data have previously been presented at the United European Gastroenterology Week (UEGW), the Digestive Disease Week (DDW) and the annual congress of the European Crohn’s and Colitis Organisation (ECCO). “The post-hoc analysis shows that cobitolimod is able to induce symptomatic remission in clinically relevant subgroups of UC patients,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “We are pleased that our results continue to meet considerable interest from the scientific community as we continue the work of taking cobitolimod through the ongoing phase IIb dose optimisation study CONDUCT.”  The publication has the title “Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis”, and the publication can be found at www.dldjournalonline.com, Atreya R et al. Dig Liver Dis. 2018 Oct;50(10): 1019-1029. Contact InDex Pharmaceuticals:Peter Zerhouni, CEOTel: +46 8 508 847 35peter.zerhouni@indexpharma.com Cobitolimod in briefCobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in active ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Based on the encouraging results from earlier studies InDex is now performing the phase IIb study CONDUCT to evaluate higher doses and dose frequencies than investigated in previous studies with cobitolimod. The goal of the study is to optimise the treatment and achieve substantially higher efficacy, while maintaining the compound’s excellent safety profile. The CONDUCT study will include 215 patients with left-sided moderate to severe active ulcerative colitis at 90 sites in 12 countries. It is a randomised, double blind, placebo-controlled study for evaluating cobitolimod’s efficacy and safety in inducing clinical remission compared to placebo. The dose optimisation study investigates three different dose strengths of cobitolimod and two different dose frequencies. The objective is to have top line results from the study in the first half of 2019. Cobitolimod is also known as Kappaproct® and DIMS0150.  InDex Pharmaceuticals in briefInDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

Interim report January – September 2018

Kai Wärn, President and CEO:“The third quarter was largely characterized by a continuation of the warm and dry weather in central and northern Europe, that had a subdued effect on demand for lawn mowing products and services, while demand for watering products was positively affected. This was reflected in the decrease of net sales adjusted for changes in exchange rates in Husqvarna Division by 5% and the increase by 23% in Gardena Division. Net sales for the total Group increased 1% adjusted for changes in exchange rates. Operating income for the Group, excluding items affecting comparability* referring to restructuring related costs, declined to SEK 225m (433). The lower income was affected by low demand for higher margin lawn mowing products and parts in the Husqvarna Division. Gardena benefitted from the warm and dry European weather that helped to prolong the season for watering products. Consumer Brands reported a slightly lower operating income affected by challenging raw material prices related to tariffs. Operating income for Construction was higher, however adjusted for prior year’s integration costs the operating income was unchanged. As previously announced, we are now taking firm actions to address the underperforming Consumer Brands Division by exiting certain low-margin petrol-powered products mainly in North America and adjusting manufacturing capacity and central resources to reflect the less complex and more focused Group. The measures are expected to be accretive to the Group´s financial performance already from next year. The actions will also release resources and energy that can be focused on building on our strengths in premium offerings under the core brands of Husqvarna and Gardena in areas such as robotic lawnmowers, digitization and technology for battery powered products. Following several years of strong financial improvements, 2018 will deviate from that trend. Hence, the highest priority for 2019 is to restore the improvement momentum. Key deliverables to accomplish this include realizing price increases, restoring the balance between the efficiency programs and costs for profitable growth activities and delivering the savings of the restructuring of Consumer Brands Division. A successful execution of these deliverables form the base to achieve the 10% operating margin target in 2019.” Third quarter 2018 · Net sales increased to SEK 8,042m (7,449), corresponding to a currency adjusted* increase of 1%. · Group operating income, excluding items affecting comparability* of SEK -349m referring to restructuring, decreased to SEK 225m (433). · Operating cash flow* declined to SEK 628m (1,132). · Restructuring measures related to Consumer Brands Division being executed (see page 5). Telephone conferenceA combined press and telephone conference, hosted by Kai Wärn, President and CEO, and Jan Ytterberg, CFO, will be held at Husqvarna Group’s office, Regeringsgatan 28, Stockholm at 10:00 CET on October 19, 2018. To participate, please dial +46 (0) 8 566 184 30 (Sweden) or +44 (0) 8 448 228 902 (UK) ten minutes prior to the start of the conference. Conference ID: Husqvarna or 1693525. The conference call will also be audio cast live on www.husqvarnagroup.com/ir . A replay will be available later the same day.

Interim report for 1 January – 30 September 2018

THIRD QUARTER[1] · Net sales amounted to SEK 665.1 (686.4) million · CDON Marketplace increased sales from external merchants with 22 percent and gross profit with 19 percent, while continuing the phaseout of low-margin own inventory sales · Qliro Financial Services increased total operating income by 36 percent and the loan book by 51 percent · Nelly grew by 11 percent for the second quarter in a row · The gross margin increased by 2 percentage points to 26.3 (24.3) percent · Operating income before depreciation, amortization and impairment increased to SEK 19.0 (12.9) million · Operating income improved to SEK 0.7 (-4.4) million · Profit after tax including discontinued operations amounted to SEK -1.8 (-2.0) million · Basic and diluted earnings per share including discontinued operations amounted to SEK -0.01 (-0.01) FIRST NINE MONTHS[1] · Net sales amounted to SEK 2,188.3 (2,196.9) million · The gross margin increased to 23.4 (22.8) percent · Operating income before depreciation, amortization and impairment was SEK -16.1 (37.6) million · Operating income amounted to SEK -68.5 (-14.8) million · Profit after tax including discontinued operations amounted to SEK -2.5 (-30.2) million, including tax and interest expenses of SEK 70 million attributable to CDON Alandia 2012 · Basic and diluted earnings per share including discontinued operations amounted to SEK -0.02 (-0.20) · Cash and cash equivalents increased to SEK 577.2 (433.8) million by the end of the period SEK million  2018 2017 2018 2017 July-Sep  July-Sep  Jan-Sep  Jan-Sep Net sales  665.1  686.4  2,188.3  2,196.9 Gross profit  175.3  166.5  512.7  501.0 Gross margin, %  26.3%  24.3%  23.4%  22.8% Operating income before 19.0  12.9  -16.1  37.6 depreciation, amortization andimpairment  Operating margin before 2.9%  1.9%  -0.7%  1.7% depreciation, amortization andimpairment, % Operating income   0.7  -4.4  -68.5  -14.8 Operating margin, %  0.1%  -0.6%  -3.1%  -0.7%  [1]Lekmer and HSNG are recognized as discontinued operations in the consolidated accounts.  STRONG UNDERLYING GROWTH AND NEW FINANCIAL TARGETSThe third quarter shows strong underlying growth. CDON Marketplace increased sales from external merchants by 22 percent, while continuing the phaseout of low-margin own inventory sales. Qliro Financial Services increased total operating income by 36 percent and the loan book by 51 percent. Nelly grew net sales by 11 percent for the second quarter in a row, and the proportion of own brands was 44 percent of sales. In addition, the Group's gross margin increased by 2 percentage points to 26.3 percent. Since June 2018, our strategy has been to operate Qliro Financial Services, CDON Marketplace and Nelly as three independent companies. The intention is to create the best conditions for the companies’ development and thus increase shareholder value. The work with potential structured deals, divestments or a stock listing is proceeding according to plan. We have set new financial targets for the subsidiaries and appointed new CEOs to both CDON Marketplace and Nelly. Qliro Financial Services continues to growSince its inception, Qliro Financial Services has built its offering of financial services to consumers and merchants. Going forward, the primary aim is to utilize economies of scale and capitalize on the existing service offerings. The focus is on attracting more merchants and rolling out the consumer services launched in Sweden, to the other Nordic countries as well. The company has over 30 merchants connected to its platform and more than half of the business volume comes from online merchants not owned by the group. Over the past year, 1.9 million consumers have used the company’s digital financial services. The loan book grew by 51 percent to over SEK 1.2 billion with the fastest growth in personal loans. Total operating income increased by 36 percent and total operating expenses increased by 32 percent, including new commercial initiatives and recruiting of personnel working with attracting and onboarding new merchants. The new initiatives are key to strengthen the position as an independent company. The transaction volumes are currently negatively impacted by CDON Marketplace phasing out of sales from own inventory. The financial development is dependent on the e-commerce volumes and thereby the recruitment of new merchants. Qliro Financial Services new financial target is to achieve an operating income before depreciation and amortization of SEK 100 – 125 million in 2019. This target may be complemented with longer-term targets when the new CEO has joined. CDON Marketplace accelerates transformationTo strengthen its position as an independent company, CDON Marketplace accelerated its transformation into a marketplace for external merchants, complemented by sales from own inventory. The marketplace model and dropshipment (selling directly from suppliers’ inventory) set a foundation for growth with lower stock levels and capital requirements over time. The number of visits and active customers to CDON Marketplace increased in the quarter. External merchant sales increased by 22 percent. Meanwhile, the phase out of sales from own inventory continued, especially in the consumer electronics segment with low-margins. This provides the right long-term conditions for a strong market position with higher margins and profitability, while having a negative effect on sales during the transformation. Consequently, the gross margin rose sharply from 10.1 percent to 14.8 percent in the quarter and it is expected to continue to increase along the transformation. To reflect the transformation, the new financial targets are based on the sales growth of external merchants and on the traditional operating margin before depreciation and amortization. We estimate that operating income before depreciation and amortization will be positive for the full year 2019.  Nelly increases sales and profitNelly is one of the most well-known online fashion brands among women aged 18 to 29 in the Nordics. At its core is its own brand, complemented by a well-curated portfolio of approximately 200 external brands. Nelly’s focus on profitable growth led to an increase of 7 percent in number of visits, 12 percent in number of orders, 15 percent in number of customers and 5 percent in average shopping basket size for the quarter. Thus, sales rose 11 percent. 44 percent of all sales were our own brand. Operating income before depreciation and amortization improved somewhat to SEK 24 million. This was, however, a significant improvement in underlying profitability since last year’s operating income was positively affected with SEK 6 million due to the divestment of Members.com. Nelly has a successful growth strategy, and we are now raising the target for growth while maintaining the operating margin target. Financial flexibilityQliro Group’s gross profit and operating income before depreciation and amortization increased during the quarter. Our three companies have strong positions in dynamic and growing segments of e-commerce. In addition, we have a strong financial position. The Group’s cash amounted to SEK 577 million and the net cash of the e-commerce business amounted to SEK 301 million. Our companies have strong markets positions and are driving forces in the shift to online commerce. Stockholm, October 19, 2018Marcus Lindqvist, President and CEO SIGNIFICANT EVENTS DURING AND AFTER THE THIRD QUARTER Consolidated situationA consolidated situation arose when the subsidiary Qliro AB (a credit market company under Finansinspektionen’s supervision), in accordance with the Capital Requirements Regulation, was considered to be the main business of the group, which occurred at the end of Q2 when Qliro AB accounted for more than half of the Group’s total assets. The consolidated situation consists of the parent company Qliro Group AB and Qliro AB and has been assigned a special institution number. Certain rules for the credit market company therefore also apply to the parent company, such as the capital adequacy regulations. The consolidated situation (parent company and Qliro AB) was well-capitalized as at September 30, 2018. Kristoffer Väliharju CEO of CDON MarketplaceOn September 13, 2018, it was announced that Kristoffer Väliharju has been appointed CEO of CDON Marketplace. Kristoffer was Chief Operating Officer at CDON Marketplace since June 2017 and replaced Magnus Fredin who chose to leave after three years. Kristoffer has previous experience from working for Dustin and Dell. Anna Ullman Sersé CEO of NellyOn October 9, it was announced that Anna Ullman Sersé had been appointed permanent CEO of Nelly. Prior to that, she was Interim Head of Nelly since April 2018 and Head of Business Development at Qliro Group since 2016. Anna was formerly a management consultant at Accenture Interactive.  New financial targetsThe Board of Qliro Group resolved on October 18 to set new financial targets of the subsidiaries. For further information, see the separate press release and page 3 of this report.Conference callAnalysts, investors and the media are invited to a conference call today at 10 a.m. To participate in the conference call, please dial:Sweden 08 5033 6574UK +44 330 336 9125US +1 929 477 0324PIN code to participate: 8827683. The presentation material and webcast will be published at www.qlirogroup.com.  For additional information, please visit www.qlirogroup.com or contact:Marcus Lindqvist, President and CEONiclas Lilja, Investor RelationsTelephone: +46736511363ir@qlirogroup.com About Qliro GroupQliro Group is a leading Nordic e-commerce group in consumer goods and related financial services. Qliro Group operates CDON.COM, the leading Nordic online marketplace, the fashion brand Nelly and Qliro Financial Services, offering financial services to merchants and consumers. In 2017 the Group had sales of SEK 3.4 billion. Qliro Group’s shares are listed on the Nasdaq Stockholm MidCap segment under the ticker symbol QLRO.  This information is information that Qliro Group AB is required to disclose under the EU Market Abuse Regulation. The information was released for publication through the agency of the above-mentioned contacts at 8 a.m. on Friday, October 19, 2018.

Sivers IMA Holding completes a directed new share issue of SEK 43.4 million

The subscription price has been determined by a bookbuilding procedure and corresponds to a discount of 5.5 percent compared to yesterday’s closing price. Subscribers in the Directed issue are a limited number of qualified and institutional investors, of which a majority of the shares are subscribed for by a small-cap fund owned by a leading Swedish pension company, Swedbank Robur Ny Teknik and Nordic Cross Small Cap Edge. Sivers IMA has recently received a number of new contracts for chip delivery to major international players active in fiber and fifth generation mobile networks (5G). In order to take advantage of the positive trend, the Board has decided on a directed issue of approximately 43.4 MSEK. The reason for deviating from shareholders' preferential rights is to strengthen the company's financial position in a timely and cost-effective manner in order to meet the increasing demand from customers while broadening and strengthening the ownership base. "We are very pleased with the development of our new major customers and partners that demand a high level of delivery capability. Through the directed new share issue, we can effectively support this with new capital while broadening the company's ownership base with qualified shareholders. It is therefore very pleasant that we can announce an issue of MSEK 43.4 and welcome one new small-cap fund as a shareholder in Sivers IMA Holding, and that Swedbank Robur Ny Teknik and Nordic Cross Small Cap Edge further increase their holdings in the company, "says Anders Storm, CEO of Sivers IMA. For existing shareholders, the issue entails a dilution effect of approximately 6.3 percent of the capital and votes in the Company. The company's total number of outstanding shares increases from 111,445,825 shares to a total of 118,445,825 shares. The issue means an increased share capital of3 500 000 SEK from 55 722 912.50 to 59 222 912.50SEK. Redeye AB acted as financial adviser to the Company in connection with the Directed issue. For more information, please contact:  Anders Storm, CEO Tel: +46 70 262 6390 E-mail:anders.storm@siversima.com   Erik Penser Bank is appointed Sivers IMA Holding ABs Certified Adviser on Nasdaq First North. Tel: +46 8 463 80 00 This information is insider information that Sivers IMA is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on October 19, 2018, at 08:00 CET.  Sivers IMA Holding AB is a leading and internationally renowned supplier, publicly traded under SIVE at Nasdaq First North Stockholm. The wholly owned subsidiaries Sivers IMA and CST Global develop, manufacture and sell cutting-edge chips, components, modules and subsystems based on proprietary advanced semiconductor technology in microwave, millimeter wave and optical semiconductors. Headquarters in Stockholm, Sweden. Learn more at http://siversima.com.

Flexion Mobile Plc is growing its game developer base in China

LONDON, 19th of October, 2018 – Flexion Mobile Plc ( NASDAQ: FLEXM) , the London-based company that helps game developers maximise the growth potential of their android games, today announced it is expanding its partnership with YOOZOO Games, one of the leading Chinese Entertainment companies. After 12 months of successful collaboration based on the title Legacy of Discord, Flexion and YOOZOO Games have agreed to extend their co-publishing agreement and include YOOZOO Games’ recently launched title Rise of Ragnarok. In 2017, the top grossing title Legacy of Discord from YOOZOO Games was launched by Flexion in channels such as Amazon App Store and Samsung Galaxy Apps. This was Flexion’s first big title from China and the performance has exceeded expectations. To date, Legacy of Discord has successively topped the top grossing charts in 57 countries and regions, reaching TOP 3 in 94 countries. “We are proud of our achievements over the last 12 months and it has been a great experience working with YOOZOO Games, one of the leading Chinese companies in our space. They have really showed us and the market their ambitious plans by securing top western IP and it is an honour for us to be part of their expansion”, says Jens Lauritzson, CEO of Flexion Mobile Plc. The Chinese mobile games market is the world’s largest market representing approximately 25% of the total revenues with local giants such as Netease and Tencent dominating the charts. As domestic Chinese competition and regulatory approvals have made life more difficult for developers many are now looking for ways to expand outside of China. This is where Flexion plays an important role and can help and assist them navigate the western distribution landscape. “We are currently seeing strong demand from Chinese developers who are coming to western markets. It is very difficult for developers to stay focussed on making great games for global markets and at the same time become experts in regional marketing and distribution. That’s why we are busier than ever right now”, concludes Lauritzson.

Smooth sailing for Stena Line's battery hybrid vessel

“It's really exciting to be running with electrical power on the Stena Jutlandica. This project is an important part of our focused efforts to find ways of reducing our impact on the environment. As both the size and cost of batteries decrease, battery operation is becoming a very attractive alternative to traditional fuel for shipping since emissions should be possible to completely eliminate in the future,” says Erik Lewenhaupt, Head of Sustainability at Stena Line. The project to convert Stena Jutlandica on the Gothenburg-Frederikshavn route to a battery hybrid vessel is being carried out in steps. Step one, which is presently underway, is about switching to electrical operation to reduce the use of diesel generators, as well as for maneuvering and powering the bow thrusters when the ship is in port. In the second step, battery power will be connected to two of the four primary machines, which means that the Stena Jutlandica will be able to run on electrical power for about 10 nautical miles inside the Gothenburg archipelago out to Vinga Lighthouse. In step three, all four primary machines will be connected to the batteries and the ship will be able to cover the 50 nautical miles between Sweden and Denmark solely on electrical power. Positive effects have already been noted after just one month. “As an example, we've been able to strongly reduce our use of the diesel generators and now only need to use one instead of three. Another positive effect concerns safety; by having constant access to electricity, we minimize the risk for power outages”, says Johan Stranne, Senior Chief Engineer on the Stena Jutlandica. Only in step one, the environmental savings from using battery power for reduced generator usage and maneuvering in port amounts to about 500 tons of fuel, 1,500 tons of CO2. This in turn corresponds to the annual emissions from approximately 600 cars. The reason for execution in multiple steps is to enable testing and assessment while the project is underway. If the project is successful, battery power can be considered for other vessels within the Stena Line fleet. Work with step two has begun and the goal is for implementation within about three years. The technical solutions in the first step have been developed by Stena Teknik in collaboration with the Callenberg Technology Group, with half of the funding for the project coming from the Swedish Transport Administration and the EU.

“Solid profitability, weaker demand in some customer segments”

“There are more uncertainties in the global economy and that has affected some customers’ investment decisions”, said Mats Rahmström, CEO and President of the Atlas Copco Group. “As expected, the semiconductor business had a negative order development in the quarter”. Compared to previous year, orders received during the third quarter increased 6% to MSEK 23 440 (22 062), an organic decline of 1%. Revenues increased 13% to MSEK 23 675 (21 033), an organic growth of 6%. The operating profit increased to MSEK 5 263 (5 002). Excluding items affecting comparability, the adjusted operating profit margin was 22.5% (22.2). “We continue to introduce innovations that help our customers provide even better products and services that increase their productivity. We focus on developing products that save energy and service solutions that are smarter and more digital,” said Mats Rahmström. Examples of innovative products that were launched in the quarter is a high-efficient and energy saving oil-injected screw compressor, and a range of generators that reduce emissions and ensure low energy consumption. A new controller for assembly applications to support Industry 4.0 and fast tool rebalancing was also introduced.“In the quarter, we announced the acquisition of the cryogenics business of Brooks Automation. Finding and acquiring companies that bring additional innovation power and strengthen our existing business is an important part of our strategy for growth,” said Mats Rahmström.

New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the initial phase II study of MIV-711, which demonstrated disease-modifying activity in patients with moderate knee osteoarthritis after only six months of treatment, will be presented during the American College of Rheumatology (ACR) annual meeting, which will take place from 19-24 October 2018 in Chicago, USA.   The presentation will be given by the study’s lead investigator Dr. Philip Conaghan, Professor of Musculoskeletal Medicine at the University of Leeds in the UK, and will be made on Sunday October 21st: Abstract 429: The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor MIV-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis InitiativeAuthors: P. G. Conaghan, M. A. Bowes, S. R. Kingsbury, A. Brett, G. Guillard, Å. Jansson, C. Wadell, R. Bethell and J. Öhd Details of all presentations for the 2018 ACR annual meeting are available at the conference website:https://www.rheumatology.org/Annual-Meeting For further information, please contact:Uli Hacksell, CEO, Medivir AB, mobile: +46 (0)73 125 0615Erik Björk, CFO, Medivir AB, mobile: +46 (0)72 228 2831 About disease modification in osteoarthritisOsteoarthritis affects over 30 million adults in the US 1), and as many as 240 million people worldwide. There are currently no disease-modifying therapies approved for the treatment of the disease. The ultimate goal for a treatment that inhibits structural damage or targets the underlying pathophysiology associated with osteoarthritis is to bring clinical benefit, such as reduction of pain. It is however possible that structural endpoints could be accepted as valid outcome measures for accelerated approval in the US. To date, all approved osteoarthritis treatments affect only day to day symptoms and have no effect on the degenerative changes in the diseased joint 2). About MIV-711MIV-711 is a potent and selective inhibitor of cathepsin K, the principal protease involved in breaking down collagen in bone and cartilage. It is being developed to slow or reverse the progressive degeneration of joints affected by osteoarthritis, and is therefore a potential DMOAD. Since there are no DMOADs approved for use currently, the standard of care for osteoarthritis patients is based on changes in life style and the use of analgesics. The long-term use of analgesics by osteoarthritis patients is associated with an increased risk of side effects such as gastrointestinal bleeding and opioid dependency. DMOADs therefore represent a very large and attractive market opportunity. Medivir estimates that the US market alone is greater than USD 6 billion annually for a drug that impacts disease progression, even if its use was restricted to patient populations with moderate osteoarthritis in weight-bearing joints. Work to find a commercial partner for future development is ongoing. 1) https://www.cdc.gov/arthritis/basics/osteoarthritis.htm2) https://www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf About MedivirMedivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda® for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Lehto Group Plc: Lehto declines its financial outlook for the year 2018

Updated outlook 19 October 2018: Lehto estimates that the Group’s net sales for 2018 will grow by about 20-25% from 2017 (EUR 597.6 million in 2017) and operating profit is expected to be approximately 5-6% of net sales (2017: 10.8%). The decrease in the estimated operating profit is due to further decreased project margins, particularly in the ‘Social Care and Educational Premises’ and ‘Building Renovation’ service areas, and slightly lower estimate in the Group’s net sales. The declined net sales estimate is mainly due to delay of project starts in ‘Social Care and Educational Premises’ service area. Business in Housing and Business Premises service areas is progressing as planned. In ’Building Renovation’ service area Lehto operates on pipeline renovations and complete renovations. In complete renovation unit projects have not progressed as planned and regardless of the corrective actions the project margins have further declined and there are many loss-making projects in the unit. Complete renovation operations have altogether a significant negative effect on Lehto Group’s operating profit in 2018. Lehto is rapidly seeking alternative solutions in order to abandon the unprofitable parts of ’Building Renovation’ service area. The decisions are communicated latest by the end of this year. In the ‘Social Care and Educational Premises’ service area project margins have developed negatively too and there are also loss-making projects. The new management of the service area, appointed in August this year, has taken actions to develop project management. In addition, operations are more clearly focused on developing product concepts and utilizing more efficiently Lehto’s own manufacturing. These actions are supposed to gradually improve project margins. The profitability of the year 2018 also loaded by the non-recurring costs caused by the expansion of factory capacity and higher than estimated material and subcontracting costs. The outlook is based on the information on the progress of ongoing construction projects and the company’s estimate of construction projects to be started and sold in 2018. The main risks associated with the development of net sales and operating profit are related to the completion of ongoing projects within the estimated timeframe and costs and the development of the apartment sales. The previous outlook, published on 9th August 2018 in half-year financial report, was as follows: Lehto estimates that the Group’s net sales for 2018 will grow by about 20-30% from 2017 (EUR 597.6 million in 2017), and operating profit is expected to be approximately 8-9% of net sales (10.8% in 2017).

Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO

The poster presentation – with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors­ – was given by the coordinating investigator Professor Ahmad Awada, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. The poster is available on Cantargia’s website, www.cantargia.com. The presentation included data from the cutoff date, October 5, 2018, on 16 heavily pretreated patients with advanced colorectal cancer (9), non-small cell lung cancer (3) or pancreatic cancer (4) treated with weekly infusions at escalating dose levels from 1 mg/kg to 6 mg/kg. Prior to CAN04, the patients had received an average of 4 different cancer therapies. The most common side effects of CAN04 were infusion related reactions and related events, such as nausea, fatigue and fever. These side effects were generally associated with the first dose and were reversible. It can be concluded that 6 mg/kg is a safe dose and the maximum tolerated dose of CAN04 is higher. The trial is now investigating treatment at 10 mg/kg of CAN04 before moving into phase IIa. “I am very pleased with the results obtained so far. CAN04 has generally been well tolerated using repeated dosing. The good safety profile and initial effects are encouraging and supportive for the next step in the trial, which is combination with chemotherapy”, said Prof. Ahmad Awada, the coordinating investigator of the CANFOUR trial. The initial biomarker analysis shows that the serum levels of IL-6 were reduced in 11 out of 14 patients after two weeks and serum levels of CRP were reduced in 9 out of 11 patients with available samples. Levels of IL-6 and CRP are often increased in cancer patients and are associated with disease progression. Preliminary efficacy results show that five patients achieved stable disease, eight progressed and three could not be evaluated. One patient with NSCLC had stable disease for six months. ”Presenting the first clinical dataset from CAN04 treatment of patients with advanced cancer at a major cancer conference is an important milestone for Cantargia. The results have strengthened our view that CAN04 can become an important future cancer therapy. We look forward to the last step in the Phase I part and the initiation of Phase IIa in NSCLC and pancreatic cancer using an expanded number of clinical sites,” said Göran Forsberg, CEO of Cantargia. The primary objective of the Phase I part of CANFOUR is to assess safety and tolerability of weekly CAN04 in order to define the Maximum Tolerated Dose/Recommended Phase II Dose. Patients with relapsed or refractory non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), breast or colorectal cancer are eligible in the initial part of the trial using a 3+3 dose escalation design. The Phase I part of the trial is currently in the final stage and is planned to be finalized during Q4 2018 with phase IIa also starting Q4 2018. Besides monotherapy, combination with cisplatin/gemcitabine in NSCLC or gemcitabine/nab-paclitaxel in pancreatic cancer at an earlier stage of the disease will be studied in phase IIa. More details on the trial design can be found at www.clinicaltrials.gov . For further information, please contact Göran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on October 20, 2018, at 12:30. About CantargiaCantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.

BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease

Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company’s patent application in Europe, EP09738534.8, for its Parkinson’s disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018. The granted concept patent in Europe protects the company’s innovative treatment strategy for Parkinson’s disease. Corresponding patents have previously been granted in the US and Japan. BioArctic’s patent strategy is to protect our treatment strategy conceptually, with broad claims that prevent competitors from using the same treatment strategy, complemented by specific substance patents to provide protection against generics and biosimilars. The company has an active patent strategy covering all major geographic markets, including the US, Japan, China and Europe. ”The granted concept patent in Europe, which protects the company’s innovative treatment strategy for Parkinson’s disease, is an in important part of the company’s patent strategy. Today there is no disease-modifying treatment on the market and we want to contribute with innovative and effective treatments that improve the Parkinson patients’ quality of life,” said Gunilla Osswald, CEO of BioArctic. For more information, please contact:Gunilla Osswald, PhD, CEOE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 Christina Astrén, Director IR and CommunicationsE-mail: christina.astren@bioarctic.seTelephone: + 46 70 835 43 36 This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact persons above, on October 21, 2018, at 09.00 a.m. CET. About BioArctic’s Parkinson ProgramBAN0805 is a drug candidate (an antibody against alpha-synuclein) for the treatment of Parkinson’s disease. The aim is to develop a disease-modifying treatment that stops or slows down disease progression. Collaboration with AbbVie was started in 2016 regarding the continued development of the company’s Parkinson program, focusing on BAN0805 with follow-up projects and diagnostics. BioArctic is preparing for the application to the U.S. Food and Drug Administration (FDA) for the initiation of a clinical study of BAN0805 in the U.S., an IND. The project is based on research from Uppsala University in Sweden. The antibodies PD1601 and PD1602 (against alpha-synuclein) are both Parkinson’s disease follow-up projects with the goal to develop a disease-modifying treatment that stops or slows down disease progression. The projects are conducted in collaboration with AbbVie. About Parkinson’s DiseaseParkinson’s disease is the second most common neurodegenerative disease, after Alzheimer’s disease. Parkinson’s disease is a progressive disease of the nervous system that affects the ability to move due to reduced levels of dopamine in the brain. Tremor is the best-known sign of the disease. As the second most common neurodegenerative disease, after Alzheimer’s disease, Parkinson’s disease affects a large number of individuals and their families. Parkinson’s disease affects a younger patient group, which means that many who fall ill are still at working age, with considerable financial consequences for the individual and society. Patients with Parkinson’s disease suffer from an extensive loss of nerve cells in a certain part of the brain. In the nerve cells of the Parkinson brain there are so called Lewy bodies consisting of accumulated alpha-synuclein, a protein normally regulating neurotransmitters. Research has shown that mutations in the alpha-synuclein gene lead to Parkinson’s disease. About BioArcticBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com 

Beijer Ref AB Q3-2018

Net sales for the third quarter of 2018 increased by 41% compared with the corresponding period in the previous year and totalled SEK 3,607 million (2,555). The operating profit for the third quarter of 2018 totalled SEK 339 million (217), an increase of 57% compared with the same period last year. The profit for the period totalled SEK 240 million (149). Profit per share totalled SEK 1.88 (1.16). Beijer Ref AB and Mitsubishi Heavy Industries Air Conditioning Europe LTD completed the formation of the subsidiary 3D Plus in the UK, with Beijer Ref as the majority shareholder. The acquisition of the Spanish air conditioning company Lumelco S.A. strengthens the Group’s position in field of air conditioning in Southern Europe. Repurchases of 181,559 class B shares took place during the quarter. The purpose of the repurchase is to secure access to shares in accordance with the company’s long-term incentive scheme, 2018-2021. Comments by the CEO Growing market creates strong quarter We can look back on another quarter of strong growth. Net sales increased by 41 per cent and the profit increased by 57 per cent compared with the same period in 2017. This is our strongest third quarter ever. Adjusted for acquisitions and currency effects, net sales increased organically by approximately 16 per cent and the profit by 42 per cent. All regions are reporting growth in line with our expectations, although Europe does stand out. Of the European regions, the Nordic region has distinguished itself just a little extra. An unusually warm summer resulted in record net sales and profits for the region, with an organic increase in net sales of 30 per cent, while the profit doubled. The profit for the quarter shows once again that our market is strong. The F-gas regulation in Europe is accelerating the phasing out of existing refrigerants, known as fluorinated gases, and is one of the main reasons why demand for Beijer Ref’s products is increasing. The phase-out programme is continuing, and we see no signs of reduced activity. The UN recently issued an updated climate report highlighting how urgent it is that global warming remains at a maximum of 1.5 degrees by the year 2100. This is half a degree lower than the goal of the Paris Agreement. Achieving this new goal requires substantially increased measures, according to the IPCC, the UN’s climate panel. Our industry has a great responsibility in this matter and we must be proactive if this goal is to be achieved. Beijer Ref’s focus on developing eco-friendly solutions therefore feels even more urgent. We have a long tradition and a great deal of knowledge of such technology in Europe. We are now passing on this know-how to our companies on other continents. The fact that the economy remains strong also means that end customers are prepared to invest and upgrade their refrigeration and air-conditioning systems to an even greater extent, which benefits us. We also want to grow through acquisitions in Europe and in the rest of the world. During the quarter, Beijer Ref acquired the Spanish air conditioning distributor Lumelco. This deal consolidates the Group’s position within the HVAC segment in Beijer Ref’s biggest region, Southern Europe. The company distributes several strong brands, but primarily has exclusive distribution rights with Mitsubishi Heavy Industries, one of Beijer Ref’s strategic partners. Strengthening and developing relationships with our main suppliers is in line with our strategy. Lumelco is included in our accounts as of August this year. During the transfer phase to eco-friendly refrigeration technology, we have seen sharp increases in the price of HFC refrigerants with the most negative environmental impact. These price increases are a direct consequence of the European regulatory framework for the phasing out of F-gases. At present these price rises have slowed down, and the assessment is that prices will remain stable over the next few quarters. Our logistics chain is one of our strengths, and we are working to create sustainable, modern solutions that deliver efficiency throughout the entire flow. At the beginning of the year we opened a new, large, automated logistics centre in the Netherlands, known as the Beijer Ref Support Center. This enables us to achieve efficiency improvements above all in the areas of purchasing, logistics and back office. As another step in the same direction, we recently opened a similar centre in Auckland, New Zealand. Passing on best practice within the Group is important and an advantage that we want to use to the maximum. All in all, we are satisfied with the period and we enter the fourth quarter with both humility and strong self-belief. Going forward, we want to grow further. With increased profits, low interest rates and a strong cash flow, we are well placed to make more supplementary acquisitions. Per Bertland  CEO Third quarter of 2018 NET SALES  Beijer Ref increased its net sales by 41 per cent to SEK 3,607 million (2,555) in the third quarter of 2018. A strong global economy, favourable weather conditions that increase demand for air conditioning, and price rises in particular for refrigerants have resulted in continued strong growth in net sales. All regions report an increase in net sales of more than 20 per cent in the third quarter. Adjusted for exchange rate changes and acquisitions, organic growth in net sales was 16 per cent. A weakened Swedish krona resulted in currency effects of SEK 195 million (-22), corresponding to 8.8% since most of the company’s net sales take place in currencies other than Swedish kronor. PROFIT  The Group’s operating profit totalled SEK 339 million (217) during the third quarter, an increase of 57 per cent. The ongoing transition to eco-friendly refrigeration systems had a positive impact on the profit for the period and also resulted in increased demand for HVAC and OEM, which are future growth segments for Beijer Ref. Adjusted for exchange rate changes and acquisitions, the organic improvement in the operating profit was 42 per cent. CASH FLOW  Cash flow from operating activities before change in working capital was SEK 829 million during the first nine-month period of 2018, compared with SEK 500 million for 2017, primarily due to the significantly improved profit. Working capital increased by SEK 585 million during the first nine-month period compared with SEK 134 million the previous year. This produces cash flow from operating activities of SEK 243 million, compared with SEK 366 million the previous year. The change in working capital between the years is due primarily to sales growth and some build-up of stocks. INVESTMENTS  The Group’s investments in fixed assets including business combinations totalled SEK 1,011 million (72) during the first nine-month period and relate primarily to the acquisitions of Tecsa, Heatcraft and Lumelco, which were financed by external borrowing from existing bank partners. During the period the company also invested the net sum of SEK 70 million in the repurchase of own shares after deduction of the option premium received. SIGNIFICANT EVENTS DURING THE QUARTER   On 2 July 2018, Beijer Ref AB and Mitsubishi Heavy Industries Air Conditioning Europe Ltd completed the formation of the subsidiary 3D Plus, with Beijer Ref as the majority shareholder. The new company is now operating under the leadership of a new CEO. 3D Plus’s head office is in Slough, with regional offices planned in the UK and Ireland. The formation of the subsidiary is only having a marginal effect on net sales in 2018, but it is considered to have good growth potential. The acquisition of the Spanish air conditioning company Lumelco S.A. is included in the company’s accounts as of August and strengthens the Group’s position in the HVAC segment in Beijer Ref’s biggest region, Southern Europe. The company is a long-time distributor of Mitsubishi Heavy Industries’ products in Spain and Portugal, one of Beijer Ref’s strategic suppliers. The company has net sales of approximately SEK 400 million and over 60 employees. The takeover has only a marginal effect on the profit in 2018. The acquisition is, however, expected to generate long-term positive effects in terms of both net sales and profit. During the quarter, the company exercised the AGM’s authorisation to repurchase its own shares following a decision on a long-term incentive scheme for senior executives. In total, the company repurchased 181,559 shares during the quarter and now holds 774,809 shares at an average purchase value of SEK 107. The incentive scheme runs between 2018-2021. The costs of the scheme are in line with the Board’s proposal and the AGM’s decision, i.e. SEK 8 million, and were charged to the company’s operating profit in 2018. IMPORTANT EVENTS AFTER THE END OF THE PERIOD In the fourth quarter, Beijer Ref AB will establish a commercial paper scheme with a financial envelope of SEK 1,500 million as a complement to Beijer Ref’s bank financing. The organiser of the scheme is Handelsbanken and the issuing agents are Handelsbanken and Nordea. The company will guarantee available credit facilities corresponding to the amount issued. RISK DESCRIPTION  The Beijer Ref Group’s operations are subject to a number of business environment factors, the effects of which on the Group’s operating profit can be controlled to varying degrees. The Group’s operations depend on general economic trends, primarily in Europe, which determine demand for Beijer Ref’s products and services. Acquisitions are normally associated with risks, for example loss of key employees. Other operating risks, such as agency and supplier agreements, product liability and delivery commitments, technical development, warranties, dependence on key individuals, etc., are analysed continually. Where necessary, measures are taken to reduce the Group’s risk exposure. In its operations, Beijer Ref is subject to financial risks such as currency risk, interest rate risk and liquidity risk. The Parent’s risk profile is the same as that of the Group. For further information, see the Group’s Annual Report. ACCOUNTING POLICIES  This interim report was prepared in accordance with IAS 34, the Swedish Annual Accounts Act and RFR 2. Beijer Ref continues to apply the same accounting policies and valuation methods as described in the most recent annual report. Analyses of effects regarding the implementation of IFRS 15 - Revenue from Contracts with Customers and IFRS 9 - Financial Instruments have been performed at both Group and subsidiary level. The analyses show that the new standards do not have any material impact on the Group’s financial statements other than increased disclosure requirements. The prospective method is applied from January 2018. IFRS 16 Leases – a new leasing standard that comes into effect on January 1, 2019. This standard requires that assets and liabilities attributable to all leases and rental agreements be recorded in the balance sheet. The Group is currently evaluating the effects. The Group’s total assets will increase and at the same time, operating profit will increase compared with the current amount because some of the leasing payments will be recognized as interest expenses. Also, a several of the Group’s key figures will be impacted by the new standard. This interim report for Beijer Ref AB (publ) has been submitted following approval by the Board of Directors. Malmö, 22 October 2018 Beijer Ref AB (publ) Per Bertland, CEO & President For more information: Per Bertland, CEO – +46 (0)705-98 13 73 Maria Rydén, CFO - +46 (0)73-429 25 65 This information is information that Beijer Ref AB is obliged to make public pursuant to the EU MarketAbuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 22 October 2018. AUDITOR’S REPORT  Beijer Ref AB (publ), corp. reg. no. 556040-8113 INTRODUCTION  We have reviewed the condensed interim financial information (interim report) of Beijer Ref AB (publ) as of 30 September 2018 and the nine-month period then ended. The board of directors and the CEO are responsible for the preparation and presentation of the interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review. SCOPE OF REVIEW  We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Report Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. CONCLUSION  Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company. Malmö, 22 October 2018 PricewaterhouseCoopers AB Lars Nilsson                                    Mikael Nilsson Authorized Public Accountant            Authorized Public Accountant Auditor in charge Financial calendar  The Interim Report for the fourth quarter 2018 will be published on 30 January 2019. The Annual Report for 2018 will be published in March 2019. The Annual Meeting of shareholders will be held on 10 April 2019 in Malmö. The Interim Report for the first quarter 2019 will be published on 16 April 2019. The Interim Report for the second quarter 2019 will be published on 12 July 2019. The Interim Report for the third quarter 2019 will be published on 22 October 2019.  www.beijerref.com

Swedbank's Interim report third quarter 2018

Third quarter 2018 compared with second quarter 2018 · Continued lending growth strengthened net interest income · Higher income from asset management and cards raised net commission income · Lower other income due to the income from the sale of UC in the second quarter · Costs in line with expectations · Good credit quality · High capitalisation 1) Results from Q1 2018 and onwards reflect the adoption of IFRS 9 Financial instruments and prior periods have not been restated. Refer to Note 1 for further information.2) 2017 results have been restated for changed presentation of commission income. Refer to Note 1 for further information.3) Includes income from sale of UC of SEK 677m in second quarter 2018.4) Includes income from sale of Hemnet of SEK 680m in first quarter 2017.5) Other income includes the items Net insurance, Share of profit or loss of associates, and Other income from the Group income statement. For more information:Gregori Karamouzis, Head of Investor Relations, Telephone +46 72 740 63 38Josefine Uppling, Press Officer, Telephone +46 76 114 54 21 This announcement involves the disclosure of inside information Swedbank AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Markets Act (2007:528), the Swedish Financial Instruments Trading Act (1991:980) and the regulatory framework of Nasdaq Stockholm. This information was sent to be published on 23 October 2018 at 7.00 CET.

TOMRA: Strong quarter fueled by high business activity in Sorting

TOMRA Systems ASA delivered strong results in the third quarter 2018, on the back of healthy growth in Tomra Collection Solutions and high business activity in Tomra Sorting Solutions.  Revenues in the third quarter 2018 ended at 2,247 MNOK, up 21% from 1,855 MNOK in third quarter last year. Organic, currency adjusted revenues were up 14% for the group, 9% for Tomra Collection Solutions and 20% for Tomra Sorting Solutions. Gross margin was 44% in the quarter, a slight increase from 43% in third quarter 2017, reflecting stable margins in Tomra Collection Solutions and improved margins in Tomra Sorting Solutions. Operating expenses amounted to 587 MNOK in third quarter, up from 496 MNOK in third quarter last year. The increase was due to continued high business activity, ramp-up costs in new deposit markets and acquisition of BBC (BBC consolidated into group financials from March 2018). EBITA reached 408 MNOK in third quarter 2018, up 35% from same period last year.    Cash flow from operations in third quarter 2018 were 433 MNOK, compared to 375 MNOK in third quarter 2017. Collection Solutions: Nurturing base while positioning for new markets Revenues in the business area equaled 1,135 MNOK in the third quarter 2018, up from 1,024 MNOK in third quarter last year. After adjustment for currency changes, revenues were up 9%. Gross margin was 43%, unchanged from last year. Operating expenses amounted to 240 MNOK, up from 202 MNOK last year, mainly due to cost related to the preparation for new deposit markets. EBITA was 244 MNOK, up from 236 MNOK third quarter last year.  In August 2018, TOMRA entered into a five-year agreement with the Queensland scheme operator, Container Exchange (CoEx), for the operation of 10 Collection Refund Points. Stefan Ranstrand, TOMRA President and CEO explains: “Each TOMRA Collection Refund Point will be a modern depot equipped with 9-12 TOMRA reverse vending machines and located in the greater Brisbane, Gold Coast, Sunshine Coast and Toowoomba areas.” Sorting Solutions: Strong revenue contribution from Recycling Revenues equaled 1,112 MNOK in third quarter 2018, up 20% in local currencies, adjusted for acquisitions (BBC). Gross margin was 46%, up from 43% same period last year due to higher activity and product mix. Operating expenses were up 18%, due to higher activity, the acquisition of BBC and currency effects. EBITA increased from 83 MNOK in third quarter 2017 to 184 MNOK in third quarter 2018, positively influenced by strong topline growth and improved gross margin. Continued strong order intake lead to a solid order backlog of 1,579 MNOK at the end of third quarter 2018, up from 1,226 MNOK at the end of third quarter 2017. “Revenues in the Food business stream were stable while the order intake was somewhat down compared to third quarter last year but is still up year-to-date. Recycling enjoyed significant positive development in both revenues and order intake. Mining also had strong improvement in revenue, order intake and backlog. We are satisfied with the results.”, says Stefan Ranstrand, TOMRA President and CEO. Asker, 23 October 2018 TOMRA Systems ASA For questions, please contact: Espen Gundersen, Deputy CEO/CFO: +47 66 79 92 42 / +47 97 68 73 01 Elisabet V. Sandnes, SVP Head of Group Strategy & Investor Relations: +47 97 55 79 15 Webcast link: https://events.webcast.no/tomra/kvartalspresentasjoner/tomra-systems-asa-q3-presentation-2018 There will be a Q&A after the presentation and the recorded webcast will be made available on TOMRA’s webpage www.tomra.com.

Hexagon strengthens its construction solutions portfolio for AEC (Architecture, Engineering, Construction) market with Bricsys acquisition

Hexagon AB, a global leader in digital solutions, today announced the acquisition of Bricsys, a fast-growing developer of CAD (computer-aided design) software that has been at the forefront of providing open, collaborative construction technology solutions since its founding in 2002.Its CAD platform, BricsCAD, supports 2D/3D general, mechanical, and sheet metal design and building information modelling (BIM) in one system. It’s 100% based on the de facto standard design format (.dwg), providing designers, engineers, and BIM professionals powerful access to the huge potential of vertical CAD applications created by thousands of third-party developers. Bricsys also offers its own set of time-saving, artificial intelligence-driven add-ons – from conceptual modelling to seamless BIM workflows and cloud connectivity.“Hexagon has long been a leader in structural & process piping design. The Bricsys acquisition extends our domain expertise into building design, adding walls, floors, doors, and other construction related features,” says Hexagon President and CEO Ola Rollén . “More importantly, we can now provide the AEC market with an end-to-end platform – with conceptual design, CAD design, BIM software and collaboration tools, project and cost controls, in-field construction execution tools (work packages), and progress documentation (reality capture) – to connect, automate, and ultimately 'autonomise’ the entire building and construction ecosystem through our HxGN SMART Build solution.”Headquartered in Ghent, Belgium, Bricsys  will be fully consolidated as of today, operating within Hexagon’s PPM division. The company's turnover for 2017 amounted to approximately 13 MEUR. For further information, please contact:Maria Luthström, Head of Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.com Kristin Christensen , Chief Marketing Officer, Hexagon AB, +1 404 554 0972, media@hexagon.com 

OX2 builds largest subsidy-free wind power project in the Nordics

The project includes wind farms Ponsivuori in Southern Ostrobothnia, Verhonkulma in Southwest Finland as well as Långmossa and Ribäcken in Ostrobothnia. OX2 is the current owner and the main contractor for the construction. OX2 will also manage the technical and commercial operation when the wind farms are up and running at the beginning of 2020. Total production is estimated at approximately 360 GWh per year. The selected turbine is the Nordex N149 4.0-4.5 MW, the total height of which falls between 200 and 230 metres.“The project marks a milestone both in OX2’s history and the industry as a whole confirming that we are now able to build wind power in the Nordics without financial subsidies. We have enjoyed great cooperation with Ingka Group for many years, so it's especially rewarding to reach this milestone with Ingka Group,” says Paul Stormoen, Managing Director of OX2 Wind. “We want to have a positive impact on people and the environment by accelerating the transition to a low carbon economy. One part of this commitment includes to become energy independent by 2020 and with the investments in wind farms, we take a leap in efforts to produce as much renewable energy as our global units consume,” says IKEA Retail Finland’s Sustainability Manager Jessica Lehtinen.OX2 has previously sold four wind farms to Ingka Group, three of which are located in Sweden and one in Finland. The first project was acquired in 2011 and the most recent one in Northern Finland in 2017. OX2 is managing the technical and commercial operation for all these wind farms and in addition OX2 manages the Ingka Group's wind farm in Lithuania. More information about the wind farms involved in the project: · At the Långmossa wind farm in Malax Ostrobothnia, a total of 7 wind turbines will be built. Contractors: Suvic Oy (foundation, roads, network), Nordex Energy GmbH (turbines), EPV Alueverkko Oy (grid connection). ·  At the Ribäcken wind farm in Malax Ostrobothnia, a total of 5 wind turbines will be built. Contractors: Suvic Oy (foundation, roads, network), Nordex Energy GmbH (turbines), EPV Alueverkko Oy (grid connection). · At Ponsivuori wind farm in Kurikka, South Ostrobothnia, 7 wind turbines will be built. Contractors: Keski-Suomen Betonirakenne Oy (foundations, roads, network), Nordex Energy GmbH (turbines), Caruna Oy (grid connection). · At Verhonkulma wind farm in Marttila, Southwest Finland, 6 wind turbines will be built. Contractors: Empower PN Oy (foundations, roads, network), Nordex Energy GmbH (turbines), Caruna Oy (grid connection). For more information please contact:Paul Stormoen, Managing Director OX2 Wind, T +46 (0)70-671 18 18, paul.stormoen@ox2.com

World premiere for SaltX EnerStore - large-scale energy storage in salt

Today, outside of SaltX headquarters in Stockholm the company will display the demonstration unit for partners, investors, press and other stakeholders. Stockholm is the first stop on the world tour where SaltX technology will be displayed in cities like Milan, Boston and Shanghai. The demonstration unit is a copy, but smaller scale, of the pilot plant that SaltX is installing together with Vattenfall in Berlin, Germany. "Our solution for storing thermal energy in nano-coated salt, is the first in the world. With this demo unit, we will show potential customers how EnerStore can store surplus energy from example wind power and then use it as district heating. "- says Karl Bohman, CEO of SaltX. The pilot plant at Vattenfall's Reuter C works in Berlin has a storage capacity of 10 MWh and is charged with excess energy from wind power and is discharged as district heating when demand is highest in the morning or evening.  For further information, please contact:Karl Bohman, CEO: tel: +46 70 560 02 68 ******************************************** About EnerStoreEnerStore is an energy storage solution that stores electric power and releases heat and steam -providing cheap peak shifting of energy to cities and industries. The solution is based on nano-coated salt - a patented SaltX technology.  Renewable energy is replacing fossil fuels globally and therefore it is a growing demand for balancing, peak shifting and abortion technologies to supply renewable energy when needed. Today there are many different geographies that have an increased supply of renewable electricity and at the same time have a demand for heat and steam. In Europe for example, 50 percent of the energy consumed is for heating. About SaltX TechnologySaltX Technology - www.saltxtechnology.com- develops and sells patented energy storage technology. Main customers are major global OEM partners and energy companies such as Alfa Laval, Vattenfall, Mobile Climate Control and Rheem. SaltX Technology's share is listed on Nasdaq Stockholm First North Premier. SaltX Technology’s Certified Adviser is FNCA Sweden AB.  StockholmOctober 23, 2018

Invitation – Presentation of Sobi’s Q3 2018 results

On 31 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ)  (Sobi™) will publish its report for the third quarter 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English. The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference. To participate in the telephone conference, please call:SE: +46 8 566 42 697UK: +44 203 008 98 08US: +1 855 753 22 36  Click here to go to the live webcast.  After the live event the webcast will be available on-demand via the same URL. --- About Sobi™Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.    For more information please contact  Media relations Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager President, Head of Investor Relations+46 708 734 095 +1 347 224 0819, +1 212 579 0506                    linda.holmstrom@sobi.com  jorgen.winroth@sobi.com

Interim Report Third Quarter 2018

Third quarter 2018 Continuing operations   · Order intake 24,192 million SEK · Revenues 24,283 million SEK · Operating profit 5,205 million SEK · Operating margin 21.4% · Adjusted operating profit 4,587 million SEK · Adjusted operating margin 18.9% · Profit after financial items 5,065 million SEK · Earnings per share 3.14 SEK · Cash flow from operations 5,399 million SEK Discontinued operations · Order intake 16 million SEK · Revenues 155 million SEK · Operating profit -158 million SEK Group Total · Order intake 24,209 million SEK · Revenues 24,438 million SEK · Operating profit 5,047 million SEK · Operating margin 20.7% · Adjusted operating profit 4,429 million SEK · Adjusted operating margin 18.1% · Earnings per share 3.01 SEK · Cash flow from operations 5,328 million SEK Additional information may be obtained from Sandvik Investor Relations, phone +46 8 456 14 94 (Ann-Sofie Nordh), +46 8 456 11 94 (Anna Vilogorac) or e-mailing info.ir@sandvik.com A webcast and conference call will be held on 23 October 2018 at 13:30 CET. Information is available at home.sandvik/investors   Stockholm, 23 October 2018 Sandvik Aktiebolag (publ) Björn Rosengren President and CEO This information is information that Sandvik AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at about 12:00 CET on 23 October 2018. 

Bygghemma Group strengthens position in Finland through acquisition of Edututor

Mikael Olander, President and CEO of Bygghemma Group, on the acquisition: “I want to welcome Edututor and its competent management to Bygghemma Group. We constantly strive to improve our category expertise and Edututor is a company that is a good match with our acquisition criteria. The Company holds a strong position in its segments – a position that will now help to strengthen Bygghemma Finland’s category expertise and leadership considerably. Our objective going forward is to continue to supplement our rapid organic growth in Finland with selective acquisitions.”Edututor was founded in 2010 and, since then, has had a compound annual growth rate (CAGR) of around 37 percent. The company conducts sales through a number of online stores, the largest of which are Grillikauppa.com, Led-Valot.fi and Paista.fi. In 2017, the company had sales of approximately EUR 4.5 million, with an operating profit of around EUR 120 thousand.Bygghemma will continue to operate Edututor as an independent entity within the DIY segment in Finland. For more information, please contact: Mikael Olander, President and CEO of Bygghemma GroupTel: +46 708 19 43 00E-mail: mikael.olander@bygghemmagroup.seKimmo Lähteenmäki, CEO of Bygghemma FinlandTel: +358 40 720 6892E-mail: kimmo.lahteenmaki@bygghemma.fi   www.bygghemmagroup.comThis information was submitted for publication, through the agency of the contact persons set out above, at 13:00 CEST on 23 October 2018.About Bygghemma GroupBygghemma Group is the leading online supplier of home improvement products in the Nordic region. We offer our customers a broad product range at attractive prices, with convenient home delivery. We conduct operations in two segments: DIY and Home Furnishing. DIY comprises sales of products from well-known brands for homes and gardens, and Home Furnishing comprises sales of furniture and home decor, mainly under proprietary brands. Bygghemma Group includes a wide range of webstores, such as Bygghemma, Trademax, Chilli and Furniturebox. Bygghemma Group had sales of approximately SEK 4.4 billion in 2017, has its head office in Malmö and is listed on Nasdaq Stockholm Mid Cap.